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Resumo 
A Doença Inflamatória Intestinal (DII) é uma patologia de carácter crónico e recidivante que 
afeta o trato gastrointestinal e cuja etiologia ainda não se encontra completamente esclarecida. 
Dado que, até ao momento, ainda não foi encontrada a cura para a DII e o recurso ao tratamento 
farmacológico convencional conduz a resultados que são claramente insatisfatórios, o 
desenvolvimento de estratégias alternativas que sejam eficazes para prevenir a progressão desta 
doença continua a constituir objeto de intensa investigação. Por outro lado, os polifenóis da 
dieta, aliando a sua potencial atividade anti-inflamatória ao seu efeito antioxidante, têm sido 
considerados promissores na prevenção e tratamento de várias doenças inflamatórias crónicas 
e, por esta razão, têm recebido particular atenção no caso da DII. 
Neste contexto, o trabalho desenvolvido na presente Dissertação teve como objetivo, em 
primeiro lugar, contribuir para o esclarecimento dos mecanismos moleculares subjacentes à 
atividade anti-inflamatória de dois polifenóis estruturalmente diferentes, a antocianina 
cianidina-3-glucósido (C3G) e o estilbeno resveratrol (Resv), normalmente presentes na dieta 
Mediterrânica, e, em segundo lugar, comparar esses efeitos com os de um fármaco 
convencional, o ácido 5-aminosalicílico (5-ASA), nas mesmas condições experimentais. Para 
esse efeito, as células HT-29 foram inicialmente tratadas com os polifenóis, individualmente 
ou em combinação com o 5-ASA, em concentrações previsivelmente atingíveis no intestino (25 
μM no caso dos polifenóis e 500 μM no caso do 5-ASA) e, posteriormente, expostas a uma 
mistura de citocinas (IL-1α, TNF-α e IFN-γ) durante um determinado período de tempo. 
Numa primeira fase deste trabalho, foi demonstrada a capacidade da C3G e do Resv 
diminuírem quer a produção de mediadores pro-inflamatórios, como o óxido nítrico e a 
prostaglandina E2, quer a expressão de enzimas pro-inflamatórias, como a iNOS e a COX-2, 
sem afetarem, no entanto, a ativação do fator nuclear kB, em células estimuladas pelas citocinas. 
Contudo, nestas células, a quantidade de STAT1 ativada diminuiu significativamente no 
núcleo. Foi também demonstrado que o Resv, ao contrário do 5-ASA, inibiu a ativação da JNK, 
mas nem o Resv nem o 5-ASA foram capazes de inibir a ativação da p38 MAPK nas mesmas 
células estimuladas.  
Numa segunda parte do trabalho, foi investigado o envolvimento das vias do Nrf2 e do 
PPAR-γ no efeito protetor referido da C3G e do Resv nas células HT-29 sob ação das citocinas, 
em comparação com o fármaco 5-ASA. Ambos os compostos demonstraram serem capazes de 
induzir a via do Nrf2, de aumentar a expressão de RNA mensageiro de duas enzimas 
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importantes, a hemoxigenase-1 e a glutamato cisteína ligase, de aumentar a relação entre o 
glutatião reduzido (GSH) e o glutatião oxidado (GSSG) e de inibir a produção de espécies 
reativas nessas células estimuladas pelas citocinas. Adicionalmente, o Resv e o 5-ASA, mas 
não a C3G, aumentaram a quantidade de PPAR-γ no núcleo das mesmas células estimuladas.  
Atendendo à diferença de concentrações usadas neste estudo, os dados obtidos sugerem que 
tanto a C3G como o Resv possuem uma capacidade anti-inflamatória e antioxidante superior à 
do fármaco convencional 5-ASA.  
Embora os resultados deste estudo in vitro não tenham indicado um efeito aditivo ou 
sinergético entre a associação da C3G ou do Resv com o 5-ASA, a ocorrência desse efeito em 
modelos animais da doença ou em humanos não pode ser excluída.  
Em conclusão, os resultados deste estudo contribuem para o esclarecimento dos mecanismos 
de ação anti-inflamatória da C3G e do Resv, ao revelarem o seu envolvimento em vias de 
sinalização celular críticas no processo inflamatório, reforçam o carácter promissor destes 
compostos como nutracêuticos adjuvantes da terapêutica convencional e abrem caminho à 
seleção de outros compostos naturais para o combate da doença inflamatória intestinal.
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Abstract 
Inflammatory Bowel Disease (IBD) is a chronic and relapsing disorder of the gastrointestinal 
tract, whose etiology remains not fully understood. Given that, until now, IBD does not have 
cure and the results achieved with the conventional pharmacological treatment are clearly 
unsatisfactory, there is a great interest in exploring alternative strategies effective in limiting 
IBD progression. On the other hand, dietary polyphenols, allying their putative 
anti-inflammatory activity to their antioxidant effect, have been considered promising 
molecules for the prevention and treatment of several chronic inflammatory disorders and, for 
this reason, they have been receiving particular attention in the case of IBD.  
In this context, the work developed in the present Thesis aimed, primarily, to contribute for 
an extensive clarification of the molecular mechanisms underlying the anti-inflammatory 
effects of two structurally different polyphenolic compounds, the anthocyanin 
cyanidin-3-glucoside (C3G), and the stilbene resveratrol (Resv), both present in the 
Mediterranean diet, and secondly to compare these effects with those of a well-known 
anti-inflammatory drug, 5-aminosalicylic acid (5-ASA), in the same experimental conditions. 
With this purpose, a human intestinal cell line (HT-29) was employed and upon cell treatment 
with each polyphenol per se or in combination with 5-aminosalicylic acid (5-ASA), at the 
concentrations predictably reached at the intestinal level (25 μM for the polyphenols and 500 
μM for 5-ASA), the cells were exposed to a combination of cytokines (IL-1α, TNF-α and IFN-γ) 
for a certain period of time.  
In the first phase of this study, it was demonstrated the ability of C3G and Resv to counteract 
the production of cytokine-induced pro-inflammatory mediators, such as nitric oxide (NO) and 
prostaglandin E2 (PGE2), and the expression of cytokine-induced pro-inflammatory enzymes, 
namely iNOS and COX-2, without affecting the activation of nuclear factor kB (NF-kB), but 
decreasing the amount of activated STAT1 in the nucleus of HT-29 cells. It was also shown 
that, unlike 5-ASA, Resv inhibited the activation of JNK but neither Resv nor 5-ASA were able 
to inhibit the activation of p38 MAPK in cytokine-stimulated HT-29 cells.  
In a second stage of this work, the involvement of Nrf2 and PPAR-γ pathways in the 
anti-inflammatory action of C3G and Resv were investigated in comparison with 5-ASA. It was 
demonstrated that both C3G and Resv were able to induce Nrf2 activation, to increase the 
ARE-regulated mRNA expression of two important enzymes, hemoxygenase-1 (HO-1) and 
glutamate cysteine ligase (GCL), to enhance the ratio of reduced glutathione (GSH) to oxidized 
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glutathione (GSSG) and to inhibit the production of reactive species, in cytokine-challenged 
cells. Furthermore, unlike C3G, Resv and 5-ASA increased the amount of PPAR-γ in the 
nucleus of these stimulated cells.  
Considering the difference in the concentrations used in this study, the obtained results 
suggest that both C3G and Resv could have a higher anti-inflammatory and antioxidant capacity 
than the conventional drug 5-ASA.  
Although the undertaken in vitro studies did not provide evidence to support an additive or 
synergistic effect resulting from the association of C3G or Resv with 5-ASA, such effect cannot 
be excluded in animal models of the disease or in human patients.  
In conclusion, the results of this study contribute not only to clarify the action mechanisms 
behind the anti-inflammatory effects of C3G and Resv, by revealing their involvement in key 
inflammation-related cellular signalling pathways, but also to reinforce the envisagement of 
these compounds as promising nutraceuticals in combination to conventional drugs and to open 
windows for the selection of other natural compounds to defeat inflammatory bowel disease.  
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Chapter 1 - General Introduction 
3 
General Introduction 
1. Intestinal homeostasis - a finely tuned balance 
The intestinal compartment constitutes the largest barrier tissue of the human body, with a 
surface area of approximately 200-400 m2, which is colonized by about 100 trillion 
microorganisms, mostly bacteria, collectively called microbiota or commensal flora [1-3]. The 
quantity and diversity of bacteria vary along the intestine, which is possibly explained by 
differences in host genetics and by interactions with the external environment [3, 4]. Due to 
millions of years of co-evolution, the relationship established between the host and the 
commensal flora is of a symbiotic nature, since the microbiota increases the digestion capacity 
of the host, helps him in preventing pathogen colonization and contributes to intestinal 
physiology and immunology, benefiting, in turn, from the nutrients and the mild temperature 
of the human body [2-5]. However, not neglecting this mutually beneficial relationship, the 
close proximity with this huge number of microorganisms constitutes a great challenge to the 
host, who has to tolerate them, avoiding overreactions that, otherwise, could lead to the damage 
of the intestinal tissue and, at the same time, should remain vigilant against potentially 
threatening signals derived from the presence of these microorganisms [2-4]. In addition, since 
the intestine serves as a portal of entry for nutrients into the body, human organism has to cope 
with a myriad of antigens, frequently ingested through the diet, such as food antigens or 
environmental toxins or even antigens from pathogenic microorganisms [4, 5]. Therefore, 
intestinal epithelial cells (IECs), located in the interface between the intestinal lumen, inhabited 
by a multitude of microorganisms, and the lamina propria, densely populated by immune cells, 
assume a privileged position, playing a daunting task of segregating, physically and 
biochemically, these such diverse environments, but also of integrating signals between the 
microbiota and the host immune system [1, 5, 6]. Thus, in order to preserve the intestinal 
homeostasis, a friendly and balanced interaction between the commensal flora, the intestinal 
epithelium and the local immune cells is continuously required [7]. A breakdown in this 
dynamic cooperation can result in intestinal inflammation, typically present in a well-known 
pathology, the Inflammatory Bowel Disease [7].  
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2. Inflammatory Bowel Disease 
2.1 Overview 
The Inflammatory Bowel Disease (IBD) is a group of idiopathic and chronic inflammatory 
disorders of the gastrointestinal tract, encompassing, as main forms, the Crohn’s Disease (CD) 
and the Ulcerative Colitis (UC) [8]. Up to this date, IBD does not have cure and it is a lifelong 
disorder, whose clinical course is characterized by alternating periods of relapses and 
remissions. Therefore, this disease accounts for a huge economic impact to the healthcare 
systems, associated with the constant need for visits to physicians, frequent hospitalizations and 
palliative drugs. On the other hand, it involves indirect costs with great impact in the economy 
of the countries, related to the decrease in patient quality of life and the consequent loss of 
productivity or increase in absenteeism [8-11]. This becomes even more impressive if we take 
into account that IBD affects normally people during their economically productive adult age 
(age peak for CD is 20-30 and for UC is 30-40) [12]. 
IBD is estimated to have the highest incidence and prevalence rates in industrialized 
countries, mainly in countries of North Europe and of United States of America [11]. In 
agreement with the World Gastroenterology Organisation Global Guidelines of 2010 [13], 
those rates are rising in areas with previous low-incidence, namely in countries of Eastern 
Europe and Asia, for reasons not fully determined. 
Until now, the etiology of IBD remains uncertain, but it is believed that IBD is a 
multifactorial disorder, in which the interplay between a genetic predisposition and 
environmental factors, such as stress, diet and antibiotic intake, induces an aberrant immune 
reaction to commensal microorganisms, culminating in the perpetuation of uncontrolled and 
exacerbated inflammatory and oxidative responses, which lead to serious intestinal injury [2, 7, 
12, 14, 15]. 
Although the main conditions of IBD (CD and UC) have some overlapping characteristics, 
the inflammation in UC is diffuse and typically restricted to the mucosa of the colon, whereas, 
in CD, it is focal, transmural and sporadically granulomatous in the ileo-cecal or ileo-colic 
areas, and may affect the whole gastrointestinal tract, particularly the ileum and the colon [9, 
10]. The major symptoms of IBD include diarrhoea, tenesmus, abdominal pain, nausea, 
vomiting, fever, weight loss and fatigue, varying from mild to severe in periods of relapses and 
even vanishing in periods of remissions [13, 16]. Moreover, IBD patients can suffer not only 
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from intestinal complications, including bowel perforation and fistulas, toxic megacolon and 
even, in most severe cases, colorectal cancer, but also from extra-intestinal complications, 
affecting a multitude of organs, such as the skin, the liver and the kidney [9, 13, 16, 17]. 
Therefore, the complexity of intestinal and extra-intestinal manifestations with insidious 
beginning in these patients and the appearance of symptoms frequently shared with other 
gastrointestinal pathologies, make the diagnosis of IBD a difficult task even for a trained 
specialist [9]. Thus, the accurate diagnosis of IBD implies taking into account the medical 
history and the clinic evaluation of the patient, together with laboratory, endoscopic, histologic 
and radiologic findings [8, 18].  
 
2.2 Molecular mechanisms underlying Inflammatory Bowel Disease 
Although the molecular mechanisms underlying IBD are still uncertain, it is known that 
some of them are related to dysfunctions in the structure and in the function of the intestinal 
epithelium as an anatomical barrier (section 2.2.1) and others are correlated to the loss of 
intestinal epithelium ability to properly modulate the interactions between intestinal microbiota 
and the immune system (section 2.2.2) [5, 12]. 
2.2.1 Intestinal epithelial barrier and its dysfunction in Inflammatory Bowel 
Disease 
“Good fences make good neighbours”, by Robert Frost (1914) 
The intestinal epithelium, the largest of the mucosal surfaces of the human body, is 
composed by a single-layer of columnar cells, organized into crypts and villi, which are 
continuously renewed by pluripotent intestinal epithelial stem cells, present in the base of 
intestinal crypts [1]. Pluripotent stem cells give rise to several subtypes of specialized mature 
epithelial cells (Figure 1), including enterocytes, goblet cells, Paneth cells and enteroendocrine 
cells [19, 20].   
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Figure 1 - Illustration representing some specialized intestinal epithelial cells existing in jejunum and its 
organization into crypts and villi (reproduced with permission from [19]). 
 
 
Being located between luminal microorganisms (in the apical side) and immune cells (in the 
basolateral side), the intestinal epithelial barrier has to resort to some strategies to keep these 
environments apart. This is accomplished thanks to the existence of the apical junctional 
complex along with desmosomes, to the production of mucus and antimicrobial peptides and 
also to the secretion of IgA, all of which reinforce the intestinal epithelial barrier, either physical 
or biochemically, as discussed below [3, 21]. Therefore, a breakdown in the mechanisms that 
normally minimize the contact between the luminal bacteria and the intestinal mucosal surface 
may contribute to the development of IBD [3]. 
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A - Junctional complex  
IECs are structurally and functionally polarized cells, with an apical surface facing the 
luminal milieu and a basolateral surface facing the basement membrane and the lamina propria 
[22]. Under normal conditions, the paracellular space between IECs is sealed by the apical 
junctional complex (Figure 2), which is formed by the tight junction (TJ) and the subjacent 
adherens junction [21]. Tight junctions are composed by transmembrane proteins, such as those 
belonging to claudin family, scaffolding proteins and regulatory molecules, including kinases, 
and they are considered of great importance in the regulation of TJ permeability [21, 23]. 
Adherens junctions are formed by a family of transmembrane proteins called cadherins, and 
together with desmosomes (Figure 2), reinforce the cellular proximity between IECs [21]. 
Numerous studies have reported changes in the expression and structure of several intestinal TJ 
proteins in IBD patients [22, 23]. However, until now, it is not clear whether the impairment of 
the transmembrane proteins that integrate the junctions is a cause or a consequence of intestinal 
inflammation [12]. 
 
Figure 2 - Schematic illustration showing the junctional complex and the desmosome of an intestinal epithelial 
cell (modified from [21]). 
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B - Mucus layer  
The intestinal epithelium is covered by a mucus layer (Figure 3), mainly composed by 
mucins (highly glycosylated proteins) and by other molecules, such as trefoil peptides, which 
are produced by a specific type of epithelial cells, the goblet cells [24]. Until now, 20 different 
mucins (MUCs) have been identified, being classified as secretory or membrane-associated 
mucins. MUC2, the first recognized human secretory mucin, is considered the major secretory 
intestinal mucin [24]. 
 
 
 
 
Figure 3 - Schematic drawing representing some mechanisms used by IECs to prevent the invasion of bacteria 
(reproduced with permission from [3]). 
 
Goblet cells are present in a greater amount in the distal colon than in the upper small 
intestine, which seems to be correlated with the increasing number of microorganisms 
harboured throughout the intestine (103 to 108 organisms per gram of luminal contents in the 
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small intestine and 1010 to 1012 organisms per gram in the colon) [2, 19]. Therefore, contrasting 
with small intestine, where the mucus layer is thinner and discontinuous, in the large colon the 
mucus lining is stratified in two sheets: the inner, denser and therefore more resistant to 
microbial invasion, and the outer, looser and highly populated by microorganisms [2, 4, 19].  
The importance of a proper mucus layer becomes evident in mice deficient in MUC2, which 
spontaneously develop colitis [2]. Further, more evidence demonstrates that colon tissue 
obtained from CD patients has a disturbed mRNA expression of MUC2 and of MUC12, being 
the latter also decreased in colonic samples from UC patients [25]. On the other hand, it has 
been reported that impairments in mucin glycosylation can also lead to defects in mucus barrier, 
enhancing the susceptibility to experimentally induced colitis observed in mice [24, 26]. 
Therefore, it has been suggested that alterations either in mucin production or in mucin 
glycosylation can be related to the pathophysiology of IBD [24]. 
 
C - Antimicrobial peptides 
Beyond the mucus layer, an extra immune mechanism that reduces the contact between the 
luminal microorganisms and the IECs involves the secretion of antimicrobial peptides (AMPs), 
namely defensins, cathelicidins, lactotransferrin and lysozyme, by several IECs, such as 
enterocytes/colonocytes, goblet cells and Paneth cells [3, 27]. The AMPs become trapped in 
the mucus layer, acting as a biochemical barrier [4], as depicted in Figure 3. The majority of 
AMPs are capable of killing bacteria by enzymatic attack on the cell wall or by destabilizing 
the inner membrane of Gram-negative bacteria [3].  
Some recent research found that impairment of beta-defensin 2 expression predisposed 
individuals to colonic CD [28], which suggests that the role of defensin peptides should not be 
undervalued in the context of IBD.  
 
D - Immunoglobulin A 
The accumulation of Immunoglobulin A (IgA) in the intestinal lumen (Figure 3) is another 
mechanism of protection used by intestinal epithelial barrier in order to prevent the invasion of 
luminal bacteria either by trapping them in the mucus layer or by inducing the phagocytic 
clearance of microorganisms that penetrate the intestinal barrier [1, 3, 4]. IgA is secreted by 
plasma cells in the lamina propria, as dimeric IgA, and transcytosed into the intestinal lumen 
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through IECs [3]. The process of IgA transcytosis is mediated by a glycoprotein, the polymeric 
immunoglobulin receptor (pIgR), which undergoes an endoproteolytic cleavage near the plasma 
membrane of IECs, allowing the release of its secretory component into the lumen together 
with IgA, forming the secretory IgA complex. In IBD, it has been suggested that, for some 
reason not fully understood, the expression of pIgR is downregulated, the transcytosis of 
dimeric IgA is reduced and IgA seems to be accumulated in the lamina propria. All of these 
defects can impair IgA trafficking and its accumulation in the intestinal lumen, contributing to 
IBD pathogenesis [29]. 
On the other hand, according to Macpherson and collaborators [30], patients with either form 
of IBD, in the active phase, produce high levels of IgG and low levels of secretory IgA. The 
authors pointed that the high production of IgG, towards proteins existent in the cytoplasm of 
commensal bacteria, was related to the episodes of relapses, observed in those patients. In line 
with this, some authors suggest that the shift from the secretion of protective subtype antibodies 
(IgA) to aggressive subtype antibodies (IgG) can be subjacent to the development of the 
mucosal inflammation in IBD patients [31].  
 
E - Pattern Recognition Receptors  
Despite the previously described mechanisms employed by intestinal epithelium to insulate 
bacteria from the intestinal surface, microbe-associated molecular patterns (MAMPs) can be 
detected by IECs or by immune cells, through evolutionarily conserved receptors, termed 
pattern-recognition receptors (PRRs), namely toll-like receptors (TLRs) and nucleotide 
oligomerization domain (NOD)-like receptors (NLRs) [2, 6].  
 
E.1 Toll-Like Receptors 
TLRs are a class of transmembrane glycoproteins constitutively or inducibly expressed by 
different cell types in the intestinal tract, namely IECs, macrophages, dendritic cells and CD4+ 
T cells. These receptors are capable of recognizing multiple MAMPs, such as 
lipopolysaccharide (LPS) and flagellin, and can be grouped according to their localization either 
on the cell surface (TLR1, 2, 4, 5, 6) or in intracellular compartments (TLR3, 7, 8, 9), such as 
endosomes and lysosomes [32-34]. TLRs are conjugated proteins formed by an extracellular or 
luminal ligand-binding domain containing leucine-rich repeat motifs and a cytoplasmic 
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Toll-interleukin-1 receptor homology (TIR) domain [32, 34]. The TIR domain is crucial for the 
interaction between homo and heterodimeric TLR subunits and also for the anchorage of 
cytoplasmic adaptor molecules, including myeloid differentiation primary response 88 protein 
(MyD88), TIR domain-containing adaptor protein inducing IFN-β (TRIF) and TRIF-related 
adaptor molecule (TRAM) [32, 35]. Activation of TLRs generally culminates in the activation 
of a well-known signalling cascade, the nuclear factor-kB (NF-kB), to elicit a pro-inflammatory 
response, attempting to eradicate the potential pathogens [2, 11, 12]. Conversely, in the absence 
of pathogenic agents, accelerating research has demonstrated that the intestinal epithelium takes 
advantage of signals derived from commensals, through TLR activation, to strengthen its 
function as a barrier, for instance, by increasing the production of mucus or the transport of IgA 
into the lumen, and also to maintain the tolerance of immune cells against microbiota (as it will 
be discussed below, in 2.2.2-D section) [1, 2, 11]. As highlighted above, although the intestine 
must preserve the reception of signals derived from commensals to maintain the intestinal 
homeostasis, the intestine has also to develop strategies to avoid the hyper-stimulation of 
pro-inflammatory signalling pathways, namely NF-kB, towards commensals [1, 6, 36]. 
Therefore, in normal conditions, TLRs are positioned preferentially on the basolateral surface 
of IECs as well as in intracellular compartments in detriment of IEC apical surface, decreasing 
their accessibility by commensals, and, on the other hand, the commensal bacteria by 
themselves can inhibit NF-kB activation. This is accomplished, for example, by inhibiting the 
degradation of the inhibitor of kappa B (IkB) and thereby preventing the entry of NF-kB in the 
nucleus or by inducing the expression of peroxisome proliferator-activated receptor gamma 
(PPAR-γ), which is also capable of inhibiting NF-kB pathway, as referred below on section 
2.3.5 [1, 2, 5, 6]. However, in the case of IBD, IECs display higher expression of some TLRs 
at their apical side than in physiological conditions, thus increasing the possible interaction with 
commensal microorganisms [32, 37, 38]. Accordingly, it seems possible that IECs upregulate 
the expression of TLRs during intestinal inflammation upon stimulation with cytokines, such 
as TNF-α and IFN-γ [32, 37]. The sustained dysregulation of TLR signalling and the consequent 
over-activation of the pro-inflammatory NF-kB cascade are believed to contribute to chronic 
intestinal inflammation and so to IBD pathogenesis [7, 12, 32].  
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E.2 Nucleotide Oligomerization Domain (NOD)-Like Receptors  
NLRs are cytoplasmic proteins, structurally formed by an N-terminal effector domain 
(usually a caspase recruitment domain, CARD), a central conserved nucleotide-binding 
oligomerization domain (NOD) and a carboxy-terminal leucine-rich repeats (LRRs) [35, 38]. 
NOD1 and NOD2 were the first NLRs to be reported and they are activated by different 
peptidoglycan motifs, D-γ-glutamyl-meso-diaminopimelic acid and muramyl dipeptide, 
respectively [35]. While NOD1 is ubiquitously expressed in human cells, NOD2 is mainly 
expressed in epithelial cells, phagocytes and dendritic cells [38]. Both NOD1 and NOD2 
expressions are normally low in intestinal epithelial cells, but can be upregulated by 
inflammatory stimuli, such as IFN-γ [11, 38]. Upon activation, NOD1 and NOD2 lead to the 
activation of NF-kB and mitogen-activated protein kinases (MAPKs), resulting in the 
transcription of several pro-inflammatory genes [12, 39].  
NOD2 was the first gene to be connected to IBD and it is well-accepted that polymorphisms 
in NOD2 are strongly related to CD [40-42]. Although, there are several possible explanations 
for the involvement of NOD2 mutations in the pathogenesis of CD, one of the most debated 
hypothesis suggests that the absence of NOD2 expression by Paneth cells results in a defective 
production of AMPs, allowing the proliferation of bacteria in the intestinal crypts and making 
the intestinal barrier and the intestinal milieu more exposed to the stimulation by antigens [17, 
43], as illustrated in Figure 4. 
 
 
 
Figure 4 - Schematic representation illustrating the possible contribution of NOD2 mutations in the pathogenesis 
of CD (adapted from [42]). 
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2.2.2 Host immune responses and their dysregulation in Inflammatory Bowel 
Disease 
The intestinal immune system, often referred to as gut-associated lymphoid tissue (GALT), 
is a particular component of the immune system, which plays a crucial role in promoting 
immune responses against potential pathogens as well as in promoting tolerance against dietary 
antigens or commensal microorganisms [44].  
 
A - Gut-Associated Lymphoid Tissue  
GALT is divided into two different types of compartments, the inductive and the effector 
compartments [45], as shown in Figure 5. The inductive compartments are organized lymphoid 
tissues, such as Payer’s patches (PPs; located in the small intestine and particularly abundant in 
the distal ileum), colonic patches (located in the colon and rectum), mesenteric lymph nodes 
(MLNs) and isolated lymphoid follicles (ILFs). The effector compartments include the 
lymphocytes present throughout the epithelium and the lamina propria [19, 45].  
 
 
Figure 5 - Illustration of the gut-associated lymphoid tissue. SED, subepithelial dome; TDA, thymus-dependent 
area (reproduced with permission from [45]). 
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B - Uptake of luminal antigens and their presentation to immune cells 
Mature PPs comprise B-cell follicles and T-cell areas, which are separated from the intestinal 
lumen, thanks to the follicle-associated epithelium (FAE) and the subepithelial dome (SED). 
The most important characteristic of FAE is the existence of Microfold (M) cells [6, 45]. These 
cells are specialized epithelial cells, which have a reduced mucus layer and a modified apical 
and basolateral surfaces, making them able to capture antigens and deliver them to professional 
antigen-presenting cells (APCs), mainly dendritic cells (DCs), in the epithelium or in the SED 
[6, 46]. M cells are not exclusive of PPs and they can also be present over ILFs in the colon 
[19]. Although M-cell-mediated-transcytosis is a common route of antigens uptake (Figure 
6B), there are also other possible routes used by enterocytes and by mononuclear phagocytes 
to uptake luminal antigens.  
 
 
Figure 6 - Some routes of antigen uptake at the intestinal level. A) Epithelial cells capture antigens and present 
processed antigens to intraepithelial lymphocytes (IEL) or to lamina propria lymphocytes (LPL) or transfer already 
processed antigens to dendritic cells. B) M cells uptake antigens and deliver them to dendritic cells. C) Dendritic 
cells uptake antigens through the extension of their finger-like projections (reproduced with permission from [46]). 
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In fact, it is known that gut epithelial cells can also mediate active endocytosis and process 
and present antigens bound to major histocompatibility complex (MHC) class I or class II 
molecules to intraepithelial lymphocytes or lamina propria lymphocytes (Figure 6A), but, 
apparently, they are not able to prime naïve T cells, due to the lack of co-stimulatory molecules 
expression [6, 46]. Although the significance of these data awaits further investigations, it 
seems that through that way, IECs contribute to T cell non-responsiveness and consequently to 
natural tolerance [6, 47, 48]. Further, IECs can also transfer already processed antigens to DCs 
(Figure 6A) [46]. DCs are mononuclear phagocytes, which have a major importance in the 
initiation and the development of intestinal immunity against pathogens and in the promotion 
of tolerance against commensal microorganisms [49]. These professional APCs have been 
reported throughout the intestine, in PPs, in ILFs and in MLNs, but they can also be found in 
the lamina propria and in association with the villous epithelium [50]. Until now, the 
mechanisms underlying the ability of DCs to acquire directly antigens have remained uncertain. 
However, some recent studies suggest that DCs, positioned inside the intestinal epithelium, can 
capture luminal antigens through the extension of their finger-like projections (Figure 6C) [51]. 
Another possible mechanism used by DCs to uptake antigens is through interaction with 
antigen-channeling goblet cells [49, 51]. In secondary lymphoid organs (PPs and MLNs), 
antigen-loaded DCs present the antigens to adaptive immune cells [3, 52]. Beyond DCs, 
macrophages are another type of mononuclear phagocytes with great abundance in the intestinal 
lamina propria. Macrophages can also sample luminal antigens directly, extending their 
trans-epithelial dendrites (TEDs) [49, 51]. In contrast to DCs, macrophages remain in close 
contact with IECs, acting as highly effective phagocytes to promote the clearance of antigens 
[52].  
 
C - General adaptive immune dysfunctions in Inflammatory Bowel Disease - the 
classical point of view in confrontation with recent findings 
The majority of studies indicate that chronic intestinal inflammation, observed in patients 
with IBD, is essentially related to the intensive recruitment and inappropriate retention of 
mucosal activated CD4+ T-helper (Th) lymphocytes, which proliferate and differentiate from 
naïve CD4+ Th cells into several subtypes of T-cells, including Th1 and Th2 cells [2, 40, 53]. 
Until a few years ago, it was argued that CD pathogenesis was related to an exaggerated Th1 
response, whereas UC pathogenesis was related to an exaggerated Th2 response [53, 54]. While 
Chapter 1 - General Introduction 
16 
Th1 cells can mediate immunity against intracellular pathogens, producing pro-inflammatory 
cytokines, such as TNF-α and IFN-γ, which, in turn, among other mechanisms, promote the 
release of further large amounts of pro-inflammatory cytokines from macrophages, Th2 cells 
can mediate immunity against extracellular pathogens, secreting cytokines, such as IL-4, IL-5 
and IL-13, which induce B cell activation and promote antibodies production [55]. Further, Th1 
and Th2 cells can cross-regulate each other and, thus, cytokines produced by Th1 inhibit the 
differentiation of naïve T cells into Th2 cells and vice-versa [55].  
The Th1/Th2 dichotomy was greatly supported by intestinal tissue sections collected from 
patients with active CD, demonstrating increased levels of Th1-polarizing cytokines (namely 
IL-12) in comparison with normal tissues and UC patients [53]. However, evidence gathered 
over the last years has demonstrated that the Th1/Th2 paradigm claimed for IBD was too 
simplistic and the overlapping cytokine profile underlying CD and UC justified the need to 
update that concept [53, 56]. In fact, the recognition, in more recent years, of another 
subpopulation of T lymphocytes, Th17 cells, has reinforced the requirement of changing the 
traditional Th1/Th2 paradigm [2, 54]. Th17 cells, present in the intestine, mainly in the terminal 
ileum, after being stimulated by IL-6, TGF-β and IL-23, following the activation of dendritic 
cells and/or activated epithelial cells, are able to secrete pro-inflammatory cytokines, namely 
IL-17 and IL-21, which lead to the recruitment of other cells, such as neutrophils [20]. Many 
studies have demonstrated that the production of Th17-related cytokines are increased in 
intestinal biopsies and in lamina propria mononuclear cells of patients with CD and UC, being 
possibly implicated in the pathogenesis of both forms of IBD, but particularly in CD [2, 53, 54, 
57].  
On the other hand, although UC was initially related to a Th2 profile, the levels of IL-4, a 
classical Th2 cytokine, did not show to be augmented in UC patients, which suggested that UC 
patients do not show all of the features of classical Th2 cells [17, 57]. Actually, it has been 
suggested that UC patients present an atypical Th2 profile, characterized by the existence of 
elevated amounts of IL-13 secreted by CD1d-restricted non-classical natural killer T cells (NKT 
cells) [14, 20, 56-58]. Accordingly, in a mouse model for UC, it was demonstrated that the 
suppression of IL-13, produced by NKT cells, could prevent colitis development [17, 57]. 
However, some contradictory results have emerged in more recent studies, since it has been 
reported that patients with UC did not show high levels of IL-13. Altogether it becomes quite 
clear that further work is mandatory in this field to better elucidate this issue [57]. Furthermore, 
it has been reported a disturbed balance between the number of regulatory T cells (Treg cells) 
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and of effector T cells in active IBD, existing a preferential differentiation of naïve T cells into 
effector T cells, instead of into Treg cells, in those patients [11]. Treg cells produce 
anti-inflammatory cytokines, such as IL-10 and TGF-β, and they show to be central players in 
suppressing immune responses, ensuring tolerance towards commensal microorganisms [57].  
 
D - Intestinal epithelial cells in the orchestration of host immune responses 
Contrary to what was initially believed, IECs may be not merely important to segregate the 
intestinal lumen from the intestinal milieu, but may be also crucial to modulate the function of 
host immune cells, for instance, through the secretion of cytokines and chemokines, which 
interfere directly or indirectly with the function of antigen-presenting cells and, thereafter, with 
the subsequent cellular and humoral adaptive immune responses [1, 5, 6, 42]. Although this 
theme is still in its infancy, several authors are increasingly interested in studying the influence 
of IECs over the host immune responses and how the dysregulation of this finely-tuned balance 
can be implicated in the IBD pathogenesis. Some examples of the possible influence of IECs 
over the host immune regulation are discussed below, either in physiological conditions or in 
IBD. 
 
D.1 Immune regulation in physiological conditions 
As shown in Figure 7A, after recognition of commensal bacteria via PRR signalling, IECs 
secrete, for instance, thymic stromal lymphopoietin (TSLP), transforming growth factor-β 
(TGF-β) and retinoic acid (RA), which convert DCs and macrophages into a tolerogenic 
phenotype [1, 5, 6, 59]. Therefore, IECs-conditioned DCs induce the differentiation of naïve 
CD4+ T-cells into regulatory T cells (Treg), by a TGF-β and RA-dependent mechanism, induce 
the maturation of B cells into IgA-secreting plasma cells and promote the imprinting of 
gut-homing phenotype on primed T-cells and B-cells [1, 2, 5, 60].  
On the other hand, macrophages, conditioned by IEC-derived TSLP and by 
contact-dependent interaction with IEC-expressed semaphoring 7A (SEMA7A), produce 
IL-10, leading to the expansion in number of Treg cells Figure 7C [1, 5, 7].  
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Figure 7 - Representative illustration showing some examples of the orchestration of host immune responses by 
intestinal epithelial cells in physiological conditions (reproduced with permission from [1]). 
 
Furthermore, IECs can also release a proliferation-inducing ligand (APRIL) and a B-cell 
activating factor (BAFF), which induce IgA class switching and the production of IgA by B 
cells (Figure 7D) [1, 6, 7, 60]. Furthermore, IEC-derived TSLP induces the production of 
APRIL and BAFF by macrophages, increasing the stimulation of B cells (Figure 7D) [1].  
Also, it has been suggested that IECs-derived signals, including IL-7 and IL-15, regulate the 
recruitment, the maturation and even the function of intraepithelial lymphocytes (IELs) (Figure 
7B). IELs are a specific subset of T cells, which are localized between IECs, establishing 
intimate contact with those cells, and whose development and function are not fully clarified 
[1, 5].  
Moreover, it is known that IECs can still regulate innate lymphoid cells (ILCs). ILCs are a 
recently identified population of innate immune cells present in the intestine, which revealed to 
be important to the maintenance of intestinal homeostasis, but whose involvement in the 
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development of the inflammatory process is not fully understood [1, 4, 7]. According to their 
developmental requirements and different patterns of cytokine expression, ILCs are divided 
into three groups that present functional similarities with CD4+ Th1, Th2 and Th17 cells [1]. 
However, in spite of being important sources of cytokines, they lack the main features of Th 
immune cells, including recombined antigen-specific receptors [1, 4, 20, 57]. There are some 
examples of the regulation of ILCs by IECs. For instance, it has been described that IEC-derived 
TSLP, IL-25 and IL-33 can stimulate the group 2 of ILCs. However, IL-25 produced by IECs 
is also capable of suppressing the function of the group 1 and 3 of ILCs, by preventing, for 
instance, the production of pro-inflammatory cytokines by intestinal macrophages [1, 7, 20]. 
 
D.2 Immune regulation in Inflammatory Bowel Disease 
A decreased production of TSLP by IECs has been described in CD patients, which makes 
these cells incapable of polarizing DCs into a tolerogenic phenotype [54]. Accordingly, some 
evidence suggests that in IBD patients, DCs promote the differentiation of naïve CD4+ T-cells 
into Th1 and Th17 cells, instead of into Treg cells, promoting an abnormal pro-inflammatory 
response against commensals [11]. Furthermore, some data demonstrate that both intestinal 
DCs and macrophages, present in the lamina propria of IBD patients, produce elevated levels 
of pro-inflammatory cytokines, as compared to cells of healthy individuals, which is also in line 
with the dysregulation of the tolerance against commensals [39, 52]. Also, T cells from IBD 
patients appear to be refractory to TGF-β, which may contribute to the dysregulation of host 
immune responses, and consequently to the perpetuation of chronic intestinal inflammation [7, 
17, 20].  
 
E - Gathering thoughts 
Taking the above observations together, it is possible to infer that, in physiological 
conditions, IECs have an active role in the maintenance of an environment propitious to a 
peaceful interaction with the commensal bacteria, however, they may be also pivotal to the 
breaking down of the normal tolerance towards commensals, resulting in intestinal disease [42, 
47]. This can be understood considering not only the possible impairment in the functions of 
the intestinal epithelium as an anatomical barrier, making it vulnerable to the invasion by 
commensal bacteria and by pathogenic agents, but also in light of the decreased production of 
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tolerogenic mediators and/or increased production of pro-inflammatory mediators, which, all 
together, contribute to the perpetuation of the intestinal inflammation and oxidative stress, 
described in IBD patients [11, 54]. However, although much is known about the interplay 
between commensals and IECs and their contribution to the alteration of IEC function, 
involving, for instance, the increase in the production of mucus and AMPs, knowledge on the 
mechanisms underlying the control of host immune responses by IECs is scarce, being this, 
perhaps, a reason for several authors underappreciate the actual value of IECs in the IBD 
context [5].  
 
2.3 Cellular signalling cascades of great relevance in Intestinal Inflammation 
2.3.1 Nuclear Factor-kB (NF-kB) pathway  
The nuclear factor-kB (NF-kB) is one of the most studied transcription factors, detected in 
both immune and non-immune cells, involved in the regulation of several important 
physiological events, including inflammation, oxidative stress, apoptosis, survival and immune 
responses [61-65].  
In mammals, NF-kB is composed of five different subunits organized into homo and 
heterodimers: p65/RelA, c-Rel and RelB and the precursor proteins p105 and p100, processed 
into p50 and p52, respectively [62]. The most common activated dimer of NF-kB is formed by 
p65 with p50 [66]. In resting cells, NF-kB dimers reside predominantly in the cytoplasm, in an 
inactive form, sequestered by inhibitory proteins of the IkB family, namely IkB-α, IkB-β and 
IkB-ε [64, 66].  
Two different NF-kB-activation pathways have been described, the canonical/classical and 
the alternative/non-classical pathway [61]. However, the classical NF-kB pathway is the most 
frequently observed, being activated by a large number of stimuli, including pro-inflammatory 
cytokines, namely IL-1 and TNF-α, microbial products, such as LPS, and oxidative stress [62, 
64, 66-69]. In general terms, the NF-kB-activators stimuli converge to the activation 
(phosphorylation) of the IkB kinase (IKK) complex, constituted by IKKα/IKK1 and by 
IKKβ/IKK2 as catalytic subunits and by IKKγ/NEMO as the regulatory subunit. Once 
activated, the IKK complex (mainly the IKKβ subunit) phosphorylates IkB-α on 32 and 36 
serine residues, which is then ubiquitinated and degraded via proteasomal degradation, allowing 
the translocation of free NF-kB dimers into the nucleus [64, 66, 70]. Growing evidence suggests 
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that post-translational modifications of NF-kB components are required for the full 
transcriptional activity of NF-kB, namely phosphorylation and acetylation [62, 64, 66]. 
Activated NF-kB binds to DNA kB sites and regulates the expression of several genes, such as 
genes encoding pro-inflammatory enzymes (inducible nitric oxide synthase, iNOS; 
cyclooxygenase-2, COX-2) and pro-inflammatory cytokines or chemokines (IL-1, TNF-α, 
IL-8, IL-6, IL-12) which, in turn, may lead to the recruitment of immune cells, with the 
subsequent production of further pro-inflammatory mediators, perpetuating the inflammatory 
response and leading ultimately to intestinal injury (Figure 8) [65-68].  
 
 
Figure 8 - Schematic representation showing that NF-kB activation promotes the transcription of 
pro-inflammatory genes and maintains active intestinal inflammation (adapted from [63]). 
 
In fact, although NF-kB pathway is truly important to maintain the intestinal homeostasis 
(as already referred in previous sections), chronic hyper-activation of this pathway contributes 
to chronic intestinal inflammation and therefore to IBD pathogenesis [12, 61, 65, 71]. 
Consistently, some reports demonstrate that NF-kB is highly activated in IECs and also in 
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macrophages isolated from the inflamed mucosa of patients with IBD [63, 66, 72-74]. Also, 
evidence shows that NF-kB up-regulation can be closely related to the severity of intestinal 
inflammation [73]. For this reason, the inhibition of this potent pro-inflammatory signalling 
cascade has been widely investigated to control inflammatory diseases, as IBD, with successful 
results already verified in several animal models [63, 66, 73]. Furthermore, some drugs 
currently used for the treatment of IBD patients, such as anti-TNF-α monoclonal antibodies and 
corticosteroids, are able to inhibit NF-kB pathway, further supporting the relevance of this 
pathway in the context of intestinal inflammation [66, 73].  
 
2.3.2 Janus Kinase/Signal Transducer and Activator of Transcription 
(JAK/STAT) pathway 
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling 
pathway is another relevant signalling cascade in the IBD context, playing an important role in 
several cellular processes, namely cell growth, differentiation, proliferation, apoptosis and 
inflammation [75, 76].  
In mammals, there are four types of JAKs, (JAK1, JAK2, JAK3 and TYK2) and seven types 
of STATs (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6), which can form 
homo or heterodimers [77]. The major activators of JAK/STAT pathway are cytokines, mainly 
interferons and interleukins, and growth factors [75, 78]. Given the crucial role of IFN-γ in the 
pathogenesis of IBD [79] and the recognition that IFN-γ biological responses are primarily 
mediated by JAK/STAT pathway [80], the involvement of this signalling cascade has been 
investigated in the context of IBD.  
It is known that the binding of IFN-γ to its cell-surface receptor (IFN-γ receptor, IFNGR) 
leads to the activation of JAK1 and JAK2 through auto- and/or trans-phosphorylation [81]. 
Activated JAKs phosphorylate IFNGR, providing a docking-site for the recruitment of STAT1 
[78, 81, 82]. JAKs also have the ability to phosphorylate STAT1 on its tyrosine (Tyr) residue, 
at position 701, which makes STAT1 ready to homodimerize and to translocate into the nucleus. 
There, it binds to specific DNA consensus sequences to initiate the transcription of 
STAT-responsive genes, such as genes encoding pro-inflammatory enzymes (e.g. iNOS), 
pro-oxidant enzymes (e.g. NADPH oxidase 1) and chemokines (e.g. CXCL9, CXCL10 and 
CXCL11) (Figure 9) [82-88].  
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Figure 9 - Schematic picture illustrating the activation of JAK/STAT pathway and the subsequent enhancement 
of the transcription of pro-inflammatory genes (modified from [78]). 
 
Accumulating evidence suggests that STAT1 phosphorylation on its serine residue, at 
position 727, is mandatory to the maximization of its transcriptional potency [88, 89]. This 
phosphorylation can be carried out by several serine kinases, such as MAPKs [87, 89].   
It is important to bear in mind that the regulation of the biological actions of STAT proteins 
is also dependent on negative regulators [78]. For instance, suppressors of cytokine signalling 
(SOCs) proteins can block the recruitment of STATs by binding to IFNGR or JAKs’ sites or 
even by targeting STATs for proteasomal degradation [76, 89]. Phosphatases, including SHP1 
or SHP2, are another type of negative regulators of JAK/STAT pathway that can induce the 
dephosphorylation of JAKs and STATs, leading then to the inactivation of these proteins [75, 
78, 88, 89]. More recently, another group of proteins called PIAS (protein inhibitors of activated 
STAT) have been investigated. PIAS constitute a family of proteins implicated in the inhibition 
of STAT-mediated gene activation through many mechanisms, namely inhibiting DNA binding 
and promoting the conjugation of small ubiquitin-like modifier (SUMO) proteins to STAT1 
[76, 89, 90]. SUMOylation is a post-transcriptional modification that, in the case of STAT1, 
seems to negatively regulate STAT1-mediated genes responses, since it inhibits STAT1 Tyr701 
phosphorylation, prevents STAT1 DNA binding and also promotes its dephosphorylation 
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[91-93]. 
Taken into account the above observations, it is possible to deduce that beyond NF-kB 
pathway, the modulation of JAK/STAT pathway, particularly of IFN-γ/STAT1 pathway, should 
be valued in the scope of IBD. In fact, beyond its contribution to the transcription of several 
pro-inflammatory and pro-oxidant genes, as already mentioned, this signalling cascade can also 
be involved in the acquisition of radiation resistance by patients, during radiotherapy treatment 
[94]. Given that IBD patients exhibit a high risk of developing colorectal cancer as compared 
to healthy population [95], the use of anti-inflammatory compounds with the potential to inhibit 
this pathway can be of redoubled interest for IBD patients. In the last years, in vitro and in vivo 
studies concerning the inhibition of JAK/STAT pathway, particularly of STAT1 and STAT3, 
have led to encouraging outcomes towards the amelioration of inflammation, namely in the 
colon [82, 83, 96-98]. Actually, a selective inhibitor of JAK1 is presently in development for 
the treatment of some inflammatory disorders, such as rheumatoid arthritis and CD [77]. This 
drug, Filgotinib (GPLG0634), is currently in phase II clinical trials for the treatment of CD, 
with favourable results already achieved in preclinical models for IBD [99].  
 
2.3.3 Mitogen-Activated Protein Kinase (MAPK) pathway 
Mitogen-activated protein kinases (MAPKs) are a group of evolutionary conserved 
serine/threonine kinases which coordinate several cellular activities, including cell 
proliferation, differentiation, survival and inflammation [100, 101]. The major subgroups of 
MAPKs are the extracellular signal-regulated kinases 1 and 2 (ERK 1/2), the c-Jun N-terminal 
kinases (JNKs) and the p38 kinases [102]. Although MAPKs are activated by different stimuli, 
ERK 1/2 are preferentially activated by growth factors and JNK and p38 MAPKs are specially 
responsive to environmental stress, such as osmotic shock, and to cytokines, such as TNF-α 
[64, 102]. The activation of each MAPK requires the prior operation of two sequential kinases: 
the MAPK kinase (MAPKK) and the MAPKK kinase (MAPKKK). MAPKKKs are 
serine/threonine kinases which phosphorylate (activate) MAPKKs, which in turn activate the 
MAPKs by dual phosphorylation on threonine and tyrosine residues [102]. MAPKs can be 
inactivated by phosphatases, such as dual-specificity phosphatases (DUSPs), threonine 
phosphatases and tyrosine phosphatases [103-105].  
Given that both JNK and p38 MAPKs show to be highly activated in inflamed tissue of IBD 
patients, it is widely accepted that signal transduction pathways involving those enzymes are 
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implicated in this chronic intestinal inflammatory disease [104, 106, 107]. In fact, it is known 
their involvement in the modulation of the transcription activity of several pro-inflammatory 
transcription factors, such as NF-kB and STAT1, through phosphorylation [102, 108, 109].  In 
addition, particularly p38 MAPKs may also be involved in the post-transcriptional regulation 
of several important inflammatory genes, stabilizing, for instance, COX-2, iNOS and TNF-α 
mRNAs and promoting their translation [100, 103, 110]. Therefore, in the last years, there has 
been a considerable interest in the development of anti-JNK and anti-p38 therapies against 
intestinal inflammation [104-106]. Towards this goal, several studies have been carried out both 
in animal models and in humans [103, 104, 106, 111, 112]. However, the serious adverse effects 
reported in some clinical studies limited the application of some of these MAPK inhibitors 
[105]. More recently, some novel molecules have been tested in patients with IBD, such as 
Delmitide (RDP58) - an inhibitor of p38 and JNK, leading to significantly higher remission 
rates than that achieved with placebo and causing no serious adverse effects, which offers hope 
for the future use of these drugs in the IBD context [113]. 
 
2.3.4 Nuclear Factor-Erythroid-2-Related Factor 2 (Nrf2) pathway  
Nuclear factor-erythroid-2-related factor 2 (Nrf2) pathway has emerged as a key regulator 
of cellular antioxidant and detoxifying defences against oxidative insult [114]. 
Under basal conditions, Nrf2 is sequestered in the cytoplasm, bound to the inhibitory protein 
Kelch-like ECH-associated protein 1 (Keap1), which has the ability to target Nrf2 for 
ubiquitination followed by proteasomal degradation [115]. The release of Nrf2 from Keap1 is 
neither fully understood nor consensual, but it is thought that dissociation of the transcription 
factor Nrf2 from its repressor occurs after alterations in the structure of Keap1 triggered by 
pro-oxidants or electrophiles (Figure 10A) or after phosphorylation of serine and/or threonine 
residues of Nrf2 by specific upstream kinases, namely MAPKs (Figure 10B) [114, 115]. Once 
free, Nrf2 is able to translocate to the nucleus to heterodimerize with other proteins, namely 
small Maf proteins, and to bind to antioxidant response elements (ARE), also called electrophile 
response elements (EpRE), in enhancer sites of responsive genes, promoting the expression of 
several important antioxidant and cytoprotective enzymes, such as hemoxygenase-1 (HO-1), 
glutamate cysteine ligase (GCL) and NAD(P)H:quinone oxidoreductase-1 (NQO1) [115, 116].  
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Figure 10 - Schematic drawing representing two possible mechanisms underlying the activation of Nrf2 pathway. 
A) Pro-oxidants or electrophiles induce the dissociation of Nrf2 from its repressor (Keap1) by producing specific 
alterations in the structure of Keap1. B) Upstream kinases, namely MAP Kinases, favour the dissociation of Nrf2 
from Keap1 after phosphorylation of serine and/or threonine residues of Nrf2 (adapted from [115]). 
 
 
Beyond the antioxidant protection afforded by Nrf2 activation, this transcription factor has 
demonstrated to be crucial in the suppression of the inflammatory process, among other 
mechanisms, by counteracting some pro-inflammatory cascades, as NF-kB pathway [116]. In 
line with this, accelerating research has shown that Nrf2-deficient mice have a heightened 
susceptibility to dextran sulfate sodium (DSS)-induced colitis [116, 117] and, for all of these 
reasons, Nrf2 pathway has gained increasing attention in the context of intestinal inflammation. 
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2.3.5 Peroxisome Proliferator-Activated Receptor gamma (PPAR-γ) pathway  
Peroxisome proliferator-activated receptors (PPARs) are members of a family of nuclear 
receptors, which are ligand-dependent transcription factors, involved in many biological 
processes, such as lipid metabolism, inflammation, and cell proliferation [118, 119]. Until now, 
three subtypes of PPARs were already found: PPAR-α, PPAR-δ/β and PPAR-γ [120, 121]. 
Since the recent findings that PPAR-γ subtype is highly expressed in colonic epithelial cells 
and in some intestinal immune cells, such as macrophages, being important for the maintenance 
of the intestinal homeostasis and the prevention of experimentally-induced colonic 
inflammatory injuries, this receptor has received considerable attention in the IBD context [118, 
119]. Also, the latest relevant in vitro and in vivo studies, demonstrating that the 
anti-inflammatory effect of 5-aminosalicylic acid (non-steroid anti-inflammatory drug, 
commonly used in IBD patients) is dependent on the activation of PPAR-γ signalling cascade, 
have strengthened the importance of PPAR-γ as a target for IBD treatment [118, 122, 123]. 
In general terms, the induction of the transcriptional activity of PPAR-γ requires at first its 
binding to a specific agonist, then its heterodimerization with the nuclear retinoid X receptor 
(RXR) and further the PPAR/RXR heterodimer binding to sequence-specific regions in DNA, 
called peroxisome proliferator response elements (PPRE) [120]. The description made above 
corresponds to a conventional mechanism by which PPAR-γ positively regulates gene 
expression. However, through a mechanism (ligand-dependent) known as transrepression, 
PPAR-γ is able to negatively regulate gene expression. Transrepression is a complex 
mechanism, still under investigation, by which PPAR-γ antagonize the transcriptional activity 
of several transcription factors, such as NF-kB, STAT1 and AP-1, without interacting with 
PPRE (Figure 11) [120, 121].  
 
 
Figure 11 - Illustration for the mechanism of transrepression in which, in a ligand-dependent manner, PPAR-γ 
can antagonize NF-kB pathway (adapted from [121]). 
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This process has been invoked to explain the role of PPAR-γ against inflammation and also 
against oxidative stress [124, 125]. Transrepression has been explained by several mechanisms, 
including: a) direct protein-protein interaction between PPARs and other transcription factors, 
preventing the binding of the latter to sequence-specific regions in DNA; b) inhibition of the 
activity of upstream kinases, which modulate the activation of some transcription factors; c) 
competition for co-activator proteins that are required for the transcriptional activation of many 
transcription factors; d) prevention of the dissociation of co-repressors complexes from 
promoters, sustaining genes in a repressed state [120, 121, 126].  
Therefore, it seems reasonable the demand to discover natural and synthetic ligands of 
PPAR-γ in order to limit IBD progression [118].  
 
2.4 Oxidative stress and Inflammatory Bowel Disease 
Reactive oxygen/nitrogen species (ROS/RNS) are highly reactive oxygen/nitrogen-derived 
small-molecules, constantly produced during physiological aerobic metabolism in mammalian 
cells, which, at low and moderate concentrations, may function as signalling molecules 
involved, for instance, in defence against invading pathogens [127, 128]. However, an excessive 
generation of ROS/RNS, not efficiently counteracted by an appropriate antioxidant defence 
system, leads to oxidative/nitrosative injury of the cells and tissues [127, 128]. 
Oxidative/nitrosative stress can be truly detrimental to cellular homeostasis, since it may sustain 
chronic inflammation and be responsible for lipid and protein modifications, DNA damage and 
apoptosis [128, 129]. 
 
2.4.1 Some relevant reactive oxygen/nitrogen species produced in the intestine 
A - Reactive oxygen species (ROS) 
Mitochondrial respiratory chain is the major source of ROS in mammalian cells [127]. 
During the oxidative phosphorylation, a small amount of molecular oxygen (O2), instead of 
being fully reduced to water, generates the superoxide anion (O2● -) resulting from the transfer 
of one sole electron to molecular oxygen [128]. In cells, superoxide anion is efficiently 
converted to hydrogen peroxide (H2O2) by superoxide dismutase [127, 130]. 
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In physiological conditions, hydrogen peroxide is, then, converted to water by catalase or 
glutathione peroxidase [128]. Hydrogen peroxide that escapes from enzymatic degradation can 
be further reduced to the highly reactive hydroxyl radical (HO●), in a reaction catalysed by 
ferrous ion or by other transition metals, such as copper, chromium or cobalt (Fenton reaction) 
(Figure 12) [128]. The iron-catalysed Haber-Weiss reaction constitutes an important process 
through which hydroxyl radical is generated in biological systems, where the superoxide anion 
reduces the oxidized metal, released by the Fenton reaction, driving a reaction cycle [128].  
 
 
It has been suggested that hydroxyl radical can be extremely harmful for the intestine, 
leading to the depolymerisation of mucin, peroxidation of lipids, oxidation of proteins and 
damage of mitochondrial RNA and DNA [128, 131]. 
Apart from mitochondria, NADPH oxidase (NOX) family is another crucial source of 
superoxide anion in cells [128]. NADPH oxidase is an enzymatic complex present in multiple 
cell-types, including in IECs and in phagocytes, such as neutrophils and macrophages, which  
catalyses electron transfer from NADPH to molecular oxygen, with the subsequently release of 
large amounts of superoxide anion. Phagocytes, such as macrophages, can degrade invading 
infectious agents by a process that involves the generation of superoxide anion, as well as other 
ROS, known as respiratory burst [127]. Some studies have suggested that intestinal 
macrophages from patients with CD have an augmented oxidative burst activity when compared 
with macrophages from healthy patients, and neutrophils from IBD patients are also able to 
generate higher amounts of superoxide anion than cells from healthy patients [131].  
Furthermore, superoxide anion can also be generated by other enzymatic systems, such as 
xanthine oxidase and cyclooxygenase [127].   
Figure 12 - Reaction cycle illustrating hydroxyl radical generation from superoxide anion and hydrogen 
peroxide (Haber-Weiss reaction). 
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B - Reactive nitrogen species (RNS)  
Nitric oxide (NO) is a free radical produced enzymatically by a family of enzymes called 
nitric oxide synthases (NOSs) [132]. All these enzymes catalyse the oxidation of L-arginine, 
leading to the production of L-citrulline and to the formation of nitric oxide (Figure 13) [127, 
128, 132].  
 
 
Until now, three isoforms of NOSs were identified: the neuronal (nNOS) and the endothelial 
(eNOS), which are both constitutively expressed, and the inducible NOS (iNOS), whose 
expression is induced by some cytokines or bacterial products [127, 132].  
As previously referred in points 2.3.1 and 2.3.2, several important transcription factors, 
namely NF-kB and STAT1, can promote, upon activation, the expression of iNOS in IECs. It is 
known that both the activation of NF-kB and the expression of iNOS are abnormally 
up-regulated in inflamed tissues of IBD patients [12, 131, 132]. Consistently, NO is 
continuously overproduced in these patients [131]. Noteworthy, moderate levels of NO seem 
to be crucial to maintain intestinal homeostasis, due to its ability to ensure a proper control of 
the blood flow and to regulate the epithelial permeability and the mucus production, among 
other mechanisms. In contrast, an excessive production of NO sustained for long periods of 
time, via up-regulation of iNOS, appears to contribute to the initiation and to the maintenance 
of intestinal inflammation, a condition observed in IBD patients and explained, for example, by 
its direct cytotoxicity or by the increase in the production of nitrosamines [127, 128, 132]. In 
Figure 13 - Reactions of nitric oxide production and downstream reactive species generation. 
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fact, NO is a free radical with a weak reactivity but that can react with superoxide anion to 
produce peroxynitrite anion (ONOO-), which is a powerful cytotoxic oxidant capable of causing 
DNA fragmentation and lipid oxidation [127, 132]. Some studies show that the direct 
administration of peroxynitrite to colonic tissue is able to induce colitis in mice [127, 132]. 
Furthermore, as illustrated in Figure 13, peroxynitrite can become protonated and give rise to 
other free radicals, the nitric dioxide radical (NO2●) and the hydroxyl radical (OH●). On the 
other hand, instead of reacting to superoxide anion, NO can interact with molecular oxygen and 
generates nitrite (NO2-) and nitrate (NO3-) ions (Figure 13), which, in turn, can give rise to 
highly reactive species, such as dinitrogen trioxide (N2O3) [127]. This molecule is a potent 
nitrosating agent able to N-nitrosate multiple molecules and to produce carcinogenic 
nitrosamines [132]. 
 
2.4.2 Antioxidant defence system  
Due to the constant production of reactive species in the body, it is important that the 
antioxidant defence system is able to counterbalance this production in order to prevent the 
oxidative/nitrosative injury of the cells and tissues [131]. The antioxidant defence system can 
be organized in two main categories: the enzymatic antioxidants, including superoxide 
dismutases (SODs), catalase (CAT), glutathione peroxidase (GPX) and hemoxygenase (HO), 
and the non-enzymatic antioxidants, namely glutathione (GSH) and thioredoxin (TRX) [127, 
130].  
It has been suggested that patients with IBD have an inefficient antioxidant defence system, 
which make them more vulnerable to the effect of the overload of reactive species produced in 
the intestine, mainly during the active phases of this disease [12, 15, 131, 133]. For instance, 
pivotal studies conducted by Kruidenier et al [134, 135] pointed to an increase in the expression 
of mitochondrial manganese (Mn)-SOD, a SOD isoform, at the inflamed epithelium of patients 
with CD or UC, which was not accompanied by a parallel increase in CAT and/or GPX levels. 
As previously referred, SODs are crucial antioxidant enzymes that convert superoxide anion 
into hydrogen peroxide, which, in turn, is further neutralized to water by CAT or GPX [127]. 
In physiological conditions, it is of paramount importance that the formation of hydrogen 
peroxide does not exceed its removal and, therefore, the activity of those antioxidant enzymes 
needs to be strictly coordinated. In this context, the reported increase in the expression of 
Mn-SOD not accompanied by a subsequent increase in the expression of CAT and/or GPX, 
Chapter 1 - General Introduction 
32 
suggesting a deficient removal of hydrogen peroxide and a possible increase in hydroxyl radical 
levels (through Fenton reaction), should contribute to the oxidative damage observed in the 
intestine of IBD patients [134, 135].  
On the other hand, it has also been suggested that levels of GSH are reduced in the intestine 
of IBD patients, which can have a great impact on both enzymatic and non-enzymatic 
antioxidant defences, rendering hence intestinal cells more susceptible to oxidative injury [12, 
131]. 
 
2.5 Chronic inflammation, oxidative stress and Inflammatory Bowel Disease 
– gathering loose ends 
Although the etiology of IBD is not fully understood, it is known that an exacerbated and 
uncontrolled inflammatory response to bacteria that normally inhabit in the gastrointestinal tract 
is triggered in a genetically susceptible individual [12, 131]. It is also known that the 
overproduction of pro-inflammatory mediators, namely cytokines and chemokines, allied to the 
excessive generation of ROS/RNS by IECs and by immune cells, is not efficiently 
counterbalanced by the anti-inflammatory and antioxidant mechanisms that normally ensure 
the recovery of intestinal homeostasis in physiological situations, which explains the 
perpetuation of intestinal inflammation and oxidative stress, verified in IBD patients [12, 15, 
131, 136]. In line with this, growing evidence suggests that inflammation and oxidative stress 
play a crucial role in the etiology and in the progression of IBD (Figure 14) [12, 15, 127, 128, 
133].  
 
 
Figure 14 - Picture representing the intricate relationship between inflammation and oxidative stress and their 
contribution to the development of IBD (adapted from [15]). 
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At the cellular level, there are several examples that illustrate the intertwined relationship 
between chronic inflammation and oxidative stress, in a mechanistic perspective. Although this 
matter is still under intense investigation, it is thought that oxidative stress can keep active the 
inflammatory response by inducing an important pro-inflammatory redox-sensitive 
transcription factor, the NF-kB [137]. On the other hand, NF-kB, itself, can lead to the 
generation of further amounts of ROS/RNS, contributing to the maintenance of this vicious 
cycle, that, in turn, eventually results in serious damage to the intestinal barrier [12].  
 
2.6 Conventional pharmacological approaches: a still unsolved issue 
Until the present, IBD does not have cure and the pharmacological treatment is mainly used 
to prevent relapses, to induce or maintain the remission periods, to treat intestinal or 
extra-intestinal complications and to improve the quality of life of the patients [12, 138, 139].  
In fact, as illustrated in the therapeutic pyramid below (Figure 15), the drugs conventionally 
prescribed for the treatment of IBD can be divided in several groups, including: 
aminosalicylates, corticosteroids, immunomodulators and biologic agents [140]. 
 
 
 
Figure 15 - Therapeutic pyramid of the drugs conventionally prescribed for the treatment of IBD patients. 5-ASA, 
5-aminosalicylic acid; AZA, azathioprine; 6-MP, 6-mercaptopurine; MTX, methotrexate (adapted from [141]). 
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2.6.1 Aminosalicylates  
Sulfasalazine was the first aminosalicylate used in IBD and it is formed by the combination 
of 5-aminosalicylic acid (the active moiety) to sulfapyridine, linked by an azo bond, functioning 
as a prodrug [138]. The sulfapyridine group is used as a carrier of the 5-aminosalicylic acid 
(5-ASA), delivering it in the colon, after cleavage of the azo bond by the colonic bacterial 
azoreductase, thus avoiding an early absorption of the active compound in the upper regions of 
gastrointestinal tract [138, 142]. However, the existence of the sulfapyridine group makes 
sulfasalazine poorly tolerated by many patients and so, it was excluded from the novel 
formulations of 5-ASA [138, 143]. In the last years, there has been a great effort in developing 
increasingly sophisticated oral-5-ASA delivery systems, which have been designed in order to 
delay and/or sustain the release of 5-ASA in specific inflamed regions of the gastrointestinal 
tract [144]. Furthermore, there are also rectal formulations of 5-ASA, which can also be 
important to manage intestinal inflammation, often combined with oral forms [95, 143].  
5-ASA is envisaged as a “topical agent”, acting locally in the gastrointestinal tract [95, 142]. 
Accordingly a recent review by Williams et al [95], the clinical effectiveness of 5-ASA depends 
mostly on the mucosal concentration achieved in the gastrointestinal tract rather than on the 
systemic absorption and on the subsequent redistribution of the drug to the gastrointestinal tract. 
To date, the action mechanisms underlying the clinical efficacy of 5-ASA remain not fully 
understood. Growing data suggest that 5-ASA is able to inhibit the production of 
pro-inflammatory mediators, such as NO and PGE2, and the expression of pro-inflammatory 
enzymes, including iNOS and COX-2. These effects are generally correlated to the ability of 
5-ASA to inhibit NF-kB signalling pathway [123]. On the other hand, since it was found that 
5-ASA is an agonist of PPAR-γ, attention has been paid to the possible involvement of this 
receptor in the anti-inflammatory activity of 5-ASA [123, 139]. The antioxidant activity of 
5-ASA in in vitro studies as well as clinical evidences supporting its radical scavenger ability 
have also been reported, suggesting that this action mechanism can contribute to attenuate 
intestinal inflammation [145, 146]. 
In our days, 5-ASA is considered the first-line therapy for the treatment of mild to moderate 
UC (which accounts for 90% of patients with UC, at first presentation), and for the maintenance 
of the remission periods in these patients [142]. In the case of CD patients, the beneficial effects 
of 5-ASA can be limited. However, although the use of 5-ASA in CD patients is not consensual, 
it is still widely used in clinical practice [8, 95, 138, 140].  
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Concerning potential side effects of 5-ASA, it is known that this drug is often well-tolerated 
but it is not free of adverse effects, diarrhoea, nauseas, dyspepsia, skin rashes and headache 
being the most common [138, 143]. Furthermore, nephrotoxicity may occur sometimes and, for 
this reason, the renal function of the patients receiving this drug should be closely monitored 
[95, 138]. 
 
2.6.2 Other pharmacological options for Inflammatory Bowel Disease treatment  
Beyond aminosalicylates, there are other alternative drugs used in the treatment of IBD. As 
depicted in Figure 15, the treatment of IBD involves, normally, a “step-up approach”, which 
means that the most aggressive therapies are only selected when the softer therapies fail or are 
not sufficiently effective for the degree of severity of the disease [138, 147]. Therefore, the first 
pharmacological option for IBD patients is usually aminosalicylates, and for this reason they 
are positioned at the base of the pyramid represented in Figure 15 [8, 147]. However, if patients 
do not respond to aminosalicylates, the next therapeutic option often consists of using 
corticosteroids [8, 147]. Corticosteroids are a group of potent anti-inflammatory compounds 
used mainly for moderate to severe acute flares in IBD patients [148]. Steroids can be 
administered orally, rectally or intravenously [148]. Due to their typical adverse effects, their 
use must be avoided for long-periods and so they are not recommended to maintain the 
remission periods in patients with IBD [138]. The usual adverse effects of steroids include 
osteoporosis, Cushing syndrome and susceptibility to infection [148]. When corticosteroids fail 
or are not adequate, the next approach is usually the administration of immunomodulators, such 
as azathioprine and 6-marcaptopurine [147]. These drugs can be particularly useful in specific 
cases, such as to maintain the remission in IBD patients not responding to aminosalicylates or 
intolerant to them [147]. However, it is estimated that up to 20% of patients has to stop this 
therapy because of the harmful side effects, namely severe gastrointestinal symptoms, 
hepatotoxicity and pancreatitis [140].  
Infliximab and adalimumab are some of the anti-TNF-α monoclonal antibodies, which 
belong to the group of biologic agents used, nowadays, as a powerful pharmacological option 
in IBD, particularly in patients with moderate to severe CD, who are refractory, have 
contraindications or poor tolerance to all other pharmaceutical drugs and in patients with severe 
UC not responding to any other drugs [140]. The most serious and common adverse effects of 
these therapeutics are opportunistic infections, malignancies and autoimmunity [140].   
Despite all the therapeutic weapons currently available for the management of IBD, the 
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results achieved are clearly unsatisfactory, since many patients often become refractory or 
intolerant to the therapy and both long-term side effects and the necessity of surgery become 
almost inevitable [12].  
In this way, it is still urgent to find preventive strategies and better targeted therapies 
effective in limiting IBD progression. 
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3. Polyphenols and their benefits in health promotion and disease 
prevention 
Polyphenols are a wide group of plant secondary metabolites, which contribute to plant 
pigmentation, growth, pollination and resistance against environmental stress, pathogens and 
predators [68, 149-151].  
Concerning their chemical structure, polyphenols are generically characterized by the 
presence of one or more hydroxyl groups linked to a benzene ring and can be classified as 
flavonoids and nonflavonoids, as illustrated in Figure 16 [149, 150, 152]. Flavonoids are a 
group of polyphenolic compounds with a common structure (two benzene rings linked through 
a linear three-carbon chain, forming an oxygenated heterocycle, C6-C3-C6) and can be 
subdivided into several subgroups, including flavones, flavonols, flavan-3-ols, isoflavones, 
flavanones and anthocyanidins [149, 150]. The nonflavonoids group includes structurally 
different compounds, such as phenolic acids (C6-C1), lignans (C6-C3-C3-C6) and stilbenes 
(C6-C2-C6) [153]. 
 
 
Figure 16 - Schematic picture representing the classification of polyphenols in two groups, flavonoids and 
nonflavonoids, and their respective subgroups. 
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In nature, polyphenols are commonly linked to sugars, such as glucose or rhamnose, through 
one or more hydroxyl groups, being generally referred to as glycosylated compounds [151, 
154]. When not attached to sugars, polyphenols are referred to as being in their aglycone form 
[151].  
Until now, more than 8000 polyphenols have been identified [68, 152]. It is known that these 
compounds are highly present in human diet, through the consumption of fruits, vegetables, 
cereals and beverages, such as tea, coffee and wine [152, 155]. Red-wine, for instance, is one 
of the most rich sources of polyphenols, being very appreciated in Western Societies and taking 
part of the Mediterranean diet, which was recently recognized by The United Nations 
Educational, Scientific and Cultural Organization (UNESCO) as an intangible cultural heritage 
of humanity [130, 156, 157].  
In the last decades, a flourishing research field has been focused on the study of the positive 
effects of several dietary polyphenols in the prevention and treatment of multiple chronic 
inflammatory disorders, such as cardiovascular disease, type II diabetes, obesity, arthritis and 
IBD [130, 149, 154, 158]. Although the beneficial effects of polyphenolic compounds had been 
initially attributed almost exclusively to their antioxidant capacity, increasing evidence has 
currently proven that such beneficial effects are strongly supported by the ability of dietary 
polyphenols to interfere with essential signalling pathways and with gene regulation [149, 154, 
158]. However, the interactions established between polyphenols and cellular targets and the 
precise signalling pathways underlying polyphenol effects are far from being fully elucidated. 
It is known that the structural characteristics of polyphenols are crucial to determine their 
ability to be adsorbed and to penetrate into the lipid bilayer of the cells. Furthermore, even if 
they are not internalized, it is also known that polyphenols can still modulate the activity of 
membrane-associated enzymes and to regulate the transduction of signals, thanks to 
modifications of the plasma membrane structure and physical properties, namely fluidity and 
electrical properties, among other mechanisms [149]. Actually, very recent studies have shown 
that some polyphenols, such as resveratrol, cyanidin-3-glucoside and epigallocatechingallate 
(ECGG), can interact with specialized domains of cell membranes, known as lipid rafts, which 
are characterized by possessing a specific lipid composition, enriched in sphingomyelin and 
cholesterol, and by containing proteins related to the membrane signalling and trafficking [149, 
159, 160]. Thus, some studies suggest that the interaction of resveratrol with lipid rafts is 
implicated in the activation of downstream signalling pathways, leading to the cell death of 
several cancer cells [160], whereas the disruption of lipid rafts provoked by 
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cyanidin-3-glucoside appears to be crucial for the suppression of inflammation in macrophages 
[159].  
Apart from the interaction of polyphenols with membranes, polyphenols can also interact 
specifically with enzymes, receptors and transcription factors, depending on their chemical 
features, thus addressing multiple biological targets, which could be potentially advantageous 
for disease prevention or treatment [149]. This is illustrated by some polyphenols, such as 
flavanols, which can apparently inhibit NF-kB activation in certain in vitro models, by direct 
interaction with NF-kB proteins, preventing their binding to DNA kB sites [149]. Given the 
great involvement of NF-kB pathway in the development of IBD, the inhibition of this pathway 
by dietary polyphenols is considered a promising strategy for the prevention of IBD 
progression.  
Although the low oral bioavailability of the majority of polyphenols can constitute a great 
handicap for its use in the context of many pathologies [161], in the particular case of intestinal 
diseases, including IBD, the poor oral bioavailability achieved is not, paradoxically, a true 
problem, since several studies claim that the intestine is the organ where dietary polyphenols 
achieve the highest concentrations in the human body, approximately up to several hundred µM 
[68, 156, 161]. 
Given the great diversity of dietary polyphenols, the present Thesis is focused on two 
important subgroups of polyphenolic compounds typically present in the Mediterranean diet: 
the anthocyanidins, which belong to the large group of flavonoids, and the stilbenes, which 
belong to the group of nonflavonoids. Although there are approximately seventeen 
anthocyanidins in the nature, cyanidin, delphinidin, malvidin, pelargonidin, peonidin and 
petunidin are the most relevant for the human diet, and among them, cyanidin is the 
anthocyanidin most commonly found in foods [155, 162]. In nature, these compounds normally 
occur in their glycosylated form, termed anthocyanin, rather than in their aglycone form, 
referred as anthocyanidin, since they are generally associated with sugars, such as glucose, 
galactose, rhamnose, arabinose and xylose, forming mono-, di- or trisaccharides [154, 
162-164].  
Anthocyanins (anthos, in Greek, means flower and kyanos means blue) are water-soluble 
plant pigments responsible for the blue, purple and red colours of many fruits, such as 
blueberries, blackberries, raspberries, strawberries and red grapes (Figure 17) [162, 163, 165]. 
Anthocyanins are therefore present in fruit-derived beverages, such as red-wine. It has been 
demonstrated that wine contains about 200-350 mg anthocyanins per liter [155].  
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Figure 17 - Chemical structure of anthocyanins. 
 
Chemically, anthocyanins are glycosylated, polyhydroxy or polymethoxy derivative forms 
of 2-phenylbenzopyrylium, with two benzoyl rings and a heterocyclic ring in the middle, being 
considered really unique flavonoids, since they can assume different chemical structures in 
aqueous solution, according to the pH and temperature [165]. It is known that the red flavylium 
cation is the most abundant form at very acidic pH (pH < 2) and, with the increase of pH, there 
is a rapid structural re-arrangement of its structure thanks to the loss of a proton, leading to the 
appearance of the blue quinonoidal form. However, the flavylium cation also undergoes a slow 
hydration step, yielding the uncoloured hemiketal form, which, in turn, further tautomerises to 
a chalcone (cis and trans forms) [165]. These re-arrangements of the anthocyanins’ structure 
should not be undervalued, since during the passage in the human gastrointestinal tract, the pH 
undergoes large variations and consequently the chemical forms will possibly vary as well as 
their bioactive properties [165].  
In what concerns stilbenes, the commonest compound of this group is resveratrol. 
Resveratrol is predominantly found in the skin of red grapes, in some berries and peanuts [154]. 
Moreover, red-wine, rather than white-wine, contains significant amounts of this compound. 
Chemically, resveratrol is composed of two aromatic rings joined by an ethylene bridge (Figure 
18) [166]. Although resveratrol can exist in either trans or cis form, the preferred steric form of 
this compound is the trans form [158]. Resveratrol can also exist in aglycone or in glycosylated 
form [149].  
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Figure 18 - Chemical structure of trans-resveratrol (aglycone form). 
 
In the last decades, either anthocyanins or resveratrol have been the focus of intensive 
research mainly in the context of the prevention of oxidative stress-associated diseases, such as 
atherosclerosis and diabetes, not only due to their antioxidant capacity but also due to their 
anti-inflammatory activity [167-169]. In fact, recent studies underscore their capacity as 
inhibitors of inflammation-related transcriptions factors, particularly of NF-kB, and of 
inflammatory markers, namely iNOS, COX-2 and cytokines [162, 168, 170, 171]. Therefore, 
interest has been raised in using polyphenols as promising nutraceuticals, capable of giving 
complementary benefits for the prevention and/or treatment of chronic inflammatory diseases, 
as the case of IBD [154]. 
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4. Objectives 
Given that, until now, Inflammatory Bowel Disease (IBD) does not have cure and the 
currently available pharmacological options are long-life treatments, which often bring severe 
adverse effects, it remains quite urgent to find safer and better targeted strategies efficient to 
limit IBD progression. On the other hand, dietary polyphenols are a group of compounds of 
natural origin with great abundance in fruits, vegetables, green tea and red-wine, which have 
been the focus of intensive research in the context of the prevention of several chronic 
inflammatory diseases, but whose cellular mechanisms underlying their claimed beneficial 
effects are not fully clarified. Therefore, the hypothesis from which the work presented in this 
Thesis has emerged is that natural compounds widespread in foods typically present in a 
Mediterranean diet are able to limit IBD progression, at the concentration range predictably 
reached at the intestinal level, with an efficiency similar or superior to a well-established 
therapeutic intervention, commonly prescribed for IBD patients. Therefore, the main goal of 
this work is to assay two structurally different polyphenolic compounds, one flavonoid, the 
anthocyanin cyanidin-3-glucoside (C3G), and one nonflavonoid, the stilbene resveratrol 
(Resv), both present in the Mediterranean diet, to evaluate their effects against inflammation 
and oxidative stress, which typically characterize IBD, as compared to the well-known 
anti-inflammatory drug, 5-aminosalicylic acid (5-ASA), in a human intestinal cell line (HT-29) 
as a model. 
In order to test our hypothesis and to achieve our main goal, we propose to carry out several 
tasks with the following specific objectives: 
1. To assess the ability of cyanidin-3-glucoside to suppress the inflammatory response 
induced by a combination of inflammatory cytokines, in comparison with the drug 
5-aminosalicylic acid, in HT-29 cells. In this context, the ability of C3G to counteract the 
expression of crucial pro-inflammatory mediators or the activation of transcription factors with 
a recognized importance in the development of IBD, such as NF-kB and JAK/STAT pathways, 
was evaluated (Chapter 2). 
2. To extend the previous research to a structurally different polyphenol - the well-known 
resveratrol - in order to elucidate, under a mechanistic perspective, its capacity of inhibiting the 
inflammatory process, at the same experimental conditions used for C3G, in comparison with 
5-aminosalicylic acid. The cell signalling cascades underlying Resv anti-inflammatory effect, 
including JNK and p38 MAPK pathways, beyond those of NF-kB and JAK/STAT, were 
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ascertained (Chapter 3). 
3. To elucidate the implication of Nrf2 and PPAR-γ in the protection afforded by 
cyanidin-3-glucoside and resveratrol against inflammation and oxidative stress, using the same 
in vitro model and making comparison with the drug 5-aminosalicylic acid (Chapter 4).  
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1. Abstract 
The potential use of polyphenols in the prevention and treatment of chronic inflammatory 
diseases has been extensively investigated although the mechanisms involved in cellular 
signalling need to be further elucidated. Cyanidin-3-glucoside is a typical anthocyanin of many 
pigmented fruits and vegetables widespread in human diet. In the present study, the protection 
afforded by cyanidin-3-glucoside against cytokine-triggered inflammatory response was 
evaluated in the human intestinal HT-29 cell line, in comparison with 5-aminosalicylic acid, a 
well-established anti-inflammatory drug, used in inflammatory bowel disease. For this purpose, 
some key inflammatory mediators and inflammatory enzymes were examined. Our data showed 
that cyanidin-3-glucoside reduced cytokine-induced inflammation in intestinal cells, in terms 
of NO, PGE2 and IL-8 production and of iNOS and COX-2 expressions, at a much lower 
concentration than 5-aminosalicylic acid, suggesting a higher anti-inflammatory efficiency. 
Interestingly, cyanidin-3-glucoside and 5-aminosalicylic acid neither prevented IkB-α 
degradation nor the activation of NF-kB, but significantly reduced cytokine-induced levels of 
activated STAT1 accumulated in the cell nucleus. In addition, we established that 
phosphorylated p38 MAPK was not involved in the protective effect of cyanidin-3-glucoside 
or 5-aminosalicylic acid. Taking into account the high concentrations of dietary anthocyanins 
potentially reached in the gastrointestinal tract, cyanidin-3-glucoside may be envisaged as a 
promising nutraceutical giving complementary benefits in the context of inflammatory bowel 
disease.  
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2. Introduction 
Anthocyanins belong to the family of flavonoids and constitute the largest group of water 
soluble pigments in nature, responsible for the blue and purple colours of many fruits and 
vegetables, being consequently widespread in the human diet. Due to their relatively high 
consumption, the impact of anthocyanins on health promotion and disease prevention has been 
extensively investigated in the last decades [1-7]. 
Although there is some controversy regarding bioavailability of polyphenols [8, 9], they can 
reach concentrations up to several hundred micromolar in the gastrointestinal tract [10]. This is 
due in part to their abundance in the diet and also to poor intestinal absorption. 
Recently, it was reported that dietary polyphenols can modulate intestinal inflammatory 
response, an important component of Inflammatory Bowel Disease (IBD) pathogenesis [10, 
11]. IBD is a chronic and relapsing inflammatory disorder of gastrointestinal tract that includes 
Crohn’s disease (CD) and Ulcerative Colitis (UC). In spite of its etiology remains unclear, it is 
believed that its occurrence is related to a genetic susceptibility of the patient to develop an 
exaggerated immune response to one or more promoting factors, probably commensal 
microorganisms present in the intestinal flora [12]. Consequently, an uncontrolled 
inflammation is triggered leading to tissue destruction. 5-Aminosalicylic acid (5-ASA) is a 
well-established drug used in adults, particularly in the treatment of mild to moderate active 
UC or to maintain remission periods of UC. It is known that, in most cases, 5-ASA is rapidly 
and extensively absorbed before reaching the colon [13]. Moreover, 5-ASA is not free of 
adverse effects, although it is usually well tolerated [14]. 
The beneficial effects of polyphenols, including anthocyanins, in humans were initially 
attributed to their antioxidant capacity in the prevention of diseases associated with oxidative 
stress, such as atherosclerosis and diabetes. Lately, some authors pointed out that other action 
mechanisms could be involved in the pharmacological activity of polyphenols, namely by 
interfering with essential signalling pathways and gene regulation [6, 7, 15, 16].  
Abnormal up-regulation of nuclear factor kB (NF-kB) pathway has been observed in IBD 
patients and found closely related to the severity of intestinal inflammation [17]. Activation of 
NF-kB promotes the expression of many pro-inflammatory genes, such as those for iNOS and 
COX-2 [18]. However, beyond NF-kB, other transcription factors must be taken into account, 
such as the signal transducer and activator of transcription 1 (STAT1), whose expression and 
activation are heightened in IBD patients [19]. This factor also regulates the transcription of 
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several inflammation-associated genes, including iNOS and COX-2 [20]. Furthermore, there 
are many kinase pathways involved in the regulation of inflammatory response upstream 
transcription factors, which may also be important to unveil the mechanisms underlying the 
anti-inflammatory effects of polyphenols, namely p38 MAPK pathway. Actually, it has been 
reported that the activity of p38 MAPK is increased in patients suffering from IBD [21]. 
Since increasing evidences support the efficacy of anthocyanins in modulating inflammatory 
response [5, 11], in the present study we attempted to scrutinize the mechanisms underlying 
cell signalling modulation induced by a typical dietary anthocyanin, in particular 
cyanidin-3-glucoside (C3G) -Figure 1A- which is one of the most abundant anthocyanins in 
nature, in the presence of an inflammatory stimulus. Thus, our main goal was to assess the 
protection afforded by C3G against cytokine-triggered inflammatory response in the human 
intestinal HT-29 cell line, used as an intestinal cell model, exploring its ability to counteract the 
expression of crucial pro-inflammatory enzymes and pro-inflammatory mediators, in 
comparison with 5-ASA (Figure 1B).  
Our data evidenced that cell pre-incubation with 25 µM C3G or 500 µM 5-ASA was 
effective in down-regulating the production of NO, PGE2 and IL-8 and the expression of iNOS 
and COX-2 in cytokine-stimulated HT-29 cells. Interestingly, none of the compounds affected 
NF-kB activity. Conversely, they significantly inhibited STAT1 activation by modulating its 
phosphorylation. Since C3G was used in a much lower concentration than 5-ASA, C3G 
revealed a higher anti-inflammatory efficiency. 
 
 
 
 
Figure 1 - Chemical structures of cyanidin-3-glucoside (A) and 5-aminosalicylic acid (B). 
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3. Materials and Methods 
3.1 Reagents 
Cyanidin-3-o-β-glucoside purified from natural sources was obtained from Extrasynthése 
(Genay, France). It had purity above 97% as measured by HPLC and was used as a solution in 
DMSO (5 mM) and stored in the dark, under nitrogen atmosphere, at -80oC. 
Laboratory chemicals namely dimethylsulfoxide (DMSO), sodium dodecyl sulfate (SDS), 
2,3-diaminonaphthalene (DAN), 3-(4,5-dimethylthiazol-2yl)2,5-diphenyl-tetrazolium bromide 
(MTT), phenylmethylsulfonyl fluoride (PMSF), streptomycin/penicillin, protease inhibitor 
cocktail and phosphatase inhibitors were purchased from Sigma-Aldrich Co. 
For cell culture, Dulbecco’s modified Eagle’s medium (DMEM), 0.25% trypsin, fetal bovine 
serum (FBS) and phosphate-buffered saline (PBS) pH 7.4, were obtained from 
Gibco-Invitrogen. 
Rabbit polyclonal antibody to iNOS and goat polyclonal antibody to phospho-STAT1 
(Tyr701) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); rabbit 
polyclonal antibody to COX-2 was purchased from Abcam (Cambridge, UK); rabbit polyclonal 
antibody to IкB-α and rabbit monoclonal antibody to phospho-p38 MAPK (Thr180/Tyr182) 
were purchased from Cell Signalling Technology (MA, USA); mouse monoclonal antibody to 
β-actin was purchased from Sigma-Aldrich Co and anti-rabbit, anti-mouse and anti-goat IgG 
secondary antibodies were obtained from Abcam (Cambridge, UK). 
IL-1α, TNF-α and IFN-γ were purchased from Invitrogen (NY, USA). 
 
3.2 Cell Culture  
Human colon cancer cell line (HT-29) was obtained from European Collection of Cell 
Cultures (Porton Down, Salisbury, UK). Cells were grown in DMEM supplemented with 10% 
FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37ºC in a humidified atmosphere of 
5% CO2. Cells were sub-cultured at confluence and used between the fourth and the twentieth 
passage. Before each experiment, cells at 80% confluence were starved in serum-free medium 
for 24 hours. Growth-arrested cultures, in medium without FBS, were treated according to the 
various experimental purposes. 
HT-29 cells were stimulated with a cocktail of cytokines consisting of 10 ng/ml IL-1α, 20 
ng/ml TNF-α and 60 ng/ml IFN-γ. Each cytokine was previously diluted in PBS with 1% BSA 
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and then added to cells when convenient. Cells were pre-treated with C3G, 5-ASA or both for 
1 hour before exposure to the cytokines and then maintained with the inflammatory stimulus 
for different time intervals, depending on the assay. 
 
3.3 Cell Viability   
Cell viability was assessed by the mitochondrial-dependent reduction of 
3-(4,5-dimethylthiazol-2yl) 2,5-diphenyltetrazolium bromide (MTT) to formazan, which is 
directly proportional to the number of living cells. After incubation for 24 hours with C3G 
and/or 5-ASA, 0.8x106 cells/well in 6-well plates were washed with PBS and incubated with 
MTT (0.5 mg/ml) for 1 hour, at 37ºC. Then, the medium was removed and the formazan crystals 
were dissolved in DMSO (900 µl). The extent of formazan formation was recorded at 530 nm 
in a Synergy HT plate reader. 
Results were expressed as a percentage of control cells, i.e. non-treated cells. 
 
3.4 Measurement of Nitric Oxide Production 
Nitric oxide production, in intestinal cells, was determined by measuring the amount of 
nitrite accumulated in cell culture supernatants. Nitrite was measured using a sensitive 
fluorimetric assay based upon the reaction of nitrite with 2,3-diaminonaphthalene (DAN), under 
acidic conditions, to form the fluorescent product 1-(H)-naphthotriazole [22]. Briefly, at the end 
of the incubation times, the supernatants were collected and nitrite was evaluated by adding 200 
μl of freshly prepared DAN (0.025 mg/ml in 0.62 M HCl) to 200 μl of supernatant and mixed 
immediately. After 10 minutes incubation at room temperature in the dark, the reaction was 
stopped with 100 μl of 3 M NaOH. A standard curve was produced with known concentrations 
of sodium nitrite. Fluorescence intensity was read in a dual wavelength 
spectrophotofluorimeter, with excitation and emission at 365 nm and 405 nm, respectively. The 
sensitivity of the assay is 10 nM. 
 
3.5 Assessment of Prostaglandin E2 and IL-8 Production 
Confluent HT-29 cells grown on six-well plates (0.8 x 106cells/well) were treated as above. 
After 16 hours of incubation, supernatants were collected and processed for PGE2 and IL-8 
quantification, by using a competitive immunoassay kit (PGE2 EIA Kit) from Enzo Life Science 
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and an Elisa Kit from RayBiotech, Inc, respectively, according to the manufacturer’s 
instructions. The values were reported to protein content as measured by the Bradford assay 
(Bio-Rad, USA). 
 
3.6 Western-blot Analysis 
Total, cytoplasmic and nuclear cellular protein extracts from several experiments were 
prepared and analysed by Western-blotting. For total cellular protein extracts, washed cell 
pellets were resuspended in an ice-cold lysis buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 2 
mM EDTA, 10% (w/v) glycerol, 0.5% (w/v) sodium deoxycholate, 1% (v/v) Triton X-100, 1 
mM PMSF, 1/100 (v/v) protease inhibitor cocktail) for 20 minutes, on ice. Cell debris was 
subsequently removed by centrifugation at 14000 rpm for 20 minutes at 4ºC and supernatants 
were then collected and stored at -20ºC. Cytoplasmic protein extracts were collected essentially 
in the same way. Washed cells were lysed in an ice-cold buffer containing 10 mM Tris–HCl, 10 
mM NaCl, 3 mM MgCl2, 0.5% Nonidet P-40 and 1% protease inhibitor cocktail, pH 7.5, for 5 
minutes on ice. Afterwards, lysates were centrifuged at 5000 rpm for 5 minutes at 4ºC and the 
supernatants (cytoplasmic extracts) were collected and stored at -20ºC. For nuclear cellular 
protein extracts, the pellets were collected and resuspended in an ice-cold buffer with 20 mM 
Hepes, 5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 300 mM NaCl, 20% (w/v) glycerol, and 1% 
protease inhibitor cocktail, pH 7.5 and left on ice for 30 minutes. Then, lysates were centrifuged 
at 14000 rpm for 20 minutes at 4ºC and the supernatants (nuclear extracts) were saved at -80ºC. 
Protein concentration was determined by using the Bio-Rad protein assay reagent (Bradford 
assay), according to the manufacturer’s specifications (Bio-Rad, USA). 
A range of 30-80 micrograms of reduced and denatured proteins were separated by 
SDS/PAGE electrophoresis on a 10% - 12% (v/v) acrylamide gel and transferred onto 
polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences, UK) by 
electroblotting. To avoid non-specific binding, membranes were blocked with skimmed milk 
in TBS buffer supplemented with 0.1% (v/v) Tween 20 (TBS-T: 20 mM Tris–HCl, 150 mM 
NaCl, 0.1% Tween 20) and then probed with antibodies against iNOS, COX-2 and IкB-α, 
overnight at 4ºC and against phospho-STAT1 and phospho-p38 MAPK, 3 hours at room 
temperature, with a constant low shaking. Membranes were washed three times and then 
incubated with alkaline phosphatase-conjugated secondary antibodies (2 hours, room 
temperature, constant shaking). Immunoreactive complexes were detected by fluorescence in a 
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Typhoon 9000 scanner (Amersham Biosciences). β-Actin was used as control for protein 
loading. Bands were analysed using the ImageQuant TM software from Amersham 
Biosciences. 
 
3.7 Evaluation of NF-kB (p65) Activity 
DNA-binding activity of NF-kB-p65 was measured in nuclear extracts using the TransAMTM 
NF-kB-p65 protein assay (Active Motif, CA, USA), an ELISA-based method with high 
sensitivity and reproducibility.  
For preparation of nuclear extracts, washed cells were lysed in an ice-cold buffer containing 
10 mM Tris–HCl, 10 mM NaCl, 3 mM MgCl2, 0.5% Nonidet P-40 and 1% protease inhibitor 
cocktail, pH 7.5, for 5 minutes on ice. Afterwards, lysates were centrifuged at 5000 rpm for 5 
minutes at 4ºC and the supernatants (cytoplasmic extracts) were collected and stored at -20ºC. 
The pellets were collected and resuspended in 50 µl of Complete Lysis Buffer (a solution 
provided by Active Motif, CA) and left on ice for 30 minutes. Then, lysates were centrifuged 
at 14000 rpm for 20 minutes at 4ºC and the supernatants (nuclear extracts) were saved at -80ºC.  
DNA binding activity of p65 was evaluated with 15 µg of nuclear protein, according to the 
manufacturer’s protocol and the results expressed in relative terms. 
 
3.8 Statistical Analysis  
All data were expressed as means ± SEM of at least 3 independent assays, each one in 
duplicate. Differences between groups were analysed by one-way analysis of variance 
(ANOVA), Tukey’s was used as appropriate. Values of p<0.05 were accepted as statistically 
significant. 
  
Chapter 2 – Anti-inflammatory action of C3G vs 5-ASA in HT-29 cells 
66 
4. Results 
4.1 C3G and/or 5-ASA did not affect cell viability of HT-29 cells 
In order to assess the cytotoxic effect of C3G and 5-ASA, a MTT assay was performed upon 
24 hours of cell incubation with the compounds. As illustrated in Figure 2, neither C3G, in the 
concentration range of 12.5 to 50 µM, nor 500 µM 5-ASA alone or in combination with 25 µM 
C3G, affected the percentage of cell viability relative to the control (cells without the 
compounds). In contrast, the cytokines, at the concentrations used as a cell stimulus, induced a 
decrease of cell viability to about 50 per cent (data not shown).  
In the present study, both C3G (25 µM) and 5-ASA (500 µM) were used at subtoxic 
concentrations. 
 
 
 
 
Figure 2 - Effects of C3G and 5-ASA on the cell viability of HT-29 cells. HT-29 cells were incubated for 24 hours 
with different concentrations of C3G (12.5 to 50 µM), 5-ASA (500 µM) and a combination of 25 µM C3G and 
500 µM 5-ASA. Cell viability was assessed by MTT reduction and determined as percentage of control cells 
(without compounds). Values are mean ± SEM of at least three different experiments, in duplicate. 
  
Chapter 2 – Anti-inflammatory action of C3G vs 5-ASA in HT-29 cells 
67 
4.2 C3G inhibited secretion of pro-inflammatory mediators induced by the 
cytokines more efficiently than 5-ASA, in HT-29 cells 
In order to evaluate the ability of C3G to inhibit pro-inflammatory mediators’ production, 
the levels of NO, PGE2 and IL-8 generated by cytokine-stimulated HT-29 cells were monitored.  
As shown in Figure 3A, stimulation of HT-29 cells with cytokines, for 24 hours, induced a 
strong cellular nitrite formation as compared to basal values found in non-stimulated cells. 
Treatment with 25 µM C3G, 500 µM 5-ASA or both, for 1 hour, before cytokine stimulation, 
significantly reduced the nitrite levels by about 75%. Although 25 µM C3G seems to be more 
efficient than 500 µM 5-ASA, the difference was not significant. Combination of the two 
compounds (25 µM C3G and 500 µM 5-ASA) caused no further effect. Previous studies of 
time-dependent release of NO demonstrated that until 16 hours of incubation there was no 
significant cellular nitrite formation.  
To examine whether C3G, 5-ASA, or the combination of both, inhibited PGE2 and IL-8 
production, cells were treated with/without the compounds for 1 hour and then treated with the 
cytokine mixture (IL-1α, TNF-α and IFN-γ) for 16 hours. In Figure 3B, it is clear that PGE2 
production was enhanced in response to cytokine treatment and that this increase was strongly 
inhibited by C3G by almost 65%, a higher inhibitory effect than that induced by 5-ASA (about 
50%). However, no additional significant effect was observed by the combination of C3G and 
5-ASA.  
Likewise, IL-8 production was deeply increased by the cytokines, but only C3G was able to 
significantly inhibit this production. In fact, as evidenced in Figure 3C, the presence of 5-ASA 
did not suppress the IL-8 production, contrary to C3G, which led to a decrease in its production 
by about 20%. The combination of C3G with 5-ASA did not improve the suppressive effect, 
which was similar to that of C3G alone.  
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Figure 3 - C3G and 5-ASA inhibit the production of pro-inflammatory mediators induced by cytokines in HT-29 
cells. Cells were pre-incubated with 25 µM C3G or 500 µM 5-ASA or both (25 µM C3G plus 500 µM 5-ASA) 
and then treated with cytokines for a certain period of time. NO (A), PGE2 (B) and IL-8 (C) production by cells 
were measured as described in “Materials and Methods”. Values are mean ± SEM of at least three different 
experiments, in duplicate. ***P<0.001 vs Control, ##P<0.01, ###P<0.001 vs Cytokines, $$P<0.01, $$$P<0.001 vs 
5-ASA plus Cytokine mixture. 
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4.3 C3G, like 5-ASA, inhibited cytokine-induced up-expression of iNOS and 
COX-2 in HT-29 cells 
In order to assess whether the C3G or 5-ASA-induced decrease in the pro-inflammatory 
mediators levels, observed into the cell culture media, was exerted via inhibition of the 
inducible forms of NO synthase and cyclooxygenase, protein expressions of these enzymes 
were determined by Western-blotting. As shown in Figure 4, in non-stimulated cells, the 
expression levels of iNOS (Figure 4A) and COX-2 (Figure 4B) were very low or undetectable. 
However, in response to cytokine stimulation and after 24 hours or 16 hours, the levels of iNOS 
and COX-2, respectively, were up-regulated. When cells were pre-treated with the compounds 
in study their expression was significantly reduced. Worth of notice is the difference in the 
concentrations used in this work, i.e., 25 µM C3G and 500 µM 5-ASA. These concentrations 
were previously tested by some of us, in other studies, either with anthocyanins or with 5-ASA 
[6, 23]. Thus, as shown in Figure 4A the inhibitory effect of C3G is slightly smaller than that 
of 5-ASA, this is not relevant bearing into consideration the highest concentration of 5-ASA 
(20 times). 
Regarding to COX-2 expression (Figure 4B), C3G more efficiently down-regulated COX-2 
expression than 5-ASA and the combination of C3G and 5-ASA afforded a much better 
protection than the individual compounds. 
 
 
Figure 4 - C3G inhibits cytokines-induced up-expression of iNOS and COX-2, like 5-ASA, in HT-29 cells. Cells 
were pre-incubated with 25 µM C3G or 500 µM 5-ASA or both (25 µM C3G plus 500 µM 5-ASA) and then 
treated with a combination of cytokines. iNOS (A) and COX-2 (B) expressions were evaluated after 24 hours or 
16 hours, respectively, in total extracts by Western blotting, as described in “Materials and Methods”, and 
expressed as percentage of control. Values are mean ± SEM of at least three different experiments, in duplicate. 
***P<0.001 vs Control, #P<0.05, ##P<0.01, ###P<0.001 vs Cytokines. 
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4.4 C3G and/or 5-ASA did not inhibit cytokine-induced NF-kB activation in 
HT-29 cells  
In an attempt to clarify the biochemical mechanism underlying the activation of iNOS, 
COX-2 and IL-8 observed in cytokine-stimulated HT-29 and the corresponding protection in 
pre-treated cells with C3G and/or 5-ASA, we evaluated the putative effects on NF-kB 
activation. As shown in Figure 5, cells stimulation for 30 minutes led to a decrease of 
cytoplasmic IkB-α by about 70% of the control, i. e. non stimulated cells. Some decrease was 
observed as soon as 15 minutes (data not shown), but more intensely at 30 minutes. However, 
cells pre-incubation with C3G and/or 5-ASA did not hamper cytokine-induced IkB-α 
degradation.  
 
 
 
Figure 5 - Neither C3G nor 5-ASA prevent the cytokine-induced IkB-α degradation in HT-29 cells. Cells were 
pre-incubated with 25 µM C3G or 500 µM 5-ASA or both and then treated with a combination of cytokines for 
30 minutes. IkB-α degradation was evaluated in cytoplasmic extracts by Western blotting, as described in 
“Materials and Methods”. Values are mean ± SEM of at least three different experiments, in duplicate. ***P<0.001 
vs Control. 
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Given that p65 accumulation and DNA binding in the cell nucleus is critical in regulating 
the expression of target genes, we decided to determine whether the down-regulation of iNOS 
and COX-2 expression and the inhibition of pro-inflammatory mediators’ production, by the 
compounds under study, would be due to the suppression of NF-kB transcriptional activation. 
To test this hypothesis, cells were treated as referred and the DNA binding activity of p65 was 
measured, as described in materials and methods. As shown in Figure 6, although cells 
stimulation with cytokines increased the DNA binding activity of p65 up to approximately 
4-fold, neither C3G nor 5-ASA alone or in combination interfered with p65 transcriptional 
activity, in our assay conditions.  
 
 
 
 
Figure 6 - C3G and 5-ASA do not suppress the activation of NF-kB-p65 in HT-29 cells. Cells were pre-incubated 
with 25 µM C3G or 500 µM 5-ASA or both and then treated with a combination of cytokines for 30 minutes. 
NF-kB activation was evaluated in nuclear extracts by a DNA-binding activity assay. Values are mean ± SEM of 
at least three different experiments, in duplicate. ***P<0.001 vs Control. 
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4.5 C3G and/or 5-ASA reduced the levels of cytokine-induced 
phosphorylated STAT1 in the nucleus of HT-29 cells 
Considering that STAT1 is another important transcription factor that may be behind the 
protective effect of C3G and/or 5-ASA, we further examined the effect of these compounds on 
the levels of phosphorylated (activated) STAT1, in the cell nucleus. For this purpose, a 
Western-blotting analysis was carried out. As well as in the activation time course of NF-kB, 
cytokine-induced phosphorylation of STAT1 started at 15 minutes after the insult but became 
much stronger at 30 minutes (data not shown). It is worthwhile to note that, as illustrated in 
Figure 7, the pre-incubation with either C3G, 5-ASA or both led to a decrease in the nuclear 
content of this activated transcription factor, in about 50%. As happened with the other targets 
studied, the combination of C3G and 5-ASA did not show more benefit than the compounds 
alone.  
 
 
 
Figure 7 - C3G and 5-ASA reduce the levels of cytokine-induced STAT1 activation in HT-29 cells. Cells were 
pre-incubated with 25 µM C3G or 500 µM 5-ASA or both and then treated with a combination of cytokines for 
30 minutes. STAT1 phosphorylation was evaluated in nuclear extracts by Western blotting, as described in 
“Material and Methods”. Values are mean ± SEM of at least three different experiments, in duplicate. ***P<0.001 
vs Control, #P<0.05, ##P<0.01 vs Cytokines. 
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4.6 C3G, like 5-ASA, did not affect the cytokine-induced phosphorylation of 
p38 MAPK, in HT-29 cells 
Given that many transcription factors can be phosphorylated and activated by upstream 
kinases, like p38 MAPKs, it became important to explore whether anti-inflammatory action of 
C3G and 5-ASA was mediated through the p38 MAPK pathway in HT-29 cells. Thus, we next 
analysed the ability of C3G and 5-ASA to inhibit the cytokine-induced phosphorylation of p38 
MAPK. Treatment of cells with the mixture of cytokines significantly induced the 
phosphorylation of p38 MAPK at 30 minutes. However, at this time, C3G and/or 5-ASA did 
not counteract this process, as it is shown by Western-blotting technique (Figure 8).  
 
 
 
 
Figure 8 - Failure of C3G and 5-ASA to inhibit cytokine-induced phosphorylation of p38 MAPK in HT-29 cells. 
Cells were pre-incubated with 25 µM C3G or 500 µM 5-ASA or both and then treated with a combination of 
cytokines for 30 minutes. Phosphorylation of p38 MAPK was evaluated in total extracts by Western blotting, as 
described in “Material and Methods”. Values are mean ± SEM of at least three different experiments, in duplicate. 
***P<0.001 vs Control. 
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5. Discussion 
In the last years, many studies have been carried out demonstrating the important role of 
anthocyanins in the prevention and treatment of chronic inflammatory diseases [5, 7]. It is 
known that health effects of polyphenols depend on the ingested amount and on the achieved 
bioavailability which deeply differs among the various polyphenols [8]. In what concerns 
anthocyanins, it is believed that their bioavailability is low, but it is also known that these 
compounds are unique because they can exist in many different molecular forms, in a dynamic 
equilibrium, and the currently used analytical methods underestimate the bioavailability data 
[2, 9]. Apart from this, many studies confirm that anthocyanins can be very active at the 
intestine level, reaching high concentrations in the gastrointestinal tract, which may be 
explained by their abundance in diet and poor absorption [8, 9]. This fact makes anthocyanins 
very attractive for exploring their anti-inflammatory potential in IBD context, in particular that 
of cyanidin-3-glucoside (C3G), one of the most abundant anthocyanins in nature. 
The present study was undertaken to provide new insights into cellular signalling 
mechanisms underlying the ability of C3G to protect intestinal cells (HT-29), against 
pro-inflammatory stimulus, in comparison with 5-aminosalicylic acid (5-ASA). A combination 
of cytokines containing IL-1α, TNF-α, and IFN-γ was selected as a pro-inflammatory stimulus, 
since it is known that these cytokines are rapidly released by injured tissue or infection and are 
effective as inducers of the expression of different pro-inflammatory genes, depending on the 
cell type [24-26]. 
Thus, in the intestinal cell line used in this work, C3G was able to efficiently inhibit the NO 
production (Figure 3A) counteracting the iNOS expression (Figure 4A) like 5-ASA, but at a 
much lower concentration. NO is a free radical produced from the amino acid L-arginine by 
nitric oxide synthase (NOS) enzyme. Although NO, in constitutive levels, has a physiological 
role in maintaining adequate perfusion and regulation of microvascular and epithelial 
permeability [27], persistent overproduction of NO via up-regulation of iNOS is associated with 
inflammatory response leading to gut barrier injury [28]. The protective effects of C3G, with 
respect to iNOS and NO production, are very interesting because they revealed that this 
anthocyanin, which is a natural polyphenol widespread in plants, acted in a very similar way to 
5-ASA, which in turn is a potent anti-inflammatory therapeutic agent, commonly used in 
clinical practice. Furthermore, C3G acted in a concentration 20 times lower than 5-ASA. 
Nonetheless, the combination of the two compounds did not provide better protection over the 
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individual compounds, excluding either additive or synergistic effects. 
In contrast to the effect on iNOS, C3G/5-ASA combination demonstrated a higher protection 
for COX-2 expression than that provided by the individual compounds (Figure 4B). COX-2 is 
the inducible form of COX and its expression is up-regulated in the inflamed gut of IBD patients 
[29]. Thus, high levels of prostaglandins have also been found in the mucosa of IBD patients 
[29] leading to the perpetuation of inflammation [30]. In this way, we also proved the ability of 
C3G to prevent PGE2 biosynthesis and in agreement with COX-2 results, C3G inhibited PGE2 
production more significantly than 5-ASA (Figure 3B), bearing into consideration the much 
lower concentration of C3G used to achieve this inhibitory effect. However, the combined 
effects of C3G plus 5-ASA on PGE2 production were similar to that of C3G, revealing no 
advantage in adding 5-ASA over C3G. Also, of note is that this cell line expresses mRNA for 
IL-8 and secretes it after stimulation [31]. Actually, we observed such overproduction, but only 
C3G pre-treatment was able to significantly reduce it (Figure 3C). 
Although it is known that the transcriptional regulation of iNOS and COX-2 is complex [32, 
33], the nuclear factor kB is one of the most important regulators of pro-inflammatory genes 
expression and it is well-established that its activation is significantly induced in intestine of 
IBD patients [17, 34]. So, the effects observed in pre-treated HT-29 cells with either C3G or 
5-ASA could be due to the suppression of NF-kB activation. This activation process can be 
initiated by a wide variety of different stimuli, which lead to the phosphorylation and 
degradation of the NF-kB inhibitory molecules, IkB proteins [17]. In the present study, we 
observed that in our assay conditions the combination of cytokines was able to induce the 
degradation of IkB-α but, unexpectedly, neither C3G nor 5-ASA inhibited such degradation 
(Figure 5). This degradative process is a crucial step for the activation of NF-kB with 
subsequent translocation to the nucleus and binding to DNA, in the classical pathway of NF-kB 
activation. However, recent evidences indicate that transcriptional activity of NF-kB also 
requires the direct modification of NF-kB proteins, namely by phosphorylation and acetylation. 
The loss of phosphorylation of p65 interferes with its DNA binding and transactivation 
activities [18, 35-37]. Taking this into account and considering that other authors have already 
reported the inhibitory effect of 5-ASA on inducible NF-kB-dependent transcription in 
intestinal epithelial cells, independent of preventing the IkB-α degradation [38], we investigated 
whether C3G or 5-ASA or both could hamper NF-kB activation, by interfering with its DNA 
binding. However, in our assay conditions, in cells pre-treated with the compounds no 
prevention of NF-kB activation was observed (Figure 6). Our findings seem to conflict with 
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those of Min et al [39], who have reported an inhibitory effect of C3G on LPS-induced NF-kB 
activation in RAW 264.7 cells. These contradictory results might be explained by the 
differences in the cell type and in the pro-inflammatory stimulus.  
Thus, our belief is that the anti-inflammatory effects of C3G observed in HT-29 cells, 
stimulated by a cocktail of cytokines, could be related to the suppression of an alternative cell 
signalling, other than NF-kB. This is consistent with reports by others showing that some 
polyphenols preferentially suppress STAT1 activation rather than NF-kB activation [40, 41]. 
The JAK-STAT signalling pathway is a common signalling pathway activated by various 
stimuli, namely interferons. The binding of a cytokine to its cell-surface receptor results in the 
activation of JAK tyrosine kinases, which in turn phosphorylate STATs. Then, STATs 
dimerize, translocate into the nucleus and activate the transcription of STAT-responsive genes, 
namely iNOS [42-45]. The present study demonstrated, for the first time, that pre-incubation of 
C3G in HT-29 cells decreased the nuclear levels of this activated transcription factor, to about 
50% (Figure 7). A similar effect was obtained by 5-ASA but at a much higher concentration 
than that of C3G. One possible explanation to such decrease in nuclear activated STAT1 levels 
could be the induction of the expression of the SOCS family of proteins by our compounds. 
These proteins are in part in charge of the negative feedback mechanism engaged by STATs. 
They can block the recruitment of STATs, bind to JAKs, or even target STATs for proteasomal 
degradation [42, 43, 46]. On the other hand, another possible explanation will be that C3G and 
5-ASA can induce the dephosphorylation of STAT1. Actually, it has been described that 
tyrosine-phosphorylated STAT1 requires to be dephosphorylated, by some nuclear 
phosphatases, in order to leave the nucleus [43, 47].  
Furthermore, there are many kinase pathways involved in the regulation of inflammatory 
response upstream transcription factors, which may also be important to understand the 
mechanisms behind the anti-inflammatory effects of C3G, namely the p38 MAPK pathway. In 
fact, this pathway has already been identified as crucial for induction of iNOS and COX-2 in 
HT-29 cells by a mixture of cytokines [48]. However, under our experimental conditions none 
of the compounds was successful in inhibiting the phosphorylation (activation) of p38 MAPK, 
revealing that p38 MAPK was not involved in the protective effect of C3G and 5-ASA.  
In conclusion, in vitro, under our experimental conditions, C3G showed to be effective in 
inhibiting cytokine-induced pro-inflammatory markers, namely NO, PGE2, IL-8, iNOS and 
COX-2, without affecting the activation of either NF-kB or p38 MAPK but significantly 
decreasing the amount of activated STAT1 in the nucleus, in HT-29 cells. Moreover, we 
Chapter 2 – Anti-inflammatory action of C3G vs 5-ASA in HT-29 cells 
77 
demonstrated, for the first time, that in comparison with 5-ASA, C3G has a stronger 
anti-inflammatory activity regarding the studied pro-inflammatory markers in particular, taking 
into account the difference in the concentrations used. However, it is known that, in vivo, 
anthocyanins suffer from spontaneous degradation and are metabolized by the indigenous 
microbiota population in the colon [49] which causes the release of aglycones of their 
glycosides and eventually the disruption of the ring [49, 50]. Thus, unanswered questions 
should lead to interesting future research to clarify the actual molecular structures underlying 
the protective effects of C3G and also to investigate the accessibility of them to the epithelium. 
Despite this and considering that current treatment options in patients with IBD are not 
curative and patients face lifelong therapy, C3G may be envisaged as a promising nutraceutical 
giving complementary benefits in attenuating inflammation and decreasing the risk for the 
development of colorectal cancer observed in these patients. 
  
Chapter 2 – Anti-inflammatory action of C3G vs 5-ASA in HT-29 cells 
78 
6. References  
1. Scalbert, A., Manach, C., Morand, C., Remesy, C. & Jimenez, L. Dietary polyphenols 
and the prevention of diseases. Crit Rev Food Sci Nutr 45, 287-306 (2005). 
2. Prior, R.L. & Wu, X. Anthocyanins: structural characteristics that result in unique 
metabolic patterns and biological activities. Free Radic Res 40, 1014-28 (2006). 
3. Wang, L.S. & Stoner, G.D. Anthocyanins and their role in cancer prevention. Cancer 
Letters 269, 281-290 (2008). 
4. He, J.A. & Giusti, M.M. Anthocyanins: Natural Colorants with Health-Promoting 
Properties. Annual Review of Food Science and Technology, Vol 1 1, 163-187 (2010). 
5. M.G., M. Anthocyanins: Antioxidant and/or anti-inflammatory activities. Journal of 
Applied Pharmaceutical Science 1, 7-15 (2011). 
6. Paixao, J., Dinis, T.C. & Almeida, L.M. Dietary anthocyanins protect endothelial cells 
against peroxynitrite-induced mitochondrial apoptosis pathway and Bax nuclear 
translocation: an in vitro approach. Apoptosis 16, 976-89 (2011). 
7. Paixao, J., Dinis, T.C. & Almeida, L.M. Malvidin-3-glucoside protects endothelial cells 
up-regulating endothelial NO synthase and inhibiting peroxynitrite-induced NF-kB 
activation. Chem Biol Interact 199, 192-200 (2012). 
8. Manach, C., Scalbert, A., Morand, C., Remesy, C. & Jimenez, L. Polyphenols: food 
sources and bioavailability. Am J Clin Nutr 79, 727-47 (2004). 
9. McGhie, T.K. & Walton, M.C. The bioavailability and absorption of anthocyanins: 
towards a better understanding. Mol Nutr Food Res 51, 702-13 (2007). 
10. Romier, B., Schneider, Y.J., Larondelle, Y. & During, A. Dietary polyphenols can 
modulate the intestinal inflammatory response. Nutr Rev 67, 363-78 (2009). 
11. Piberger, H. et al. Bilberries and their anthocyanins ameliorate experimental colitis. Mol 
Nutr Food Res 55, 1724-9 (2011). 
12. Khor, B., Gardet, A. & Xavier, R.J. Genetics and pathogenesis of inflammatory bowel 
disease. Nature 474, 307-17 (2011). 
13. Crotty, B. & Jewell, D.P. Drug therapy of ulcerative colitis. Br J Clin Pharmacol 34, 
189-98 (1992). 
14. Stein, R.B. & Hanauer, S.B. Comparative tolerability of treatments for inflammatory 
bowel disease. Drug Saf 23, 429-48 (2000). 
15. Mauray, A. et al. Nutrigenomic analysis of the protective effects of bilberry 
Chapter 2 – Anti-inflammatory action of C3G vs 5-ASA in HT-29 cells 
79 
anthocyanin-rich extract in apo E-deficient mice. Genes Nutr 5, 343-53 (2010). 
16. McCune, L.M., Kubota, C., Stendell-Hollis, N.R. & Thomson, C.A. Cherries and 
health: a review. Crit Rev Food Sci Nutr 51, 1-12 (2011). 
17. Atreya, I., Atreya, R. & Neurath, M.F. NF-kappa B in inflammatory bowel disease. J 
Intern Med 263, 591-596 (2008). 
18. Li, Q. & Verma, I.M. NF-kappaB regulation in the immune system. Nat Rev Immunol 
2, 725-34 (2002). 
19. Schreiber, S. et al. Activation of signal transducer and activator of transcription (STAT) 
1 in human chronic inflammatory bowel disease. Gut 51, 379-85 (2002). 
20. Yoshimura, A. Signal transduction of inflammatory cytokines and tumor development. 
Cancer Sci 97, 439-47 (2006). 
21. Feng, Y.J. & Li, Y.Y. The role of p38 mitogen-activated protein kinase in the 
pathogenesis of inflammatory bowel disease. J Dig Dis 12, 327-32 (2011). 
22. Wright, K., Ward, S.G., Kolios, G. & Westwick, J. Activation of phosphatidylinositol 
3-kinase by interleukin-13. An inhibitory signal for inducible nitric-oxide synthase 
expression in epithelial cell line HT-29. J Biol Chem 272, 12626-33 (1997). 
23. Dinis, T.C., Maderia, V.M. & Almeida, L.M. Action of phenolic derivatives 
(acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane lipid 
peroxidation and as peroxyl radical scavengers. Arch Biochem Biophys 315, 161-9 
(1994). 
24. Nathan, C. Nitric oxide as a secretory product of mammalian cells. FASEB J 6, 3051-64 
(1992). 
25. Kolios, G., Brown, Z., Robson, R.L., Robertson, D.A. & Westwick, J. Inducible nitric 
oxide synthase activity and expression in a human colonic epithelial cell line, HT-29. 
Br J Pharmacol 116, 2866-72 (1995). 
26. Kolios, G. et al. Ciprofloxacin inhibits cytokine-induced nitric oxide production in 
human colonic epithelium. Eur J Clin Invest 36, 720-9 (2006). 
27. Kolios, G., Valatas, V. & Ward, S.G. Nitric oxide in inflammatory bowel disease: a 
universal messenger in an unsolved puzzle. Immunology 113, 427-37 (2004). 
28. Salerno, L., Sorrenti, V., Di Giacomo, C., Romeo, G. & Siracusa, M.A. Progress in the 
development of selective nitric oxide synthase (NOS) inhibitors. Curr Pharm Des 8, 
177-200 (2002). 
29. Singer, II et al. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory 
Chapter 2 – Anti-inflammatory action of C3G vs 5-ASA in HT-29 cells 
80 
bowel disease. Gastroenterology 115, 297-306 (1998). 
30. Sheibanie, A.F. et al. The proinflammatory effect of prostaglandin E2 in experimental 
inflammatory bowel disease is mediated through the IL-23-->IL-17 axis. J Immunol 
178, 8138-47 (2007). 
31. Jijon, H.B., Panenka, W.J., Madsen, K.L. & Parsons, H.G. MAP kinases contribute to 
IL-8 secretion by intestinal epithelial cells via a posttranscriptional mechanism. Am J 
Physiol Cell Physiol 283, C31-41 (2002). 
32. Chun, K.S. & Surh, Y.J. Signal transduction pathways regulating cyclooxygenase-2 
expression: potential molecular targets for chemoprevention. Biochem Pharmacol 68, 
1089-100 (2004). 
33. Kleinert, H., Pautz, A., Linker, K. & Schwarz, P.M. Regulation of the expression of 
inducible nitric oxide synthase. Eur J Pharmacol 500, 255-66 (2004). 
34. Surh, Y.J., Na, H.K., Lee, J.Y. & Keum, Y.S. Molecular mechanisms underlying 
anti-tumor promoting activities of heat-processed Panax ginseng C.A. Meyer. J Korean 
Med Sci 16 Suppl, S38-41 (2001). 
35. Zhong, H., May, M.J., Jimi, E. & Ghosh, S. The phosphorylation status of nuclear 
NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9, 625-36 
(2002). 
36. Hoffmann, A. & Baltimore, D. Circuitry of nuclear factor kappaB signalling. Immunol 
Rev 210, 171-86 (2006). 
37. Oeckinghaus, A., Hayden, M.S. & Ghosh, S. Crosstalk in NF-kappaB signalling 
pathways. Nat Immunol 12, 695-708 (2011). 
38. Egan, L.J. et al. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 
phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J 
Biol Chem 274, 26448-53 (1999). 
39. Min, S.W., Ryu, S.N. & Kim, D.H. Anti-inflammatory effects of black rice, 
cyanidin-3-O-beta-D-glycoside, and its metabolites, cyanidin and protocatechuic acid. 
Int Immunopharmacol 10, 959-66 (2010). 
40. Liu, P.W., Chen, M.F., Tsai, A.P. & Lee, T.J. STAT1 mediates oroxylin a inhibition of 
iNOS and pro-inflammatory cytokines expression in microglial BV-2 cells. PLoS One 
7, e50363 (2012). 
41. Tedeschi, E. et al. Green tea inhibits human inducible nitric-oxide synthase expression 
by down-regulating signal transducer and activator of transcription-1alpha activation. 
Chapter 2 – Anti-inflammatory action of C3G vs 5-ASA in HT-29 cells 
81 
Mol Pharmacol 65, 111-20 (2004). 
42. Santos, C.I. & Costa-Pereira, A.P. Signal transducers and activators of 
transcription-from cytokine signalling to cancer biology. Biochim Biophys Acta 1816, 
38-49 (2011). 
43. Shuai, K. & Liu, B. Regulation of JAK-STAT signalling in the immune system. Nat 
Rev Immunol 3, 900-11 (2003). 
44. Kramer, O.H. & Heinzel, T. Phosphorylation-acetylation switch in the regulation of 
STAT1 signalling. Mol Cell Endocrinol 315, 40-8 (2010). 
45. Ramana, C.V., Chatterjee-Kishore, M., Nguyen, H. & Stark, G.R. Complex roles of 
Stat1 in regulating gene expression. Oncogene 19, 2619-27 (2000). 
46. Klampfer, L. Signal transducers and activators of transcription (STATs): Novel targets 
of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 6, 107-21 
(2006). 
47. Haspel, R.L. & Darnell, J.E., Jr. A nuclear protein tyrosine phosphatase is required for 
the inactivation of Stat1. Proc Natl Acad Sci U S A 96, 10188-93 (1999). 
48. Paul, S. et al. Anti-inflammatory action of pterostilbene is mediated through the p38 
mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev Res 2, 
650-7 (2009). 
49. Aura, A.M. et al. In vitro metabolism of anthocyanins by human gut microflora. Eur J 
Nutr 44, 133-42 (2005). 
50. Kay, C.D., Kroon, P.A. & Cassidy, A. The bioactivity of dietary anthocyanins is likely 
to be mediated by their degradation products. Mol Nutr Food Res 53 Suppl 1, S92-101 
(2009). 
 
  
 82 
  
 83 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
Resveratrol modulates cytokine-induced JAK/STAT activation 
more efficiently than 5-aminosalicylic acid: an in vitro approach 
 
 
 
Serra D, Rufino AT, Mendes AF, Almeida LM and Dinis TCP (2014), “Resveratrol modulates 
cytokine-induced JAK/STAT activation more efficiently than 5-aminosalicylic acid: an in vitro 
approach”, Published in PLos ONE 9(10): e109048. 
 
  
 84 
  
Chapter 3 –Resv downregulates JAK/STAT in intestinal cells 
85 
1. Abstract 
Background: Many advances have been recently made focused on the valuable help of 
dietary polyphenols in chronic inflammatory diseases. On the other hand, current treatment 
options for inflammatory bowel disease patients are unsatisfying and, for this reason, it is 
estimated that many patients use dietary supplements to achieve extra benefits.   
Aim: The aim of this work was to analyse under a mechanistic perspective the 
anti-inflammatory potential of resveratrol, a natural polyphenolic compound, and to compare it 
with a pharmaceutical agent, 5-aminosalicylic acid, using the intestinal HT-29 cell line, as a 
cellular model. 
Methodology and Principal Findings: In the present study, HT-29 colon epithelial cells 
were pre-treated with 25 μM resveratrol and/or 500 μM 5-aminosalicylic acid and then exposed 
to a combination of cytokines (IL-1α, TNF-α, IFN-γ) for a certain period of time. Our data 
showed that resveratrol, used in a concentration 20 times lower than 5-aminosalicylic acid, was 
able to significantly reduce NO and PGE2 production, iNOS and COX-2 expression and reactive 
oxidant species formation induced by the cytokine challenge. However, as already verified with 
5-aminosalicylic acid, in spite of not exhibiting any effect on IkB-α degradation, resveratrol 
down-regulated JAK-STAT pathway, decreasing the levels of activated STAT1 in the nucleus. 
Additionally, resveratrol decreased the cytokine-stimulated activation of SAPK/JNK pathway 
but did not counteract the cytokine-triggered negative feedback mechanism of STAT1, through 
p38 MAPK.  
Conclusion/Significance: Taken together, our results show that resveratrol may be 
considered a future nutraceutical approach, promoting remission periods, limiting the 
inflammatory process and preventing colorectal cancer, which is common in these patients. 
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2. Introduction 
In the last decades, many studies have shed light on the impact of dietary polyphenols in 
chronic inflammatory diseases, namely diabetes [1-3], atherosclerosis [2, 4] and inflammatory 
bowel diseases [5, 6]. Although the cell signalling mechanisms involved are far from being 
fully understood, many recent studies believe that the consumption of these biological 
phytochemicals can be truly advantageous to avoid or limit diseases progression [2, 3, 7-10]. 
For instance, some epidemiological studies show that a moderated intake of red wine (rich in 
polyphenols) can be useful in the prevention of cardiovascular diseases [11].  
Resveratrol (3,5,4’-trihydroxy-trans-stilbene) is a natural non-flavonoid polyphenol, found 
mainly in grapes and red-wine and is one of the most studied polyphenols [10, 12-15]. However, 
the major concerns about resveratrol (Resv) efficacy are related to its low oral bioavailability 
[16, 17] and to the possible induction of liver damage [18]. Nevertheless, previous reports 
demonstrated that resveratrol has an important role as an anti-inflammatory agent [6, 14, 19, 
20] and considering that the intestine is a target site for resveratrol action, it is of great interest 
to further understand the beneficial effects of resveratrol in an intestinal disease which is mainly 
characterized by inflammation, as the Inflammatory Bowel Disease (IBD). IBD is a chronic 
inflammatory disorder of the gastrointestinal tract, which includes Crohn’s Disease and 
Ulcerative Colitis, characterized by periods of remission and of relapses, whose etiology 
remains enigmatic [21, 22]. Until now, this disease does not have cure and consequently the 
pharmacological treatment is used to prevent and treat symptoms and still to induce or maintain 
the remission periods. There has been a huge advance in the therapy options for IBD patients 
but the conventional therapies, as the well-known anti-inflammatory 5-aminosalicylic acid 
(5-ASA), remain the cornerstone of treatment for the majority of these patients [23]. Besides, 
since existing treatment options for IBD patients often bring marginal results, dietary 
supplements have deserved increasing interest to achieve extra benefits. Therefore, the 
advantages and implications of such dietary supplements for IBD patients need to be more 
elucidated. A previous work performed in our laboratory has focused on the anti-inflammatory 
potential of the flavonoid polyphenol, cyanidin-3-glucoside, in comparison with the active 
principle, 5-ASA, in the context of IBD [8]. The aim of the present study was to extend this 
research to a polyphenol with a completely different chemical structure, the resveratrol, and to 
explore, under a mechanistic perspective, its anti-inflammatory potential as compared to 5-ASA 
(Figure 1). For this purpose, the HT-29 cell line was used as a colon epithelial cells model, 
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stimulated by a mixture of cytokines (Cyt). Cytokines are molecules rapidly released by injured 
tissues and are inducers of inflammatory response [24, 25]. Some previous studies have 
suggested that exposure of intestinal cells to a mixture of cytokines can activate inflammatory 
cascades (namely, NF-kB, MAPKs  and JAK-STAT pathways) and in turn increase the 
expression of pro-inflammatory enzymes, (iNOS and COX-2), the production of 
pro-inflammatory mediators (NO and PGE2) and the formation of reactive oxygen species 
(ROS) [26-28]. The down-regulation of these pro-inflammatory cascades emerges as a valuable 
strategy in IBD, since they are usually heightened in these patients [29-32]. 
Our data demonstrated, for the first time, the stronger anti-inflammatory efficiency of Resv 
as compared to 5-ASA, given that 25 μM Resv was more effective than 500 μM 5-ASA in 
down-regulating the production of pro-inflammatory mediators (NO, PGE2), pro-inflammatory 
enzymes (iNOS, COX-2 mRNAs and proteins) and ROS formation induced by the cytokines. 
Moreover, as it was previously verified by some of us for 5-ASA [8], Resv did not affect IkB-α 
degradation, but significantly decreased the amount of activated STAT1 in the nucleus of 
cytokine-stimulated HT-29 cells. Besides, Resv, alone or in combination with 5-ASA, 
down-regulated STAT1 activation through a dependent p38 MAPK mechanism and inhibited 
the cytokine-induced SAPK/JNK activation. Therefore, our work gives a step forward 
unravelling JAK-STAT as well as MAPK signalling as key cascades involved in Resv 
anti-inflammatory protection and in its potential anticancer action. 
 
 
 
 
Figure 1 - Chemical structures of resveratrol (A) and 5-aminosalicylic acid (B). 
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3. Materials and Methods  
3.1 Reagents 
Resveratrol purified from natural sources was obtained from Extrasynthése (Genay, France). 
Its purity was above 95%, as measured by HPLC, and it was used as a solution in DMSO (5 
mM) and stored at -20 oC. 
Laboratory chemicals namely dimethylsulfoxide (DMSO), sodium dodecyl sulfate (SDS), 
2,3-diaminonaphthalene (DAN), 3-(4,5-dimethylthiazol-2yl)2,5-diphenyl-tetrazolium bromide 
(MTT), 2′,7′-dichlorodihydrofluorescein diacetate (DCFH2-DA), phenylmethylsulfonyl 
fluoride (PMSF), Hoechst 33258,  streptomycin/penicillin, protease inhibitor cocktail and 
phosphatase inhibitors were purchased from Sigma-Aldrich Co.  
For cell culture, Dulbecco’s modified Eagle’s medium (DMEM), 0.25% trypsin, fetal bovine 
serum (FBS) and phosphate-buffered saline (PBS) pH 7.4, were obtained from 
Gibco-Invitrogen. 
Rabbit polyclonal antibody to iNOS and goat polyclonal antibody to phospho-STAT1 
(Tyr701) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); rabbit 
monoclonal antibody to phospho-p38 MAPK (Thr180/Tyr182) and rabbit polyclonal antibodies 
to phospho-SAPK/JNK (Thr183/Thr185) and to IкB-α were purchased from Cell Signalling 
Technology (MA, USA); mouse monoclonal antibodies to β-actin and to β-tubulin were 
purchased from Sigma-Aldrich Co and rabbit polyclonal antibodies to COX-2, to lamin B1 and 
anti-rabbit, anti-mouse, anti-goat IgG secondary antibodies were obtained from Abcam 
(Cambridge, UK). The Alexa Fluor 594 chicken anti-goat IgG fluorescent secondary antibody 
was bought from Alfagene (Life Technologies). 
IL-1α, TNF-α and IFN-γ were purchased from Invitrogen (NY, USA). 
 
3.2 Cell Culture  
Human colon cancer cell line (HT-29) and human liver carcinoma cell line (HepG2) were 
obtained from European Collection of Cell Cultures (Porton Down, Salisbury, UK). Both cell 
lines were grown in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin at 37ºC in a humidified atmosphere of 5% CO2. Cells were passaged weekly and 
sub-cultured at confluence. Before each experiment, cells at 80% confluence were starved in 
serum-free medium for 24 hours. Growth-arrested cultures, in medium without FBS, were 
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treated according to the various experimental purposes. 
HT-29 cells were stimulated with a combination of cytokines consisting of 10 ng/ml IL-1α, 
20 ng/ml TNF-α and 60 ng/ml IFN-γ. Each cytokine was previously diluted in 1% BSA in PBS. 
HT-29 cells were pre-treated with Resv, 5-ASA or both for 1 hour before the exposure to the 
cytokines and then maintained with the inflammatory stimulus for different time periods, 
depending on the experiment. 
 
3.3 Cell Viability  
Cell viability was assessed by the mitochondrial-dependent reduction of 
3-(4,5-dimethylthiazol-2yl) 2,5-diphenyltetrazolium bromide (MTT) to formazan, which is 
directly proportional to the number of living cells. Cells in 6-well plates (8 x 105 cells/well) 
were pre-treated with several concentrations of Resv, 500 µM 5-ASA or 25 µM Resv plus 500 
µM 5-ASA for 24 hours. At the end, cells were washed with PBS and incubated with MTT (0.5 
mg/ml) for 1 hour, at 37ºC. Then, the medium was removed and the formazan crystals were 
dissolved in DMSO (900 µl). The extent of formazan formation was recorded at 530 nm in a 
Synergy HT plate reader. 
Results were expressed as a percentage of control cells, i.e. non-treated cells. 
 
3.4 Measurement of Nitric Oxide Production 
Nitric oxide production, in intestinal cells, was determined by measuring the amount of 
nitrite accumulated in cell culture supernatants. Nitrite was measured using a sensitive 
fluorimetric assay based upon the reaction of nitrite with 2,3-diaminonaphthalene (DAN), under 
acidic conditions, to form the fluorescent product 1-(H)-naphthotriazole [33]. Briefly, at the end 
of 24 hours of incubation, the supernatants were collected and nitrite was evaluated by adding 
200 μl of freshly prepared DAN (0.025 mg/ml in 0.62 M HCl) to 200 μl of supernatant and 
mixed immediately. After 10 minutes of incubation at room temperature in the dark, the reaction 
was stopped with 100 μl of 3 M NaOH. A standard curve was produced with known 
concentrations of sodium nitrite. Fluorescence intensity was read in a dual wavelength 
spectrophotofluorimeter, with excitation and emission at 365 nm and 405 nm, respectively. The 
sensitivity of the assay is 10 nM. 
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3.5 Assessment of Prostaglandin E2 Production 
Confluent HT-29 cells grown on six-well plates (8 x 105 cells/well) were treated as described 
in cell culture. After 16 hours of incubation time, supernatants were collected and processed for 
PGE2 quantification, by using a competitive immunoassay kit (PGE2 EIA Kit) from Enzo Life 
Science, according to the manufacturer’s instructions. The values were related to protein 
content, as measured by the Bradford assay (Bio-Rad, USA). 
 
3.6 Western-blot Analysis 
As previously described [8], total, cytoplasmic and nuclear cellular protein extracts from 
HT-29 cells were prepared and analysed by Western-blotting. For total cellular protein extracts, 
washed cell pellets were resuspended in an ice-cold lysis buffer (50 mM Hepes pH 7.4, 150 mM 
NaCl, 2 mM EDTA, 10% (w/v) glycerol, 0.5% (w/v) sodium deoxycholate, 1% (v/v) Triton 
X-100, 1 mM PMSF, 1/100 (v/v) protease inhibitor cocktail) for 20 minutes, on ice. Cell debris 
was subsequently removed by centrifugation at 14000 rpm for 20 minutes at 4ºC and 
supernatants were then collected and stored at -20ºC. Cytoplasmic protein extracts were 
obtained essentially in the same way. Washed cells were lysed in an ice-cold buffer containing 
10 mM Tris–HCl, 10 mM NaCl, 3 mM MgCl2, 0.5% Nonidet P-40 and 1% protease inhibitor 
cocktail, pH 7.5, for 5 minutes on ice. Afterwards, lysates were centrifuged at 5000 rpm for 5 
minutes at 4ºC and the supernatants (cytoplasmic extracts) were collected and stored at -20ºC. 
The pellets were also collected and resuspended in an ice-cold buffer with 20 mM Hepes, 5 mM 
MgCl2, 0.2 mM EDTA, 1 mM DTT, 300 mM NaCl, 20% (w/v) glycerol, and 1% protease 
inhibitor cocktail, pH 7.5 and left on ice for 30 minutes. Then, the mixture was centrifuged at 
14000 rpm for 20 minutes at 4ºC and the supernatants (nuclear extracts) were saved at -80ºC. 
Protein concentration was determined by using the Bio-Rad protein assay reagent (Bradford 
assay), according to the manufacturer’s specifications (Bio-Rad, USA). 
A range of 30-80 micrograms of reduced and denatured proteins were separated by 
SDS/PAGE electrophoresis on a 10% - 12% (v/v) acrylamide gel and transferred onto 
polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences, UK) by 
electroblotting. To avoid non-specific binding, membranes were blocked with skimmed milk 
in TBS pH 7.6 supplemented with 0.1% (v/v) Tween 20 (TBS-T: 20 mM Tris–HCl, 150 mM 
NaCl, 0.1% Tween 20) and then probed with antibodies against iNOS, COX-2 and IкB-α, 
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overnight at 4ºC and against phospho-STAT1, phospho-p38 MAPK and phospho-SAPK/JNK 
3 hours at room temperature, with a constant low shaking. After finishing, membranes were 
washed three times and further incubated with alkaline phosphatase-conjugated secondary 
antibodies (2 hours at room temperature and constant shaking). Immunoreactive bands were 
detected by fluorescence in a Typhoon 9000 scanner (Amersham Biosciences) and analysed 
with the ImageQuant TM software from Amersham Biosciences. After analysis of target 
proteins, each blot was stripped off and reprobed with the primary antibodies against β-actin, 
β-tubulin or lamin B1, used as controls for protein loading. 
 
3.7 Total RNA Extraction and quantitative Real-Time RT-PCR (qRT-PCR) 
Total RNA was extracted from HT-29 cells seeded in six-well-plates (8 x 105 cells/well), 
after 1 hour of pretreatment with Resv and/or 5-ASA followed by 6 hours of 
cytokine-challenge, using the RNA extraction kit Aurum TM Total RNA Mini (Bio-Rad, 
Hercules, CA, USA), according to the manufacturer’s instructions. Extracted RNA was 
quantified using a NanoDrop ND-1000 spectrophotometer at 260 nm and its purity and integrity 
were assessed by ratio of absorbance at 240/260 and 280/260 nanometers. A constant amount 
of RNA (1 µg/sample) was reverse transcribed into cDNA, using the NZY First-Stand cDNA 
Synthesis Kit (NZYtech, Portugal), according to the manufacturer’s protocol. PCR reactions 
were performed with 25 µg/ml of transcribed cDNA. The primers for iNOS, COX-2 and the 
housekeeping gene HPRT-1 (hypoxanthine phosphoribosyltransferase-1) were designed using 
the Beacon Designer software (PREMIER Biosoft International, Palo Alto, CA) and the primers 
sequences were: iNOS, sense 5´- AATCCAGATAAGTGACATAAG -3’, antisense 
5’- CTCCACATTGTTGTTGAT -3’; COX-2, sense 5’- ATTATGAGTTTATGTGTTGAC -3’; 
antisense 5’- TAGGAGAGGTTAGAGAAG -3’; HPRT-1 sense 
5’- TGACACTGGCAAAACAATG -3’, antisense 5’- GGCTTATATCCAACACTTCG -3’. 
Real time-PCR was performed in 20 µl of total volume, containing 2 µl of each primer (250 
nM), 2 µl of cDNA of each sample, 10 µl of the IQ TM SYBR Green Supermix (Bio-Rad) and 
RNase-free distilled water to make up the volume to 20 µl, in a CFX96 TM Real-Time PCR 
Detection System (Bio-Rad, Hercules, CA, USA). Thermal cycling conditions were the 
following: 3 minutes at 95 ºC to activate the iTaqTM DNA polymerase, then 45 cycles, each 
consisting of a denaturation step (95ºC, 10 seconds), an annealing step (55ºC, 30 seconds) and 
an elongation step (72ºC, 30 seconds). Fluorescence measures were taken every cycle at the 
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end of the annealing step and the specificity of the amplification products was evaluated through 
the analysis of the melting curve. The efficiency of the amplification reaction for each gene was 
calculated by running a standard curve of serially diluted cDNA sample. Gene expression was 
analysed using the Bio-Rad CFX Manager 3.0 software (Bio-Rad, Hercules, CA, USA), which 
enables the analysis of the results with the Pfaffl method. The results for each gene of interest 
were normalized against HPRT-1, the housekeeping gene found to be stable under experimental 
conditions and expressed as a percentage of control cells, i.e. cytokine-stimulated cells. 
 
3.8 Fluorescence Confocal Microscopy 
HT-29 colon epithelial cells were seeded onto glass coverslips on 24 well plates (1.5 x 105 
cells/well) and treated with Resv and/or 5-ASA for 1 hour and then exposed to the cocktail of 
cytokines for 30 minutes. After this period, the cells were washed with PBS and fixed with 4% 
paraformaldehyde in PBS for 20 minutes at room temperature. Fixed cells were washed with 
PBS and permeabilized with 0.2% Triton X-100 in PBS for 2 minutes. After washing, cells 
were incubated overnight with phospho-STAT1 antibody diluted in PBS (1:50) at 4ºC. Then, 
the cells were washed twice with PBS, followed by incubation with Alexa Flour 594 conjugated 
secondary antibody diluted in PBS (1:100) for 4 hours at room temperature. After washing 
twice with PBS, the coverslips were mounted with glycerol and PBS containing the nucleic acid 
stain Hoechst (1 µg/ml).  Cells were examined under a confocal microscope (Ziess LSM 
510Meta). 
 
3.9 Evaluation of Intracellular Reactive Species 
Intracellular reactive species were assessed by using the non-fluorescent probe 
2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA), which permeates cell membranes and 
may be oxidized by reactive species, yielding the fluorescent 2′,7′-dichlorofluorescein (DCF) 
[34]. Briefly, cells in 12-well plates (4 x 105 cells/well) were previously incubated in the 
presence or in the absence of Resv and 5-ASA and further subjected to the combination of 
cytokines for 16 hours. After that period of time the cells were incubated with 5 μM DCFH2-DA 
in DMSO, at 37°C, in the dark for 15 minutes. Cells were then washed with PBS and maintained 
in 0.5 ml of PBS during the fluorescence intensity measurements in a Synergy HT plate reader 
(Bio-Tek Instruments) (excitation and emission wavelengths at 485 and 530 nm, respectively). 
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Cells were also observed in an inverted fluorescence microscope (Zeiss Axiovert 40), using a 
FITC filter.  
 
3.10 Statistical Analysis  
All data were expressed as means ± SEM of at least 3 independent assays, each one in 
duplicate. Differences between groups were analysed by one-way analysis of variance 
(ANOVA) and Tukey’s post hoc test was used as appropriate. Values of p<0.05 were accepted 
as statistically significant. 
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4. Results 
4.1 Resv up to 25 µM did not affect HT-29 cells viability 
The cytotoxicity of Resv alone or in combination with 5-ASA on HT-29 cell line was 
evaluated, upon 24 hours of cell incubation with the compounds, by the MTT assay. As 
illustrated in Figure 2A, neither Resv alone, in the concentration range of 12.5 to 25 µM, nor 
the combination of 25 µM Resv with 500 µM 5-ASA exerted cytotoxicity in HT-29 cells. 
However, at the concentration of 50 µM, Resv produced a small decrease in the cell viability 
relative to the control (untreated cells). Thus, concentrations of 25 µM Resv and 500 µM 5-ASA 
were chosen to perform the next experiments, since they proved to be subtoxic concentrations. 
As previously reported [8], the mixture of cytokines, at the concentrations selected as 
inflammatory stimulus in HT-29 cells, induced a decrease in cell viability to about 50 per cent 
(data not shown).  
Considering that Resv in high doses may be hepatotoxic, we assessed the toxicity of Resv, 
5-ASA and of both compounds in HepG2 cells as an in vitro model of human hepatocytes, in 
the same assay conditions. As illustrated in Figure 2B, none of the compounds induced loss of 
cell viability during this period of time.  
 
Figure 2 - Effects of Resv and/or 5-ASA on cell viability. Cells were incubated for 24 hours with different 
concentrations of Resv (12.5 to 50 µM), 5-ASA (500 µM) and a combination of 25 µM Resv and 500 µM 5-ASA. 
(A) HT-29 cell-line viability and (B) HepG2 cell-line viability were assessed by MTT reduction and determined 
as percentage of control cells (without compounds). Values are mean ± SEM of at least three independent 
experiments, each one in duplicate. *P<0.05 vs Control. 
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4.2 Secretion of NO and PGE2 was inhibited more efficiently by Resv than by 
5-ASA, in stimulated HT-29 cells 
To elucidate the ability of Resv alone or in combination with 5-ASA to inhibit the production 
of some pro-inflammatory mediators, the levels of NO and PGE2 generated by 
cytokine-stimulated HT-29 cells were evaluated.  
As shown in Figure 3A, stimulation of HT-29 cells with cytokines, for 24 hours, triggered 
a significant increase of cellular nitrite formation as compared to control (untreated cells), in 
agreement with previous studies. Cells treatment with 25 µM Resv, for 1 hour, before cytokine 
stimulation, significantly reduced the nitrite levels by about 50%. This inhibitory effect was not 
significantly different to that of 500 µM 5-ASA and occurred at a concentration 20 times lower. 
Also, the combination of 25 µM Resv with 500 µM 5-ASA did not cause any additional 
significant effect.  
 
 
Figure 3 - Resv decreases cytokine–induced pro-inflammatory mediators production more efficiently than 5-ASA, 
in HT-29 cells. Cells were pre-incubated with 25 µM Resv or 500 µM 5-ASA or both (25 µM Resv plus 500 µM 
5-ASA) and then exposed to cytokines (Cyt) for 24 hours or 16 hours for NO and PGE2, respectively. The NO (A) 
and PGE2 (B) production in cells was measured as described in “Materials and Methods”. Values are mean ± SEM 
of at least three independent experiments, each one in duplicate. ***P<0.001 vs Control, ##P<0.01, ###P<0.001 vs 
Cytokines.  
 
In order to draw comparison between Resv and 5-ASA on PGE2 production, cells were 
treated with the compounds for 1 hour and then exposed to the cytokine mixture (IL-1α, TNF-α 
and IFN-γ) for 16 hours. In Figure 3B, it is patent that PGE2 production was enhanced in 
response to cytokine treatment and that this increase was deeply inhibited by Resv by almost 
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75%, a higher inhibitory effect than that induced by 5-ASA (about 50%) at a concentration 20 
times higher. The combined effect of Resv and 5-ASA seemed to be stronger than that of the 
individual compounds, however data are not statistically different.  
 
4.3 Resv counteracted, in a greater extent than 5-ASA, cytokine-stimulated 
expression of iNOS and COX-2 proteins and mRNAs, in HT-29 cells  
To further investigate whether the protection afforded by Resv, with regarding to the 
pro-inflammatory mediators studied, was related to the inhibition of the inducible forms of NO 
synthase and of cyclooxygenase, the protein expressions and mRNA levels were determined by 
Western blotting and qRT-PCR, respectively. Analysing Figures 4 and 5, it is clear that protein 
and mRNA levels of iNOS and COX-2, which were hardly detectable in non-stimulated cells, 
were significantly enhanced after cytokine exposure, according to data previously reported [8].  
 
 
 
 
 
Figure 4 - Resv suppresses cytokine-induced iNOS and COX-2 expression more efficiently than 5-ASA, in HT-29 
cells. Cells were pre-incubated with 25 µM Resv or 500 µM 5-ASA or both (25 µM Resv plus 500 µM 5-ASA) 
and then challenged with a combination of cytokines. iNOS (A) and COX-2 (B) expressions were evaluated after 
24 hours or 16 hours, respectively, in total extracts by Western blotting, as described in “Materials and Methods”, 
and expressed as percentage of cytokine-stimulated cells. Values are mean ± SEM of at least three independent 
experiments, each one in duplicate. ***P<0.001 vs Control, ##P<0.01, ###P<0.001 vs Cytokines and $$$P<0.001 vs 
5-ASA plus Cytokines. 
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However, cytokine stimulatory effect was significantly reduced by pre-treating the cells with 
Resv and/or 5-ASA, for 1 hour, before the exposure to cytokines. As illustrated in Figures 4 
and 5, the extent to which Resv alone counteracted the cytokine-induced increase in COX-2 
protein and mRNA levels was clearly and statistically higher than that assigned to 5-ASA, 
particularly if the different concentrations of the compounds are taken into account (25 µM 
Resv and 500 µM 5-ASA). However, the combination of Resv with 5-ASA did not promote an 
enhancement of this effect.  
 
 
 
 
 
Figure 5 - Resv suppresses cytokine-induced iNOS and COX-2 mRNA levels more efficiently than 5-ASA, in 
HT-29 cells. Cells were pre-incubated with 25 µM Resv or 500 µM 5-ASA or both (25 µM Resv plus 500 µM 
5-ASA) and then exposed to a combination of cytokines. iNOS (A) and COX-2 (B) mRNA production was 
evaluated after 6 hours by qRT-PCR, as described in “Materials and Methods”, and expressed as percentage of 
cytokine-stimulated cells. Values are mean ± SEM of at least three independent experiments, each one in duplicate. 
***P<0.001 vs Control, ##P<0.01, ###P<0.001 vs Cytokines and $$$P<0.001 vs 5-ASA plus Cytokines.  
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4.4 Resv per se or in combination with 5-ASA did not prevent 
cytokine-induced IkB-α degradation, in HT-29 cells 
In order to verify the involvement of NF-kB pathway in the protection afforded by Resv 
alone or in combination with 5-ASA, cells were stimulated with cytokines in the absence and 
presence of the compounds and the degradation of IkB-α was analysed by Western blotting. As 
previously observed [8], 30 minutes after cells stimulation, the mixture of cytokines induced 
the degradation of IkB-α, resulting in a decrease of this protein to about 75% relative to a control 
(non-treated cells). As shown in Figure 6, Resv was not able to prevent the degradation of 
IkB-α, either alone or associated with 5-ASA. 
 
 
 
Figure 6 - Resv does not prevent IkB-α degradation induced by cytokines, in HT-29 cells. Cells were pre-incubated 
with 25 µM Resv or 500 µM 5-ASA or both (25 µM Resv plus 500 µM 5-ASA) and then exposed to a combination 
of cytokines for 30 minutes. IkB-α degradation was analysed in cytoplasmic extracts by Western blotting, as 
described in “Materials and Methods”, and expressed as percentage of control cells, i.e. cells not treated. Values 
are mean ± SEM of at least three independent experiments, each one in duplicate. ***P<0.001 vs Control. 
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4.5 Resv inhibited expression of pro-inflammatory markers in 
cytokine-stimulated HT-29 cells via JAK-STAT pathway 
In pursuit of knowing more about the mechanisms underlying the protection afforded by 
Resv against inflammation, in our experimental conditions, further pathways beyond NF-kB 
were explored, namely that involving the transcription factor STAT1. Thus, the ability of Resv 
to decrease the levels of the tyrosine (Tyr) 701 phosphorylated form of this transcription factor 
in the nucleus was monitored. As verified in Figure 7A, Resv was able to inhibit the 
cytokine-induced levels of activated (Tyr701 phosphorylated) STAT1 in the nucleus in a similar 
way to 5-ASA, but at a concentration 20 times lower. The association of Resv with 5-ASA did 
not elicit an increase in efficiency in this pathway. In order to further illustrate the ability of the 
compounds under study in decreasing the amount of Tyr701 phospho-STAT1 in the nucleus of 
cytokine-stimulated HT-29 cells, immunocytochemical studies were performed. Representative 
confocal images of HT-29 cells shown in Figure 7B denoted nuclear staining patterns consistent 
with the results of immunoblotting of the nuclear extracts. Microscopic data obtained with 
5-ASA plus cytokines and with the combination (Resv and 5-ASA) plus cytokines were very 
similar to those depicted in Figure 7B for Resv alone plus cytokines and, thus, they were not 
represented, for the sake of clarity. 
 
 
 
Figure 7 - Resv decreases activated-STAT1 levels in the nucleus of cytokine-stimulated HT-29 cells more 
efficiently than 5-ASA. Cells were pre-incubated with 25 µM Resv or 500 µM 5-ASA or both (25 µM Resv plus 
500 µM 5-ASA) and then exposed to a combination of cytokines for 30 minutes. The levels of Tyr701 
phospho-STAT1 were analysed in nuclear extracts by Western blotting (A), as described in “Materials and 
Methods” and expressed as percentage of cytokine-stimulated cells. Values are mean ± SEM of at least three 
independent experiments, each one in duplicate. ***P<0.001 vs Control and ##P<0.01 vs Cytokines. (B) 
Representative confocal microscopy pictures of non-stimulated, cytokine-stimulated and Resv pre-incubated 
HT-29 cells. Simultaneous DNA labelling with Hoechst was performed to visualize the nuclear compartments.  
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4.6 The protection afforded by Resv alone or in combination with 5-ASA 
against cytokine-induced inflammation involved MAPKs signalling, in 
HT-29 cells 
Being aware that the upstream kinases, such as p38 and SAPK/JNK MAPKs, play an 
important role in the regulation of the activation of several transcription factors, we also 
evaluated the effects of Resv, alone or in combination with 5-ASA, on p38 MAPK and 
SAPK/JNK phosphorylation (activation). It was observed (Figure 8A and 8B) that the 
combination of cytokines, after 30 min of cell-stimulation, induced the phosphorylation of p38 
MAPK and of SAPK/JNK. Resv alone or in combination with 5-ASA maintained the levels of 
activated p38 MAPK in HT-29 cells (Figure 8A), but counteracted the cytokine-induced 
activation of SAPK/JNK, in those cells (Figure 8B). On the other hand, 5-ASA alone, in such 
activated cells, did not affect neither p38 MAPK nor SAPK/JNK activation. However, cells 
pre-incubation with 5-ASA plus Resv significantly increased the suppressive effect of Resv on 
SAPK/JNK phosphorylation.  
 
 
 
Figure 8 - p38 MAPK and SAPK/JNK are involved in resveratrol protection, alone or plus 5-ASA, in 
cytokine-stimulated HT-29 cells. Cells were pre-incubated with 25 µM Resv or 500 µM 5-ASA or both (25 µM 
Resv plus 500 µM 5-ASA) and then exposed to a combination of cytokines for 30 minutes. Phospho-p38 MAPK 
(A) and phospho-SAPK/JNK (B) expressions were evaluated in total extracts by Western blotting, as described in 
“Materials and Methods”, and expressed as percentage of cytokine-stimulated cells. Values are mean ± SEM of at 
least three independent experiments, each one in duplicate. ***P<0.001 vs Control (non-treated cells), #P<0.05, 
###P<0.001 vs Cytokines, $$$P<0.001 vs 5-ASA plus Cytokines and &P<0.05 vs Resv plus Cytokines. 
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4.7 Resv, unlike 5-ASA, exerted a strong inhibition in the generation of 
intracellular reactive species, in cytokine-stimulated HT-29 cells 
It is well known that the formation of intracellular reactive species is close related to the 
inflammatory process. Thus, the ability of Resv, in comparison and associated with 5-ASA, to 
inhibit cytokine-induced intracellular oxidative stress was assessed by 
dichlorodihydrofluorescein fluorescence. A time-course analysis was carried out, following 
cytokine challenge. As shown on the top of Figure 9, the intracellular levels of reactive species 
started to increase after 8 hours of cell incubation with cytokines and were maintained until 24 
hours. To assess the effects of Resv and/or 5-ASA, the experiment was conducted with 1 hour 
of cell pre-incubation with the compounds, followed by 16 hours of incubation with cytokines. 
As evidenced in the bar graph and typically shown in the pictures on the right of Figure 9, Resv 
exhibited a stronger efficiency as an antioxidant than 5-ASA, and the association Resv and 
5-ASA seems not to potentiate the effect of Resv per se. 
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Figure 9 - Resv inhibits cytokine-induced oxidative stress in a greater extent than 5-ASA, in HT-29 cells. Cells 
were pre-incubated with 25 µM Resv or 500 µM 5-ASA or both (25 µM Resv plus 500 µM 5-ASA) for 1 hour 
and then exposed to a combination of cytokines for 16 hours. Reactive species production was measured after 16 
hours of incubation with cytokines, by oxidation of the probe dichlorodihydrofluorescein, expressed in terms of 
fluorescence intensity relative to cytokine-stimulated HT-29 cells. A time-course of HT-29 reactive species 
production following cytokine challenge is presented on the top and representative images obtained by 
fluorescence microscopy (400x) of cells at 16 hours after cytokine treatment, in the absence or presence of 25 µM 
Resv and/or 500 µM 5-ASA are presented on the right. Values are mean ± SEM of at least three independent 
experiments, each one in duplicate. **P<0.01 vs Control, #P<0.05, ##P<0.01 vs Cytokines and $P<0.05 vs 5-ASA 
plus Cytokines. 
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5. Discussion 
The growing knowledge on the cell signalling pathways, underlying the inflammatory 
process that characterizes Inflammatory Bowel Disease [22, 35], has allowed the investigation 
of better target strategies to limit IBD progression. However, despite the advances in the 
pharmacological treatment that have been made in the last years, this disease remains devoid 
of cure and, consequently, the pharmacological management is mainly used to prevent and to 
treat symptoms and still induce or maintain the remission periods [23]. On the other hand, given 
that IBD patients often become refractory to the existing therapies, several lines of evidence 
show that many patients take some form of dietary supplement to achieve extra benefits [23, 
36].  
The anti-inflammatory role of polyphenols in chronic inflammatory diseases as IBD has 
been supported by many authors, who believe that the consumption of these biological 
phytochemicals can be highly advantageous to prevent or limit disease progression [5, 6, 8]. 
Resveratrol is a non-flavonoid polyphenol, particularly abundant in grapes and red-wine, whose 
action mechanisms have been extensively studied in the last decades. However, one of the major 
concerns about Resv efficacy is related to its low oral bioavailability [16, 17]. In fact, it is 
estimated that after oral intake, Resv can be extensively metabolized in the liver and intestine, 
resulting in a very low bioavailability in humans [10, 16]. Nevertheless, there are evidences 
demonstrating that this compound is able to accumulate in specific tissues, particularly in the 
intestinal tissue, where its glucuronic acid and sulfate conjugates, the major metabolites of 
Resv, may work as a pool of the active compound that is released upon the action of 
β-glucuronidases or sulfatases [16, 37]. This suggests that Resv may be particularly attractive 
to modulate the inflammatory process settled in IBD patients.  
In the present study, it was first examined the impact of Resv, alone or in combination with 
the pharmaceutical agent 5-ASA, on the HT-29 cell viability. Afterward, considering that 
beyond its bioavailability, another major concern about Resv helpfulness is related to some 
studies pointing out that the consumption of high doses of polyphenols may be deleterious to 
the liver [18, 38], the possible hepatotoxicity of our compounds was assessed on HepG2 cell 
line. To exclude any possible toxicity, the selected concentrations for the next experiments were 
25 µM Resv and 500 µM 5-ASA. The reported capacity of Resv to reduce the levels of some 
pro-inflammatory mediators in macrophages [13] motivated us to verify its ability to counteract 
the induction of NO and PGE2 production by cytokines in HT-29 cells, comparing its action 
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with that of the drug 5-ASA. Resv showed to be efficient in inhibiting cytokine-induced NO 
and PGE2 production, in a concentration 20 times lower than 5-ASA. Accordingly, in a study 
by Zhong et al [12], Resv showed similar effects in LPS-stimulated BV-2 microglial cells. The 
combination of Resv and 5-ASA did not give any evidence of enhanced efficiency, in our 
experimental conditions.  
To assess whether the above protective effect of Resv, concerning pro-inflammatory 
mediators, was exerted via inhibition of iNOS and COX-2, both protein and mRNA production 
were evaluated. Our results showed that Resv can suppress transcriptionally the 
cytokine-induction of these two enzymes, in a greater extent than 5-ASA, revealing its 
anti-inflammatory superiority and, on the other hand, that the inhibition of iNOS and COX-2 
are related to the reduction of NO and PGE2 production induced by Resv. This is consistent 
with the results previously reported by Cianciulli et al [39], showing the ability of Resv to 
inhibit LPS-induced COX-2 and PGE2 production, in Caco-2 cells.  
The transcriptional regulation of pro-inflammatory markers is a strictly controlled event 
regulated by several transcriptional factors as NF-kB. NF-kB pathway is one of the most studied 
regulators of the transcription of pro-inflammatory genes, such as those of iNOS and COX-2. 
Besides, it is known that this pathway is usually induced in the intestine of IBD patients [29]. 
It turns out that in our experimental conditions, Resv could not prevent the degradation of IkB-α 
which is a well-established step for the classical activation of NF-kB pathway [29]. Our results 
are, hence, apparently in contradiction to those reported by Zhong et al [12], demonstrating the 
inhibition of LPS-induced activation of NF-kB pathway by Resv in microglial cells. In fact, in 
our study, Resv showed to be not able to down-regulate the activation of NF-kB pathway, either 
alone or in combination with 5-ASA. Therefore, the anti-inflammatory effect of Resv should 
be explained by the involvement of an alternative cell signalling pathway, such as JAK-STAT 
pathway, which is also induced in IBD patients [32]. In a previous study from our group, it was 
demonstrated for the first time, the ability of 5-ASA to decrease the amount of activated STAT1 
in the nucleus of HT-29 cells, by evaluating the levels of phosphorylated STAT1 at Tyr701 [8]. 
It is believed that after IFN-γ-receptor stimulation, STAT1 is phosphorylated at Tyr701, being 
this event essential for STAT1 dimerization, its translocation to the nucleus and DNA binding 
or, in other words, for STAT1 activation [40]. In the present study, Resv ability to reduce the 
levels of Tyr701 phosphorylated STAT1 in the nucleus of HT-29 cells was clearly 
demonstrated. The combination of Resv with 5-ASA showed a similar effect to that of the 
compounds alone. To our knowledge, no study dealing with the ability of Resv to reduce 
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cytokine-increased levels of Tyr701 phosphorylated STAT1, in the nucleus of HT-29 cells, has 
been reported yet. Moreover, this finding is in line with the observation of Capiralla et al [41], 
demonstrating the suppressive effect of Resv on LPS-induced phosphorylation of STAT1 at 
Tyr701 in RAW 264.7 macrophages and BV-2 microglial cells.  
The observed reduction of activated STAT1 accumulated in the nucleus induced by Resv in 
HT-29 cells, may have an extremely important impact in the context of IBD, since besides its 
implications for the inhibition of many pro-inflammatory genes, it can contribute for the 
prevention of radiation resistance acquired by IBD patients during radiotherapy treatment, 
which has been associated to high levels of nuclear STAT1 [42]. In fact, IBD patients exhibit a 
high risk of developing colorectal cancer as compared to healthy population [43] and, for this 
reason, the use of anti-inflammatory compounds with the potential to inhibit that event (acting 
as anticancer agents) can be of great importance in IBD context. Therefore, taking into account 
the range of concentrations at which Resv and 5-ASA exert anti-inflammatory effects, Resv 
proved to give further benefits in the context of IBD as compared to 5-ASA. 
Seeking more information about the protective role of Resv as compared to 5-ASA, the 
involvement of MAPK pathway was studied. MAPKs are a group of enzymes considered as 
instigative controllers of many downstream signalling pathways, with relevance, for example, 
in the activation of some transcription factors [31]. The most known subfamilies of MAPKs are 
ERK 1/2, SAPK/JNK and p38 MAPK. ERK 1/2 is strongly activated by growth factors and in 
a lesser extent by cytokines [44]. In contrast, SAPK/JNK and p38 MAPK are strongly activated 
by cytokines, such as TNF-α [44]. This report shows that, contrarily to what happens with 
5-ASA, Resv inhibited cytokine-induced phospho-SAPK/JNK levels, in HT-29 cells. The 
combination of Resv with 5-ASA seemed to enhance the ability of Resv to decrease the levels 
of this phosphorylated protein. Large body of evidence suggests that SAPK/JNK pathway is an 
important signal transduction pathway implicated in IBD [45] and for this reason there is a 
recent considerable interest in the development of anti-JNK therapies [45]. Towards this goal, 
several studies have been conducted demonstrating the effectiveness of some JNK inhibitors in 
the protection against pathophysiology features of experimentally induced IBD in some in vivo 
models [46, 47]. On the other hand, SAPK/JNK pathway is also involved in the phosphorylation 
of STAT1 at Serine 727 [48] and it is known that this specific phosphorylation is required for 
the maximization of the transcriptional potential of STAT1. In fact this post-translational 
modification is important, for instance, for the modulation of the interaction of STAT1 with 
co-activator proteins [49]. Thus, our present data suggest that the anti-inflammatory protection 
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afforded by either Resv alone or in combination with 5-ASA involves the prevention of 
SAPK/JNK activation and the subsequent impairment of the maximization of STAT1 
transcriptional potential. This is a meaningful finding in the light of the therapeutic potential of 
JNK inhibitors. 
Besides, there is accumulating evidence that p38 MAPK can also mediate the STAT1 Ser727 
phosphorylation [48, 50]. This event would enhance PIAS1 (protein inhibitor of activated 
STAT1) binding and SUMO-1 (small ubiquitin-related modifier-1) conjugation to STAT1 [51]. 
PIAS are a family of proteins implicated in the inhibition of STAT-mediated gene activation 
through many mechanisms, such as inhibiting DNA binding and promoting SUMO conjugation 
of STAT1 [40]. SUMOylation is a post-transcriptional modification that, in the case of STAT1, 
seems to function as a negative regulator, since inhibits STAT1 Tyr701 phosphorylation, 
prevents STAT1 DNA binding and also promotes its dephosphorylation [40, 51-53]. Thus, p38 
MAPK induced maximization of STAT1 transcriptional potential (by phosphorylation on 
Ser727) and this event would precede the relatively slow emergence of STAT1 SUMOylation, 
triggering a negative feedback loop through PIAS1 and SUMO recruitment [52]. Remarkably, 
our data show that cytokine-induced activation (phosphorylation) of p38 MAPK was not 
counteracted by Resv and/or 5-ASA. This probably means that the protective effect of Resv or 
Resv plus 5-ASA takes advantage of the p38 MAPK-mediated negative feedback of STAT1. 
These findings strengthen our knowledge regarding the pathways involved in the protection 
afforded by Resv, 5-ASA and the combination of Resv with 5-ASA, in activated intestinal cells. 
On the other hand, several studies demonstrate that oxidative stress and inflammation are 
closely related and therefore persistently elevated levels of ROS can contribute to the 
perpetuation of the inflammatory process and ultimately to cancer [54]. For this reason, we 
evaluated the effect of our compounds in the production of ROS. Interestingly, Resv 
pre-treatment of HT-29, before cytokine challenging, prevented the cytokine-induction of 
oxidative stress in these cells, which was not verified with 5-ASA pre-treatment. Thus, it is 
noteworthy that Resv has a more efficient antioxidant activity than 5-ASA in this type of cells. 
In conclusion, under our experimental conditions, Resv revealed a stronger 
anti-inflammatory and antioxidant activity than 5-ASA, given that in a concentration 20 times 
lower, Resv was able to efficiently decrease cytokine-induced pro-inflammatory mediators (NO 
and PGE2) production, pro-inflammatory enzymes (iNOS and COX-2) expression and 
intracellular reactive species formation. Moreover, in spite of not being able to prevent 
cytokine-induced IkB-α degradation, Resv efficiently decreased the amount of Tyr701 
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phosphorylated STAT1 in the nucleus of HT-29 cells, suggesting that JAK-STAT pathway is 
one of the key cascades involved in its anti-inflammatory activity. On the other hand, in contrast 
to 5-ASA, Resv was also able to inhibit the activation of the SAPK/JNK pathway, preventing 
the transcriptional potential maximization of the remaining Tyr701-phosphorylated STAT1. 
Furthermore Resv takes advantage of the negative feedback of STAT1, thought p38 MAPK 
pathway.  
Overall, Resv did not exhibit a synergistic effect with 5-ASA.  
Put together, data collected from our previous work and gathered from the present work 
support our belief that two polyphenols with completely different chemical structures, 
cyanidin-3-glucoside and resveratrol, abundant in a Mediterranean Diet, can assume a more 
efficient anti-inflammatory role than that of 5-ASA, a well-known pharmacological agent, used 
as the cornerstone of treatment for IBD patients. However, we are aware that the therapeutic 
value of these compounds must be confirmed by in vivo experiments, which are planned in a 
near future. 
Considering that current treatment options for IBD patients are not completely successful, 
the Mediterranean Diet (rich in those polyphenolic compounds) can be envisaged as an 
interesting strategy to promote remission periods in IBD patients, limiting IBD progression and 
even to obviate colorectal cancer, which is commonly inflicted on these patients. 
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1. Abstract 
Dietary polyphenols, allying their valuable anti-inflammatory activity to their antioxidant 
effect, have been envisaged as promising adjuvant approaches to conventional drugs usually 
prescribed for patients with Inflammatory Bowel Disease (IBD). This study investigated 
whether the nuclear factor erythroid 2 (Nrf2) and peroxisome proliferator-activated 
receptor-gamma (PPAR-γ) pathways were involved in the protection afforded by two 
polyphenols highly abundant in red-wine, cyanidin-3-glucoside and resveratrol, against 
cytokine-induced inflammation and oxidative insult in HT-29 cells, in comparison with the 
drug, 5-aminosalicylic acid (5-ASA). Our data show that cyanidin-3-glucoside and resveratrol 
induced Nrf2 activation, increased hemoxygenase-1 and glutamate cysteine ligase mRNA 
expression, enhanced reduced glutathione to oxidized glutathione ratio and inhibited reactive 
species production, in cytokine-challenged cells, at much lower concentrations than 5-ASA. 
Unlike cyanidin-3-glucoside, resveratrol and 5-ASA also increased nuclear levels of PPAR-γ 
in cytokine-stimulated cells. In conclusion, both polyphenols might be interesting as 
nutraceuticals for the prevention of IBD progression. 
 
2. Graphical Abstract 
 
Representative scheme of some signalling pathways involved in the protection afforded by C3G and Resv against 
cytokine-induced inflammation and oxidative response in HT-29 cells, in comparison with 5-ASA.  
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3. Introduction 
The human intestine is colonized by a huge number of microorganisms, chiefly in its distal 
portion, commonly called microbiota or commensal flora [1]. The relationship established 
between the host and the commensal flora is of a symbiotic nature, since, for instance, the 
microbiota increases the digestion capacity of the host and helps him in preventing pathogen 
colonization, benefiting, in turn, from both the nutrients and the warm temperature of the human 
body [1-3]. However, given the close proximity between the human intestine (with a surface 
area of approximately 200 m2) and the resident microorganisms and its constant exposure to 
pathogenic agents from the diet, the intestinal epithelium has devised strategies to avoid 
microbial breach and to assure intestinal homeostasis [1]. This is accomplished thanks to the 
intestinal epithelium’s ability to function as an efficient barrier to be underpinned by its capacity 
of triggering adequate immune responses against potential pathogens-derived signals [4-6]. 
Intestinal epithelial cells as well as immune cells express pattern-recognition receptors (PRRs), 
which after detecting microbial-associated molecular patterns (MAMPs), namely 
lipopolysaccharide and flagellin, up-regulate a panoply of pro-inflammatory signalling 
cascades, leading to the transcription of several inflammatory genes, to the production and 
release of many inflammatory mediators and to the generation of reactive oxygen and nitrogen 
species (ROS/RNS) [2, 7, 8]. Hence, cell inflammation and oxidative reactions as self-limited 
processes are involved in the orchestration of innate and adaptive immune responses in order 
to eradicate potential pathogens [9]. However, a persistent induction of intestinal inflammation 
with excessive production of reactive species can become pathological, as in the case of the 
well-known chronic inflammatory disorder of the gastrointestinal tract, the Inflammatory 
Bowel Disease (IBD) [9-11]. Although the etiology of IBD remains uncertain, it is known that 
an interplay between genetic predisposition, due, for instance, to mutations in 
nucleotide-binding oligomerization domain containing 2 (NOD2) gene, and environmental 
factors, such as stress, diet and antibiotic intake, provokes a deregulation of the immune 
reaction to dietary antigens or commensal microorganisms, culminating in the perpetuation of 
uncontrolled and exacerbated inflammatory and oxidative responses [3, 11, 12]. 
Dietary polyphenols can be considered excellent candidates as a complementary nutritional 
approach to treat chronic inflammatory diseases, as IBD, due to the growing wealth of 
information demonstrating their potent antioxidant capacity allied to their beneficial 
anti-inflammatory effect in many in vitro and in vivo models [13-16]. Furthermore, although 
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the low oral bioavailability of the majority of polyphenols can constitute a great handicap for 
its use in the context of several diseases [17], in the particular case of IBD, the poor oral 
bioavailability is not a true problem, since several studies have suggested that the intestine is 
the organ where dietary polyphenols possibly achieve the highest concentrations in the human 
body [10, 18, 19]. On the other hand, it has been reported that these compounds can modulate 
intestinal inflammatory response, which is an important component of IBD pathogenesis. In 
this context, several cell signalling pathways have been proposed as potential targets of 
polyphenols protective activity against intestinal inflammation and oxidative insult [18]. 
Nuclear factor erythroid 2 (Nrf2) signalling pathway is considered the most important cellular 
defence against oxidative stress [20], being also important in the suppression of the 
inflammatory process by counteracting some pro-inflammatory cascades, as nuclear factor 
kappa B (NF-kB) pathway, among other mechanisms [21]. Also, the peroxisome 
proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor, was recently considered 
important for inhibiting intestinal inflammatory response and defending cells from oxidative 
damage [22, 23].   
Among polyphenols, cyanidin-3-glucoside (C3G) and resveratrol (Resv) (Figures 1A and 
B, respectively) are widespread in the human diet, particularly in fruits, vegetables and 
red-wine, with recognized beneficial health effects [24]. The interest in the study of these 
polyphenols arose, at least in part, from their relatively high contents in red-wine, which is very 
much appreciated by Western Societies [10, 17]. Recently, we have shown that both 
polyphenolic compounds have a more efficient anti-inflammatory activity than 
5-aminosalicylic acid (5-ASA), a well-known anti-inflammatory drug, commonly used in the 
treatment of IBD (Figure 1C), by decreasing the production of inflammatory markers, via 
down-regulation of cytokine-induced Janus kinase/signal transducer and activator of 
transcription (JAK-STAT) pathway, in a colonic epithelial cell line [13, 14].  
 
 
Figure 1 - Chemical structures of cyanidin-3-glucoside (A), resveratrol (B) and 5-aminosalicylic acid (C). 
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To give continuity to the work previously developed and considering that inflammation and 
oxidative stress are crucial close related phenomena in the pathogenesis of IBD [11], the present 
study was conducted to elucidate the ability of these polyphenols to induce antioxidant and 
detoxifying cellular defences, via Nrf2 up-regulation, in comparison with 5-ASA, by using the 
same in vitro model, the HT-29 cell line and the same experimental conditions. On the other 
hand, since 5-ASA has been suggested to be an agonist of PPAR-γ, relying its 
anti-inflammatory activity on PPAR-γ pathway [25], another goal of this work was to scrutinize 
the involvement of this pathway in the protection afforded by either C3G or Resv against 
cytokine-induced inflammatory and oxidative events in HT-29 cells, as compared to 5-ASA. 
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4. Materials and Methods  
4.1 Reagents 
Cyanidin-3-glucoside (C3G) and resveratrol (Resv) purified from natural sources were 
obtained from Extrasynthése (Genay, France). Their purity were above 95%, as measured by 
HPLC, and they were used as a solution in DMSO (5 mM) and stored at -20 oC. 
Laboratory chemicals, namely, dimethylsulfoxide (DMSO), 
2′,7′-dichlorodihydrofluorescein diacetate (DCFH2-DA), phenylmethylsulfonyl fluoride 
(PMSF), streptomycin/penicillin, protease inhibitor cocktail, phosphatase inhibitors and 
sodium dodecyl sulfate (SDS) were purchased from Sigma-Aldrich Co.  
For cell culture, Dulbecco’s modified Eagle’s medium (DMEM), 0.25% trypsin, fetal bovine 
serum (FBS) and phosphate-buffered saline (PBS) pH 7.4, were obtained from 
Gibco-Invitrogen. 
Mouse monoclonal antibody to PPAR-γ was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA) and rabbit polyclonal antibody to lamin B1 was obtained from Abcam 
(Cambridge, UK). 
IL-1α, TNF-α and IFN-γ were purchased from Invitrogen (NY, USA). 
 
4.2 Cell Culture  
Human colon cancer cell line (HT-29) was obtained from European Collection of Cell 
Cultures (Porton Down, Salisbury, UK). Cells were grown in DMEM supplemented with 10% 
FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37ºC in a humidified atmosphere of 
5% CO2. Cells were sub-cultured at confluence and used between the fourth and the twentieth 
passage. Before each experiment, cells at 80% confluence were starved in serum-free medium 
for 24 hours. Growth-arrested cultures, in medium without FBS, were treated according to the 
various experimental purposes. 
HT-29 cells were stimulated with a cocktail of cytokines consisting of 10 ng/ml IL-1α, 20 
ng/ml TNF-α and 60 ng/ml IFN-γ. Each cytokine was previously diluted in PBS with 1% bovine 
serum albumin (BSA) and then added to cells when convenient. Cells were pre-incubated with 
25 µM C3G or 25 µM Resv per se or in combination with 500 µM 5-ASA, for 1 hour and then 
exposed to the pro-inflammatory cytokines for different time points, depending on the assay. 
The concentrations of polyphenols and 5-ASA were selected taking into consideration the range 
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of concentrations referred in the literature as being reached at the intestinal level [10, 18, 26]. 
 
4.3 Evaluation of Nrf2 DNA Binding Activity 
DNA binding activity of Nrf2 was measured in nuclear extracts using the TransAMTM Nrf2 
protein assay (Active Motif, CA, USA), an ELISA-based method with high sensitivity and 
reproducibility.  
For preparation of nuclear extracts, washed cells were lysed in an ice-cold buffer containing 
10 mM Tris–HCl, 10 mM NaCl, 3 mM MgCl2, 0.5% Nonidet P-40 and 1% protease inhibitor 
cocktail, pH 7.5, for 5 minutes on ice. Afterwards, lysates were centrifuged at 5000 rpm for 5 
minutes at 4ºC and the pellets were collected and resuspended in 50 µl of complete lysis buffer 
(a solution provided by Active Motif, CA) and left on ice for 30 minutes. Then, lysates were 
centrifuged at 14000 rpm for 20 minutes at 4ºC and the supernatants (nuclear extracts) were 
saved at -80ºC.  
DNA binding activity of Nrf2 was evaluated in 20 µg of nuclear protein, according to the 
manufacturer’s protocol and the results expressed in relative terms. 
 
4.4 Total RNA Extraction and quantitative Real-Time RT-PCR (qRT-PCR) 
Total RNA was extracted from HT-29 cells seeded in six-well-plates (8 x 105 cells/well) by 
using the RNA extraction kit AurumTM Total RNA Mini (Bio-Rad, Hercules, CA, USA), 
according to the manufacturer’s instructions. Extracted RNA was quantified using a NanoDrop 
ND-1000 spectrophotometer at 260 nm and its purity and integrity were assessed by the ratio 
of absorbances at 240/260 and 280/260 nanometers. A constant amount of RNA (1 µg/sample) 
was reverse transcribed into cDNA, using the NZY First-Stand cDNA Synthesis Kit (NZYtech, 
Portugal), according to the manufacturer’s protocol. PCR reactions were performed with 25 
µg/ml of transcribed cDNA. The primers for the HO-1, the catalytic and modifier subunits of 
glutamate cysteine ligase (GCLC and GCLM, respectively) and the housekeeping gene 
HPRT-1 (hypoxanthine phosphoribosyltransferase-1) were designed using the Beacon 
Designer software (PREMIER Biosoft International, Palo Alto, CA) and the primers sequences 
were: HO-1, sense 5´- TCACTGTGTCCCTCTCTC -3’, antisense 
5’- ATTGCCTGGATGTGCTTT -3’; GCLC, sense 5’- ATTCTGAACTCTTACCTTGA -3’; 
antisense 5’- ATCTGGCAACTGTCATTA -3’; GCLM, sense 
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5’- AACTCTTCATCATCAACTA -3’; antisense 5’- AACTCCATCTTCAATAGG -3’ and 
HPRT-1, sense 5’- TGACACTGGCAAAACAATG -3’, antisense 
5’- GGCTTATATCCAACACTTCG -3’. Real time-PCR was performed in 20 µl of total 
volume, containing 2 µl of each primer (250 nM), 2 µl of cDNA of each sample, 10 µl of the 
IQ TM SYBR Green Supermix (Bio-Rad) and RNase-free distilled water to make up the volume 
to 20 µl, in a CFX96 TM Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). 
Thermal cycling conditions were the following: 3 minutes at 95 ºC to activate the iTaqTM DNA 
polymerase, then 45 cycles, each consisting of a denaturation step (95ºC, 10 seconds), an 
annealing step (55ºC, 30 seconds) and an elongation step (72ºC, 30 seconds). Fluorescence 
measurements were taken every cycle at the end of the annealing step and the specificity of the 
amplification products was evaluated through the analysis of the melting curve. The efficiency 
of the amplification reaction for each gene was calculated by running a standard curve of 
serially diluted cDNA sample. Gene expression was analysed using the Bio-Rad CFX Manager 
3.0 software (Bio-Rad, Hercules, CA, USA), which enables the analysis of the results with the 
Pfaffl method. The results for each gene of interest were normalized against HPRT-1, the 
housekeeping gene found to be stable under experimental conditions and expressed as a 
percentage of control cells, i.e. non-stimulated cells. 
 
4.5 Measurement of Reduced (GSH) and Oxidized Forms of Glutathione 
(GSSG) 
The intracellular contents of GSH and GSSG were determined by a fluorimetric assay, as 
described by Hissin and Hilf [27]. Briefly, GSH and GSSG are measured upon their reactions 
with a fluorescent reagent, o-phthaldialdehyde (OPT), at pH 8 or pH 12, respectively. Before 
GSSG determination, GSH is complexed to N-ethylmaleimide (NEM) to prevent its oxidation 
and consequently its interference with GSSG quantification. 
After 24 hours of incubation, cells were washed twice with cold PBS, detached and 
resuspended in 500 µl of 100 mM Na2HPO4, pH 8. After addition of an equal volume of 0.6 M 
HClO4, the mixture was maintained on ice for 5 minutes. After vigorous vortex, the cellular 
extracts were centrifuged at 14000 rpm for 5 minutes, at 4ºC. Supernatants were collected and 
the respective pellets were resuspended in 1 M NaOH for protein quantification. For GSH 
quantification, 100 µl of each sample was added to 1800 µl of 100 mM Na2HPO4, pH 8 buffer, 
and to 100 µl of OPT and maintained in the dark, at room temperature, for 15 minutes, before 
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fluorescence detection. A standard curve was also prepared with known concentrations of GSH. 
For GSSG quantification, NEM was added to an aliquot of each sample for 30 minutes to 
complex GSH, and the following protocol was similar to that mentioned above to GSH 
measurement, but using 100 mM NaOH instead of Na2HPO4, to carry out the reaction at pH 12. 
Fluorescence intensity was read in a Synergy HT plate reader (Bio-Tek Instruments) (excitation 
and emission wavelengths at 350 and 420 nm, respectively). Cellular GSH and GSSG contents 
were calculated using concurrently run standard curves and expressed as nmol GSH or GSSG 
per milligram of protein. Cellular protein was determined by using the Bio-Rad protein assay 
reagent (Bradford assay), according to the manufacturer’s specifications (Bio-Rad, USA). 
 
4.6 Evaluation of Intracellular Reactive Species 
The production of intracellular reactive species were assessed by using the non-fluorescent 
probe 2′,7′-dichlorodihydrofluorescein diacetate (DCFH2-DA), which permeates cell 
membranes and may be deacetylated by cellular esterases and rapidly oxidized by reactive 
species, yielding the fluorescent 2′,7′-dichlorofluorescein (DCF) [28]. Briefly, cells in 12-well 
plates (4 x 105 cells/well) were previously incubated in the presence or in the absence of C3G 
and 5-ASA and further subjected to the combination of cytokines for 24 hours. After that period 
of time, the cells were incubated with 5 μM DCFH2-DA in DMSO, at 37°C, in the dark for 15 
minutes. Cells were then washed with PBS and maintained in 0.5 ml of PBS during the 
fluorescence intensity measurements in a Synergy HT plate reader (Bio-Tek Instruments) 
(excitation and emission wavelengths at 485 and 530 nm, respectively). Cells were also 
observed in an inverted fluorescence microscope (Zeiss Axiovert 40), using a FITC filter.  
 
4.7 Western-blot Analysis 
As previously described [13], nuclear cellular protein extracts from HT-29 cells were 
prepared and analysed by Western-blotting. Cells were washed with cold PBS and then lysed 
in an ice-cold buffer containing 10 mM Tris–HCl, 10 mM NaCl, 3 mM MgCl2, 0.5% Nonidet 
P-40 and 1% protease inhibitor cocktail, pH 7.5, for 5 minutes on ice. Afterwards, lysates were 
centrifuged at 5000 rpm for 5 minutes at 4ºC and the pellets were collected and resuspended in 
an ice-cold buffer with 20 mM Hepes, 5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 300 mM 
NaCl, 20% (w/v) glycerol, and 1% protease inhibitor cocktail, pH 7.5 and left on ice for 30 
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minutes. Then, the mixture was centrifuged at 14000 rpm for 20 minutes at 4ºC and the 
supernatants, the nuclear extracts, were saved at -80ºC. 
Protein concentration was determined by using the Bio-Rad protein assay reagent (Bradford 
assay), according to the manufacturer’s specifications (Bio-Rad, USA). Fifty micrograms of 
reduced and denatured nuclear proteins were separated by SDS/PAGE electrophoresis on a 10% 
(v/v) acrylamide gel and transferred onto polyvinylidene difluoride (PVDF) membranes 
(Amersham Biosciences, UK) by electroblotting. To avoid non-specific binding, membranes 
were blocked with skimmed milk in TBS pH 7.6 supplemented with 0.1% (v/v) Tween 20 
(TBS-T: 20 mM Tris–HCl, 150 mM NaCl, 0.1% Tween 20) and then probed with the antibody 
against PPAR-γ, overnight at 4ºC, with a constant low shaking. After finishing, membranes 
were washed three times and further incubated with the alkaline phosphatase-conjugated 
secondary antibody (2 hours at room temperature and constant shaking). Immunoreactive bands 
were detected by fluorescence in a Typhoon 9000 scanner (Amersham Biosciences) and 
analysed with the ImageQuant TM software from Amersham Biosciences. After analysis of the 
target protein, each blot was stripped off and reprobed with the primary antibodies against lamin 
B1, used as control for nuclear protein loading. 
 
4.8 Statistical Analysis  
All data were expressed as means ± SEM of at least 3 independent assays, each one in 
duplicate. Differences between groups were analysed by one-way analysis of variance 
(ANOVA) and Tukey’s post hoc test was used as appropriate. Values of p<0.05 were accepted 
as statistically significant. 
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5. Results  
5.1 Either C3G or Resv induced the activation of Nrf2, in cytokine-stimulated 
HT-29 cells 
Nuclear factor erythroid 2 (Nrf2) is a redox-sensitive transcription factor with a crucial role 
in counteracting the overproduction of reactive oxygen species as well as in inhibiting 
inflammation. Therefore, to progress our study of the mechanisms underlying the 
anti-inflammatory activity of C3G and Resv in comparison with 5-ASA, we intended to 
elucidate about their effects on this key transcription factor.  
So, in the present study, we started to ascertain the effect of a group of cytokines used as 
inflammatory stimulus on the modulation of Nrf2 activation, over time, as described in 
materials and methods. As shown in Figure 2A, Nrf2 DNA binding activity increased 
approximately twofold, compared to the levels in control cells (untreated cells) and remained 
enhanced up to 8 hours of cytokine challenge. However, after 16 hours of cytokine exposure, 
DNA binding activity of Nrf2 was similar to that of non-stimulated cells (control cells).  
 
Figure 2 – C3G and Resv increase Nrf2 activation in cytokine-stimulated HT-29 cells, in a more efficient way 
than 5-ASA. In 2A, cells were incubated with a combination of pro-inflammatory cytokines (Cyt) and the Nrf2 
DNA binding activity was evaluated over time. In 2B, cells were pre-incubated with 25 µM C3G, 25 µM Resv, 
500 µM 5-ASA or with combinations of each polyphenol with 5-ASA, for 1 hour, and then exposed to a cocktail 
of cytokines for 16 hours. The Nrf2 activation in cells was measured as described in “Materials and Methods” and 
expressed as percentage of control cells (C) (non-stimulated cells). Values are mean ± SEM of at least three 
independent experiments, each one in duplicate. *P<0.05, **P<0.01 and ***P<0.001 vs Control cells, #P<0.05, 
###P<0.001 vs Cytokines-stimulated cells.  
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Being aware that after 16 hours of cytokine-stimulation, this mixture of cytokines was no 
longer able to produce an increase in Nrf2 DNA binding activity, we investigated, at that time, 
the effect of C3G and Resv on Nrf2 DNA binding activity, in comparison with 5-ASA, in cells 
challenged or not challenged with the cytokine mixture. As depicted in Figure 2B, C3G and 
Resv per se, and the combination of C3G plus 5-ASA were successful in promoting the 
activation of Nrf2, in cytokine-exposed cells, similarly to 5-ASA. However, the stimulatory 
effect of C3G alone was clearly and statistically higher than that assigned to 5-ASA, particularly 
if the difference in the concentrations of the compounds are taken into account (25 µM C3G 
versus 500 µM 5-ASA). As compared to C3G, Resv showed a much lower activation effect of 
Nrf2, but also higher than that of 5-ASA, considering the difference in the concentrations (25 
µM Resv versus 500 µM 5-ASA). Of note is that the combination of 5-ASA with C3G or Resv 
did not increase those observed effects in cytokine-stimulated HT-29 cells. In cells not exposed 
to cytokines (control cells), DNA binding activity of Nrf2 was not induced neither by 
polyphenols, 5-ASA nor their combinations. 
 
5.2 C3G and Resv, unlike 5-ASA, up-regulated HO-1 mRNA expression, in 
cytokine-stimulated HT-29 cells 
In pursuit of knowing more about the beneficial effects of C3G and Resv in 
cytokine-stimulated HT-29 cells, we explored the ability of these polyphenols to modulate the 
expression of some Nrf2 target genes. Therefore, we evaluated the effect of those compounds 
in one ARE-regulated cytoprotective enzyme, the hemoxygenase-1 (HO-1), at a transcriptional 
level, in comparison with 5-ASA, by performing qRT-PCR (Figure 3).  
In this figure, it is observed that after a stimulation period (20 hours) of HT-29 cells with 
cytokines, the HO-1 mRNA levels were statistically similar to those in non-stimulated cells 
(control). The pre-treatment of control cells with the compounds under study, either alone or in 
combination with 5-ASA, in similar conditions, did not modify the HO-1 mRNA levels. 
Nevertheless, it is clear that in cytokine-stimulated cells, the pretreatment with either C3G or 
Resv induced per se a significant increase in the HO-1 mRNA expression. No additional 
remarkable effect was obtained with the pretreatment with C3G plus 5-ASA. In contrast with 
C3G alone, the pre-treatment with 5-ASA alone or in combination with Resv did not induce 
any increase in HO-1 mRNA levels, in cytokine-exposed cells. Therefore, it is worth of notice 
the very high efficiency of C3G and Resv in up-regulating HO-1 mRNA expression, an effect 
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not assigned to 5-ASA, in a concentration 20 times higher. 
 
 
 
 
 
Figure 3 – C3G and Resv, unlike 5-ASA, enhance mRNA expression of HO-1 in cytokine-stimulated HT-29 cells. 
Cells were pre-incubated with 25 µM C3G, 25 µM Resv, 500 µM 5-ASA or with combinations of each polyphenol 
with 5-ASA and then exposed to a cocktail of cytokines for 20 hours. The mRNA production of HO-1 was 
evaluated by qRT-PCR, as described in “Materials and Methods”, and expressed as percentage of control cells. 
Values are mean ± SEM of at least three independent experiments, each one in duplicate. ***P<0.001 vs Control 
cells, #P<0.05, ##P<0.01, ###P<0.001 vs Cytokines-stimulated cells.  
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5.3 C3G and Resv increased mRNA expression of catalytic and modifier 
subunits of GCL, in cytokine-stimulated HT-29 cells, in a much lower 
concentration than 5-ASA 
Glutamate cysteine ligase (GCL) is another ARE-regulated cytoprotective enzyme crucial 
for cellular defence against oxidative stress, by promoting the first-step of the synthesis of 
intracellular glutathione. The expressions of both GCL catalytic and modifier subunits (GCLC 
and GCLM, respectively) were evaluated, at a transcriptional level, by qRT-PCR, in HT-29 
cells challenged or not with a mixture of cytokines for 20 hours and pre-treated or not with 
C3G, Resv and/or 5-ASA. As patent in Figure 4, the expression of GCLC remained statistically 
unchanged after cytokine-exposure (Figure 4A), conversely to GCLM, whose expression 
slightly increased in cytokine-stimulated cells (Figure 4B).  
 
Figure 4 – C3G and Resv promote mRNA expression of GCLC and GCLM in cytokine-stimulated HT-29 cells, 
in a much lower concentration than 5-ASA. Cells were pre-incubated with 25 µM C3G, 25 µM Resv, 500 µM 
5-ASA or with combinations of each polyphenol with 5-ASA and then exposed to a cocktail of cytokines for 20 
hours. The mRNA production of both catalytic and modifier subunits of GCL (GCLC (4A) and GCLM (4B)) was 
evaluated by qRT-PCR, as described in “Materials and Methods”, and expressed as percentage of control cells. 
Values are mean ± SEM of at least three independent experiments, each one in duplicate. *P<0.05, **P<0.01 and 
***P<0.001 vs Control cells, #P<0.05 and ##P<0.01 vs Cytokines-stimulated cells.  
 
The pre-treatment of these cells with either C3G or Resv, alone or in combination with 5-ASA, 
before cytokine exposure, triggered a significant increase in the expression of both GCLC and 
GCLM, as compared to control cells, like with 5-ASA, but at a concentration 20 times lower 
(Figures 4A and 4B). The association of these polyphenols with 5-ASA did not significantly 
improve the effects of C3G and Resv alone. In cells not exposed to the inflammatory stimulus 
(control cells), the treatment with those compounds, in similar conditions, did not change 
significantly the expressions of GCL subunits (Figures 4A and 4B). 
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5.4 Unlike 5-ASA, C3G and Resv enhanced the GSH/GSSG ratio, in 
cytokine-exposed HT-29 cells 
Considering that C3G and Resv significantly increased the expression of GCL in 
cytokine-stimulated cells and that this enzyme is a major determinant of cellular glutathione 
levels, we evaluated the effects of those polyphenols on the reduced glutathione to oxidized 
glutathione ratio (GSH/GSSG ratio), in comparison with 5-ASA. As illustrated in Figure 5, the 
GSH/GSSG ratio did not undergo significant changes 24 hours after cytokine stimulation, 
remaining similar to that of unstimulated cells (control). However, in cytokine-exposed cells, 
the pre-incubation with 25 µM C3G or Resv alone resulted in a significant enhancement of the 
GSH/GSSG ratio. Similar results were obtained with the pre-incubation of these cells with Resv 
plus 5-ASA, but, on the contrary, neither the incubation with 5-ASA alone nor its combination 
with C3G was able to increase the GSH/GSSG ratio. In non-stimulated cells, the incubation 
with those compounds, in similar conditions, did not change the reduced/oxidized glutathione 
ratio. 
 
Figure 5 – C3G and in particular Resv enhance the GSH/GSSG ratio in cytokine-stimulated HT-29 cells, much 
more efficiently than 5-ASA.  Cells were pre-incubated with 25 µM C3G, 25 µM Resv, 500 µM 5-ASA or with 
combinations of each polyphenol plus 5-ASA and then exposed to a cocktail of cytokines for 24 hours. Cellular 
content of GSH and GSSG was measured by fluorescence intensity, as described in “Materials and Methods” and 
expressed in nmol of glutathione/mg protein. Values are mean ± SEM of at least three independent experiments, 
each one in duplicate. *P<0.05, **P<0.01 and ***P<0.001 vs Control cells, ###P<0.001 vs Cytokines-stimulated 
cells.  
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5.5 C3G, unlike 5-ASA, provoked a strong inhibition of intracellular reactive 
species production, in cytokine-stimulated HT-29 cells 
It is well-known that in response to chronic inflammation, the overproduction of intracellular 
reactive species occurs, and subsequently, several redox-sensitive transcription factors remain 
up-regulated, leading to the generation of more and more intracellular reactive species. As 
recently reported by us, this mixture of cytokines significantly increased reactive species 
production, as evaluated by dichlorodihydrofluorescein fluorescence, in a time-dependent 
manner [14]. Besides, in cytokine-stimulated cells, we have shown that the pre-incubation with 
Resv, either alone or in combination with 5-ASA, inhibited the formation of reactive species 
more efficiently than 5-ASA [14]. In this sequence, the potential protective effect of C3G was 
assessed, by using the same methodology. In agreement with the data previously reported by us 
[14], the exposure of HT-29 cells to the selected cocktail of cytokines for 24 hours, conducted 
to a significant increase in the intracellular levels of reactive species. As shown in the bar graph 
and in the top pictures of Figure 6, C3G alone exhibited a higher efficiency than 5-ASA in 
inhibiting intracellular reactive species production, particularly taking into account the 
difference in the concentrations used (25 µM C3G and 500 µM 5-ASA). The association of 
C3G plus 5-ASA did not significantly protect against reactive species formation, in 
cytokine-exposed cells. 
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Figure 6 – C3G inhibits reactive species generation in cytokine-stimulated HT-29 cells, more efficiently than 
5-ASA. Cells were pre-incubated with either 25 µM C3G, 500 µM 5-ASA or both 25 µM C3G plus 500 µM 
5-ASA for 1 hour and then exposed to a cocktail of cytokines for 24 hours. Intracellular reactive species generation 
was measured by oxidation of the probe dichlorodihydrofluorescein and expressed in terms of fluorescence 
intensity relative to cytokine-stimulated HT-29 cells. Representative images obtained by fluorescence microscopy 
(400x) of cells at 24 hours after cytokine treatment, in the absence or presence of 25 µM C3G and/or 500 µM 
5-ASA, are presented on the top. Values are mean ± SEM of at least three independent experiments, each one in 
duplicate. ***P<0.001 vs Control cells, #P<0.05 vs Cytokines-stimulated cells. 
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5.6 Resv, unlike C3G, increased the expression of PPAR-γ in the nucleus of 
cytokine-challenged HT-29 cells, similarly to 5-ASA, but in a much lower 
concentration 
Allying the knowledge about the involvement of peroxisome proliferator-activated receptor 
gamma (PPAR-γ) in the inhibition of both intestinal inflammation and oxidative events with 
some work suggesting that the anti-inflammatory action of 5-ASA is dependent on PPAR-γ 
[25], we attempted to evaluate the effects of C3G and Resv on the expression of this 
transcription factor in the nucleus of HT-29 cells, in comparison with 5-ASA. As demonstrated 
in Figure 7, none of the compounds in study was able to increase significantly the expression 
of PPAR-γ in the nucleus of cells not exposed to cytokines. However, in cells stimulated with 
the cytokines cocktail, Resv per se was able to increase the nuclear expression of this 
transcription factor in a similar extent to 5-ASA, but in a concentration 20 times lower. On the 
contrary, C3G did not enhance the nuclear expression of PPAR-γ, suggesting that this 
transcription factor is not involved in the protection afforded by this anthocyanin against the 
cytokine-induced inflammatory process in HT-29 cells.  
 
Figure 7 - Unlike C3G, Resv increases the nuclear accumulation of PPAR-γ in cytokine-stimulated HT-29 cells, 
similarly to 5-ASA, but in a much lower concentration. Cells were pre-incubated with either 25 µM C3G, 25 µM 
Resv, 500 µM 5-ASA or with combinations of each polyphenol with 5-ASA (25 µM C3G/Resv plus 500 µM 
5-ASA) and then exposed to a cocktail of cytokines for 16 hours. PPAR-γ expression was evaluated in nuclear 
extracts by Western blotting, as described in “Materials and Methods”, and expressed as percentage of control 
cells. Values are mean ± SEM of at least three independent experiments, each one in duplicate. *P<0.05 vs Control 
cells and #P<0.05 vs Cytokines-stimulated cells. 
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6. Discussion 
In spite of the etiology of Inflammatory Bowel Disease (IBD) remains unclear, it is widely 
accepted that inflammation and oxidative stress play a pivotal role in the pathogenesis of this 
disease [11].   
In the last decades, a flourishing research field has been focused on the study of the 
antioxidant and anti-inflammatory activities of several dietary polyphenols, suggesting that 
these phytochemical compounds can be envisaged as promising agents in the prevention and 
treatment of several chronic inflammatory disorders, as IBD [16, 18]. However, the precise 
cellular signalling mechanisms and targets involved in their protective effects are still under 
debate. 
Nrf2 pathway has emerged as a key regulator of cellular antioxidant and detoxifying 
defences against oxidative insult, requiring a proper regulation to assure the intestinal 
homeostasis [20]. Under basal conditions, Nrf2 is sequestered in the cytoplasm, bound to the 
inhibitory protein Kelch-like ECH-associated protein 1 (Keap1), which has the ability to target 
Nrf2 for proteasomal degradation [29]. After activation, it is known that Nrf2 translocates to 
the nucleus, heterodimerizes with other proteins, namely small Maf proteins, and binds to 
antioxidant response elements (ARE) in enhancer sites of responsive genes, promoting the 
transcription of several important antioxidant and cytoprotective enzymes, namely 
hemoxygenase-1 (HO-1) and glutamate cysteine ligase (GCL) [21]. Beyond the anti-oxidative 
protection afforded by Nrf2 activation, this transcription factor has demonstrated to be also 
crucial in the suppression of the inflammatory process, namely by down-regulating some 
important pro-inflammatory cascades, such as NF-kB [21]. In line with this, accelerating 
research has suggested that Nrf2 pathway is essential to counteract dextran sulfate sodium 
(DSS)-induced gut inflammation in mice [30] and, for this reason, the potential of dietary 
polyphenols to up-regulate Nrf2 pathway has gained attention in the context of IBD.  
Following our previous report showing that a mixture of cytokines (IL-1α, TNF-α and 
IFN-γ) in HT-29 cells induced the expression and activation of two relevant pro-inflammatory 
cascades, NF-kB and STAT1 [13], in the present study, a start aim was to investigate the effect 
of that cytokine mixture on the regulation of Nrf2 pathway. We demonstrated, for the first time, 
that the exposure of intestinal cells to a group of pro-inflammatory cytokines led, in the 
beginning, to a growing induction of Nrf2 transcriptional activation (up to 8 hours). It is 
possible to speculate that this increase of Nrf2 transcriptional activation may constitute a 
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homeostatic mechanism in order to counteract the inflammatory response and the excessive 
production of reactive species. This finding is consistent with the study of Rushworth et al [31] 
showing the ability of TNF-α to induce a prolonged Nrf2 activation in monocytes. However, in 
our experimental conditions, Nrf2 transcriptional activity returned to basal levels after 16 hours 
of cytokines exposure, suggesting that intestinal cells were no longer able to hamper the 
inflammation and oxidative stress, at least through Nrf2 pathway, after that time. This 
assumption is strengthen by our previous work, showing that intestinal cells expressed high 
levels of several pro-inflammatory markers (namely, COX-2 and PGE2) [13] as well as 
increasingly amounts of reactive species [14], 16 hours after cytokines exposition.  
Taking into account that after this stimulation period, the Nrf2 activity recovered the basal 
levels, we investigated, at this time point, the effects of C3G and Resv on the regulation of the 
activation of this transcription factor, as compared to 5-ASA. We observed that C3G and Resv, 
in a concentration 20 times lower than 5-ASA, significantly increased Nrf2 activity in 
cytokine-stimulated cells, prolonging its activation. This is in accordance with a recent study 
by Speciale et al [32], indicating that C3G was able to increase the translocation of Nrf2 to the 
nucleus of TNF-α-stimulated human umbilical vein cells (HUVECs), which is a very good 
indicator of Nrf2 activation. Moreover, Hao et al [33] have also reported that Resv showed 
similar effects in lipopolysaccharide-exposed cultured primary human cardiomyocytes. It is 
worth to note that, in our study, the combinations of C3G or Resv with 5-ASA did not improve 
the effects obtained with each polyphenol per se, demonstrating no additive or synergistic 
effects.  
Since C3G and Resv were able to promote the transcriptional activity of Nrf2, we assessed 
the effects of these dietary polyphenols on the expression of two ARE-regulated enzymes, HO-1 
and GCL, as compared to 5-ASA. HO-1 is the inducible isoform of the hemoxygenase enzyme 
that catalyses the oxidation of heme to carbon monoxide (CO), iron and biliverdin [34]. In our 
experimental conditions, and in contrast to 5-ASA, C3G and Resv significantly increased the 
expression of HO-1 in cytokine-challenged cells, at a transcriptional level. This finding can be 
seen as a point in favour of the potential use of the polyphenols in the detriment of 5-ASA, 
since the up-regulation of this enzyme has demonstrated to contribute to ameliorate 
experimentally-induced colitis [35, 36]. Besides, as occurred with Nrf2 activation, the 
combination of C3G or Resv with 5-ASA did not represent an advantage over the use of 
individual compounds to promote the HO-1 expression. Although the mechanisms behind the 
protective effect of HO-1 on colitis are not fully understood, some recent studies indicated that 
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this enzyme interferes with the expression of a crucial pro-inflammatory enzyme, the inducible 
nitric oxide synthase (iNOS), which could be a putative molecular mechanism underlying, at 
least in part, the beneficial effects of some HO-1 inducers, as reported in both in vitro and in 
vivo studies [35, 37]. Thus, strikingly, the increments of HO-1 expression promoted by the 
pre-incubation of either C3G or Resv in cytokine-stimulated cells may be related to their 
abilities to inhibit the expression of iNOS and the consequent production of nitric oxide (NO) 
in those cells, as previously reported by us [13, 14]. Concerning to GCL, this enzyme is 
responsible for the first limiting-step of the biosynthesis of the glutathione (GSH) and it 
comprises a catalytic subunit (GCLC), with all the enzymatic activity, and a modifier subunit 
(GCLM), which is enzymatically inactive but with capacity of increasing the catalytic 
efficiency of GCLC [38]. The GSH is a tripeptide recognized as the most important intracellular 
antioxidant, which can be oxidized to GSSG, by ROS/RNS, being the ratio GSH/GSSG an 
optimal indicator of the intracellular redox state [39]. Regarding to our main findings, it is 
important to highlight two aspects: firstly, the cytokine stimulation of HT-29 cells did not alter 
the expression of GCLC as compared to non-stimulated cells, whereas it enhanced GCLM 
expression in the same cells. Although there is some controversy around this issue, Franklin et 
al [40] have reported that the enhancement of GCLM expression, even not accompanied by an 
increment of GCLC, is an effective mechanism for increasing GCL activity. However, in our 
study, the levels of GSH did not suffer any change in cytokine-stimulated cells as compared to 
control cells, suggesting that the increase of GCLM alone was not sufficient to enhance the 
levels of GSH in those cells. The second important aspect to stress is that the pre-incubation of 
intestinal cells with either C3G or Resv, before cytokine-stimulation, was able to significantly 
increase the expressions of both GCLC and GCLM, as well as the ratio of GSH/GSSG. This 
contrasted with the pre-incubation of cells with 5-ASA, in which a GCLC and GCLM increase 
was observed but without a significant increase in the GSH/GSSG ratio. These findings are in 
harmony with the results obtained by Oz et al [41], revealing that green tea polyphenols were 
more efficient than the drug sulfasalazine, which is a parent compound of 5-ASA, in increasing 
the levels of colonic GSH in DSS-treated mice. 
On the other hand, although both polyphenols and 5-ASA increased Nrf2 pathway in 
cytokine-stimulated cells, only C3G and Resv [14] were able to significantly decrease the 
production of reactive species in those cells, demonstrating in some way, the antioxidant 
superiority of those polyphenols as compared to 5-ASA.  
Alongside Nrf2 pathway, PPAR-γ pathway was recently found as important for inhibiting 
Chapter 4 – C3G and Resv against inflammation and oxidative stress in HT-29 cells: comparison with 5-ASA 
135 
intestinal inflammatory response and protecting cells from oxidative damage [22, 23, 42]. In 
general terms, PPAR-γ belongs to a nuclear receptor family of ligand-dependent transcription 
factors, whose activation requires, at first, its binding to a specific agonist, then its 
hetero-dimerization with the nuclear retinoid X receptor (RXR) and further the heterodimer 
binding to sequence-specific regions in DNA, called Peroxisome Proliferator Response 
Elements (PPRE) [43]. This description corresponds to the conventional mechanism by which 
PPARs regulate gene expression. However, through a mechanism, not fully understood, termed 
transrepression, PPAR-γ is able to antagonize the transcriptional activity of several 
transcription factors, namely NF-kB, STAT1, activator protein-1 (AP-1), without interacting 
with PPRE [43, 44] and this process has been invoked to clarify the role of PPAR-γ against 
inflammation [23]. Aiming to determine whether PPAR-γ was involved in the antioxidant and 
anti-inflammatory protection afforded by C3G and Resv, in comparison with 5-ASA, we 
evaluated the effects of these polyphenolic compounds on PPAR-γ nuclear accumulation in 
cells stimulated or not with cytokines. In accordance with some compelling studies evidencing 
that the anti-inflammatory activity of 5-ASA could be dependent on the activation of PPAR-γ 
[45], 5-ASA showed to increase, in our experimental conditions, the accumulation of PPAR-γ 
in the nucleus of cytokine-exposed intestinal cells. Unlike C3G, Resv demonstrated similar 
results to 5-ASA, at a concentration 20 times lower. Altogether, our results are consistent with 
the involvement of PPAR-γ pathway in the protection afforded by Resv against inflammation 
and oxidative stress. This assumption is supported by strong evidence indicating that PPAR-γ 
can inhibit the transcriptional activation of STAT1, by transrepression, for instance, through 
direct competition for scarce amounts of co-activator molecules [46]. Remarkably, in our 
previous work, we demonstrated that, in the same experimental conditions, Resv was able to 
decrease the amount of activated STAT1 in the nucleus of cytokine-stimulated HT-29 cells 
[14], being plausible that the remaining activated STAT1 could be transcriptionally inactive in 
the nucleus of those cells, by Resv-induced PPAR-γ interference. On the other hand, it was 
found that PPAR-γ may interplay with Nrf2 pathway, inducing Nrf2 activation directly or 
through upstream pathways [23]. Therefore, it is possible that PPAR-γ activation may have 
contributed to Resv effect on the enhancement of Nrf2 transcriptional activation in 
cytokine-stimulated cells. 
Based on the above results, our work gives a step forward unravelling Nrf2 and PPAR-γ as 
signalling pathways involved in the protection afforded by Resv and C3G against 
cytokine-induced inflammation and oxidative response in HT-29 intestinal cells, making 
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comparison with the pharmaceutical agent, 5-ASA. 
In conclusion, the novel findings that we describe in our work, regarding to the beneficial 
effects of C3G and Resv against cytokine-induced inflammation and oxidative stress, 
strengthen the belief that polyphenols abundant in fruits, vegetables and red-wine, typically 
present in a Mediterranean diet, can be truly advantageous for the prevention of chronic 
inflammatory diseases, as is the case of IBD, providing even more benefit to patients than that 
obtained with conventional drugs, such as 5-ASA. However, we are conscious that in vivo 
studies must be conducted to establish evidence for the actual value of dietary polyphenols, as 
C3G and Resv, in limiting IBD progression, which are planned in a near future.  
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Concluding Remarks  
The work reported in this thesis highlights the anti-inflammatory potential of two 
polyphenols typically present in the Mediterranean diet and draws attention to their putative 
role as adjuvant approach to conventional pharmacological therapy.  
The results obtained demonstrated that both the anthocyanin cyanidin-3-glucoside and the 
stilbene resveratrol were able to efficiently decrease the production of cytokine-induced 
pro-inflammatory mediators, such as NO and PGE2, and the expression of cytokine-induced 
pro-inflammatory enzymes, namely iNOS and COX-2, without affecting the activation of 
NF-kB, but decreasing the amount of activated STAT1 in the nucleus of human intestinal cells 
(HT-29). These effects were achieved with concentrations of either cyanidin-3-glucoside or 
resveratrol twenty times lower than that at which the drug 5-ASA promoted similar effects, 
reflecting the superior anti-inflammatory efficiency of these natural polyphenolic compounds 
as compared to the pharmaceutical agent. This study also showed that resveratrol, in contrast to 
5-ASA, inhibited the activation of JNK, thus preventing the maximization of the transcriptional 
potential of STAT1, accumulated in the nucleus of cytokine-stimulated HT-29 cells. 
Furthermore, neither Resv nor 5-ASA showed to be able to decrease the activation of p38 
MAPK in cytokine-stimulated HT-29 cells, which might contribute to the inhibition of the 
transcriptional activity of the STAT1, in those cells.  
On the other hand, considering that inflammation and oxidative stress are crucial close 
related phenomena in the pathogenesis of IBD, and that Nrf2 signalling pathway has been 
recognized as the most important cellular defence against oxidative stress, being also relevant 
in the suppression of the inflammatory process, for instance, by counteracting some 
pro-inflammatory cascades, as NF-kB pathway, the ability of cyanidin-3-glucoside and 
resveratrol to induce Nrf2 pathway, in comparison with 5-ASA, was also addressed in the 
present study. It was demonstrated that cyanidin-3-glucoside and resveratrol were able to 
induce Nrf2 activation and consequently to increase the ARE-regulated mRNA expression of 
two important enzymes, HO-1 and GCL. Although the mechanisms behind the protective 
effects of HO-1 on colitis are not fully understood, some studies indicated that this enzyme is 
able to inhibit the expression of a crucial pro-inflammatory enzyme, the iNOS, which could be 
a putative molecular mechanism underlying, at least in part, the beneficial effects of some HO-1 
inducers [1, 2]. Strikingly, the increments of HO-1 expression promoted by 
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cyanidin-3-glucoside and resveratrol in cytokine-stimulated HT-29 cells can hence be related 
to their ability to inhibit the expression of iNOS and the consequent production of NO in those 
cells. Moreover, both polyphenolic compounds, as opposed to 5-ASA, were able to enhance the 
ratio of reduced glutathione (GSH) to oxidized glutathione (GSSG) and to inhibit the production 
of reactive species, in cytokine-challenged cells, even at concentrations much lower than those 
at which 5-ASA was assayed. Alongside Nrf2 pathway, PPAR-γ pathway was recently found 
as important for inhibiting intestinal inflammatory response and for protecting cells from 
oxidative damage. Actually, through a process called transrepression, PPAR-γ is able to 
antagonize the transcriptional activity of several transcription factors, namely NF-kB and 
STAT1, which might, at least in part, explain the role of PPAR-γ against inflammation. On the 
other hand, it was found that PPAR-γ may interplay with Nrf2 pathway, inducing Nrf2 
activation directly or through upstream pathways. In line with this, resveratrol was found in the 
present work to increase the amount of PPAR-γ in the nucleus of cytokine-stimulated HT-29 
cells. Therefore, it is proposed in the present work a potential involvement of PPAR-γ in the 
ability of resveratrol to counteract STAT1 activation and to enhance Nrf2 transcriptional 
activation in cytokine-stimulated HT-29 cells. Although 5-ASA showed similar effects to those 
of resveratrol, they were obtained at a 20 times higher concentration of 5-ASA. 
Moreover, it is worth noting that, although the low oral bioavailability of the majority of 
polyphenols can be considered a handicap for its therapeutic employment [3], this does not 
constitute a true problem in the particular case of IBD, since several studies [3-5] have indicated 
that the intestine is the organ where dietary polyphenols achieve the highest concentrations in 
the human body (up to several hundred µM). Therefore, the selected concentration for the 
polyphenols under this study, 25 µM, could be easily reached in the gut lumen, after 
consumption of polyphenol-rich fruits or beverages. On the other hand, the concentration of 
5-ASA, 500 µM, was selected taking into consideration the levels reached by this drug in 
colonic mucosa [6]. 
Altogether, the results of the present work testify the anti-inflammatory and the antioxidant 
properties of two structurally different polyphenolic compounds, one flavonoid, the 
anthocyanin cyanidin-3-glucoside, and one nonflavonoid, the stilbene resveratrol, both present 
in the Mediterranean diet, thus strengthening the belief that this diet, typically enriched in 
polyphenols abundant in fruits, vegetables and red-wine, can be truly advantageous for 
minimizing the periods of relapses and for limiting the progression of IBD, providing even 
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more potential benefit to patients than that obtained with conventional drugs, such as 5-ASA. 
On the other hand, by shedding light on the cellular signalling pathways through which those 
polyphenols exert their effects against inflammation and oxidative stress, these studies pave the 
way for the discovery of other compounds or for the structural refinement of pre-existing ones 
that, through modulating the expression and activation of some of the proteins involved in key 
signalling pathways, can be envisaged as useful “weapons” against intestinal inflammation and 
oxidative stress, typically present in IBD patients.  
Although in this study there is no evidence to support an additive or synergistic effect 
between cyanidin-3-glucoside or resveratrol and 5-ASA, this effect cannot be excluded in 
animal models of the disease or in human patients, since, as referred in the Introduction section, 
immune cells, such as dendritic cells, also play a crucial role in the pathogenesis of IBD and 
are not taken into account in this in vitro study. Therefore, we are aware that in vivo studies 
must be undertaken to establish evidence for the actual value of dietary polyphenols, as 
cyanidin-3-glucoside and resveratrol, in the context of IBD, either alone or in combination with 
the drug 5-ASA. 
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